<!DOCTYPE html><html>
<head>
<title></title>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body>
<a name=1></a>Aetna Medicare Advantra&#160;Central Value&#160;(PPO),&#160;Aetna Medicare Advantra Credit Value (PPO),&#160;<br/>Aetna Medicare Advantra&#160;Preferred&#160;Plan (PPO), Aetna Medicare Advantra&#160;Silver&#160;(PPO), Aetna&#160;<br/>Medicare&#160;Advantra Value (PPO), Aetna Medicare&#160;Choice&#160;II&#160;Plan (PPO), Aetna Medicare Choice&#160;<br/>Plan (PPO), Aetna Medicare Credit&#160;Plan (PPO), Aetna&#160;Medicare&#160;Discover&#160;Value Plan (PPO),&#160;<br/>Aetna Medicare DMG Prime (PPO), Aetna Medicare Elite&#160;(PPO), Aetna Medicare&#160;Elite Plan&#160;<br/>(PPO), Aetna Medicare Elite Plan 2 (PPO), Aetna Medicare&#160;Elite Plan 3 (PPO), Aetna Medicare&#160;<br/>Essential Elite Plan&#160;(PPO), Aetna Medicare&#160;Essential Plan (PPO), Aetna Medicare&#160;Explorer&#160;Elite&#160;<br/>(PPO), Aetna Medicare Explorer&#160;Plan (PPO), Aetna Medicare Explorer Premier&#160;(PPO), Aetna&#160;<br/>Medicare&#160;Explorer&#160;Premier 2 (PPO), Aetna Medicare Explorer&#160;Premier&#160;Plan (PPO), Aetna&#160;<br/>Medicare&#160;Explorer&#160;Premier Plus&#160;(PPO), Aetna Medicare&#160;Explorer&#160;Value (PPO), Aetna Medicare&#160;<br/>Freedom&#160;Core&#160;Plan (PPO), Aetna Medicare Freedom Plan (PPO), Aetna Medicare&#160;Freedom&#160;<br/>Preferred Plan (PPO), Aetna Medicare&#160;Gold Plan (PPO), Aetna Medicare Platinum Plan (PPO),&#160;<br/>Aetna Medicare Plus&#160;Plan (PPO), Aetna Medicare Preferred&#160;Premium Plan (PPO), Aetna&#160;<br/>Medicare&#160;Premier (PPO), Aetna&#160;Medicare Premier (Regional&#160;PPO), Aetna Medicare&#160;Premier&#160;1&#160;<br/>(PPO), Aetna Medicare Premier 2 (PPO), Aetna Medicare&#160;Premier Plan&#160;(PPO), Aetna Medicare&#160;<br/>Premier Plus (PPO),&#160;Aetna Medicare&#160;Premier Plus 2 (PPO), Aetna Medicare&#160;Premier Plus 2&#160;<br/>(Regional PPO), Aetna Medicare&#160;Premier Plus Plan (PPO), Aetna&#160;Medicare&#160;Prime&#160;(PPO), Aetna&#160;<br/>Medicare&#160;Prime 1&#160;(PPO), Aetna Medicare Prime&#160;Credit&#160;(PPO), Aetna Medicare Prime&#160;Premier&#160;<br/>(PPO), Aetna Medicare&#160;Select Plan (PPO), Aetna Medicare&#160;SNJ Prime Elite&#160;(PPO), Aetna&#160;<br/>Medicare&#160;The Valley Plan (PPO), Aetna Medicare&#160;Value&#160;(PPO), Aetna Medicare Value Plan&#160;<br/>(PPO), Aetna Medicare Value&#160;Plus&#160;Plan (PPO)&#160;<br/>Last Updated: 04/01/2022&#160;<br/>
<b>ABIRATERONE&#160;</b><br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Abiraterone&#160;Acetate&#160;<br/>
•&#160;&#160;Zytiga&#160;TABS&#160;500MG&#160;<br/>
NR_0009_3741 09/2014&#160;<br/>
Formulary ID: 22007: version 12&#160;<br/>
1&#160;<br/>
<hr/>
<a name=2></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Node-positive (N1), non-metastatic (M0)&#160;prostate cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The requested&#160;drug will&#160;be used in combination with a gonadotropin-<br/>
<b>Medical&#160;</b><br/>
releasing hormone (GnRH) analog or&#160;after bilateral orchiectomy.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
2&#160;<br/>
<hr/>
<a name=3></a><b>ACITRETIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Acitretin&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Prevention of&#160;non-melanoma skin&#160;cancers in high risk individuals, Lichen&#160;<br/>planus, Keratosis&#160;follicularis (Darier&#160;Disease)&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Psoriasis:&#160;The patient has experienced an inadequate&#160;treatment response,&#160;<br/>
<b>Medical&#160;</b><br/>
intolerance,&#160;or the patient has&#160;a contraindication&#160;to&#160;methotrexate&#160;or&#160;<br/>
<b>Information&#160;</b><br/>
cyclosporine.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
3&#160;<br/>
<hr/>
<a name=4></a><b>ACTIMMUNE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Actimmune&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Mycosis fungoides, Sezary syndrome.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
4&#160;<br/>
<hr/>
<a name=5></a><b>ADEMPAS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Adempas&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For pulmonary&#160;arterial hypertension&#160;(PAH) (World Health Organization&#160;<br/>
<b>Medical&#160;</b><br/>
[WHO] Group 1): PAH was confirmed by right heart&#160;catheterization. For&#160;<br/>
<b>Information&#160;</b><br/>
PAH new&#160;starts only:&#160;1)&#160;pretreatment mean pulmonary arterial pressure is&#160;<br/>greater than&#160;20 mmHg, AND&#160;2) pretreatment&#160;pulmonary capillary wedge&#160;<br/>pressure is less than or equal to 15&#160;mmHg, AND 3)&#160;pretreatment&#160;<br/>pulmonary vascular resistance&#160;is greater&#160;than or&#160;equal to 3 Wood units.&#160;<br/>For chronic thromboembolic pulmonary&#160;hypertension (CTEPH) (WHO&#160;<br/>Group 4):&#160;1) Patient has&#160;persistent or recurrent CTEPH&#160;after&#160;pulmonary&#160;<br/>endarterectomy (PEA), OR 2) Patient has&#160;inoperable CTEPH&#160;with the&#160;<br/>diagnosis confirmed by right&#160;heart&#160;catheterization&#160;AND by computed&#160;<br/>tomography&#160;(CT), magnetic&#160;resonance imaging (MRI), or&#160;pulmonary&#160;<br/>angiography.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
5&#160;<br/>
<hr/>
<a name=6></a><b>AIMOVIG</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Aimovig&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient received at least 3 months of treatment&#160;with the requested&#160;<br/>
<b>Medical&#160;</b><br/>
drug, and the patient had a reduction&#160;in migraine&#160;days per month from&#160;<br/>
<b>Information&#160;</b><br/>
baseline, OR&#160;2) The patient experienced an inadequate&#160;treatment&#160;response&#160;<br/>with a&#160;4-week trial&#160;of any of the following: Antiepileptic drugs (AEDs),&#160;<br/>Beta-adrenergic blocking agents, Antidepressants, OR 3) The patient&#160;<br/>experienced&#160;an intolerance or&#160;has&#160;a contraindication that&#160;would prohibit a&#160;<br/>4-week trial&#160;of any of the&#160;following:&#160;Antiepileptic drugs (AEDs), Beta-<br/>adrenergic&#160;blocking agents, Antidepressants.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Initial 3&#160;months,&#160;Reauthorization Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
6&#160;<br/>
<hr/>
<a name=7></a><b>ALECENSA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Alecensa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent ALK-positive&#160;non-small cell&#160;lung cancer&#160;(NSCLC), brain&#160;<br/>metastases from&#160;ALK-positive NSCLC.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
7&#160;<br/>
<hr/>
<a name=8></a><b>ALOSETRON</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Alosetron Hydrochloride&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being prescribed for a biological female&#160;or a&#160;<br/>
<b>Medical&#160;</b><br/>
person that self-identifies as a female&#160;with a&#160;diagnosis of&#160;severe diarrhea-<br/>
<b>Information&#160;</b><br/>
predominant irritable bowel syndrome (IBS) AND&#160;2) Chronic IBS&#160;<br/>symptoms lasting at least 6 months AND&#160;3) Gastrointestinal tract&#160;<br/>abnormalities have&#160;been&#160;ruled out AND&#160;4) Inadequate response to one&#160;<br/>conventional therapy (e.g., antispasmodics,&#160;antidepressants,&#160;<br/>antidiarrheals).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
8&#160;<br/>
<hr/>
<a name=9></a><b>ALPHA1-PROTEINASE&#160;INHIBITOR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Prolastin-c&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For alpha1-proteinase&#160;inhibitor deficiency: Patient must have 1)&#160;clinically&#160;<br/>
<b>Medical&#160;</b><br/>
evident&#160;emphysema and&#160;2) pretreatment serum alpha1-proteinase inhibitor&#160;<br/>
<b>Information&#160;</b><br/>
level&#160;less&#160;than 11 micromol/L&#160;(80 mg/dL by radial&#160;immunodiffusion or 50&#160;<br/>mg/dL by nephelometry).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
9&#160;<br/>
<hr/>
<a name=10></a><b>ALUNBRIG</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Alunbrig&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent ALK-positive&#160;non-small cell&#160;lung cancer&#160;(NSCLC), brain&#160;<br/>metastases from&#160;ALK-positive NSCLC.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
10&#160;<br/>
<hr/>
<a name=11></a><b>AMBRISENTAN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ambrisentan&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Pulmonary&#160;arterial&#160;hypertension&#160;(PAH) (World&#160;Health Organization&#160;<br/>
<b>Medical&#160;</b><br/>
[WHO] Group 1): Diagnosis was confirmed by right heart catheterization.&#160;<br/>
<b>Information&#160;</b><br/>
For PAH&#160;new starts only: 1)&#160;Pretreatment mean&#160;pulmonary arterial&#160;<br/>pressure is greater than 20 mmHg, 2)&#160;Pretreatment pulmonary capillary&#160;<br/>wedge pressure is&#160;less&#160;than or&#160;equal to 15 mmHg, and 3)&#160;Pretreatment&#160;<br/>pulmonary vascular resistance&#160;is greater&#160;than or&#160;equal to 3 Wood units.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
11&#160;<br/>
<hr/>
<a name=12></a><b>ARCALYST</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Arcalyst&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Prevention of&#160;gout flares&#160;in patients initiating or continuing urate-<br/>lowering&#160;therapy.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For prevention&#160;of gout&#160;flares in patients initiating&#160;or continuing urate-<br/>
<b>Medical&#160;</b><br/>
lowering&#160;therapy (e.g.,&#160;allopurinol)&#160;(new&#160;starts):&#160;1) two or more gout&#160;<br/>
<b>Information&#160;</b><br/>
flares within&#160;the previous 12 months,&#160;AND 2) inadequate&#160;response,&#160;<br/>intolerance&#160;or contraindication to&#160;maximum tolerated doses&#160;of a&#160;non-<br/>steroidal&#160;anti-inflammatory drug (NSAID) and colchicine, AND&#160;3)&#160;<br/>concurrent use with urate-lowering&#160;therapy. For prevention of&#160;gout flares&#160;<br/>in patients initiating or continuing urate-lowering&#160;therapy&#160;(e.g.,&#160;<br/>allopurinol)&#160;(continuation): 1)&#160;patient must have&#160;achieved or&#160;maintained&#160;a&#160;<br/>clinical benefit&#160;(i.e.,&#160;a fewer number&#160;of gout&#160;attacks or&#160;fewer&#160;flare&#160;days)&#160;<br/>compared to&#160;baseline, AND 2) continued use&#160;of urate-lowering therapy&#160;<br/>concurrently&#160;with the&#160;requested drug.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
For prevention&#160;of gout&#160;flares: 4 months. Other: Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
12&#160;<br/>
<hr/>
<a name=13></a><b>ARMODAFINIL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Armodafinil&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient has&#160;a diagnosis of&#160;narcolepsy and&#160;the diagnosis is&#160;<br/>
<b>Medical&#160;</b><br/>
confirmed by sleep&#160;lab evaluation OR&#160;2) The patient has a diagnosis of&#160;<br/>
<b>Information&#160;</b><br/>
Shift Work&#160;Disorder&#160;(SWD) OR 3) The patient&#160;has a&#160;diagnosis of&#160;<br/>obstructive&#160;sleep apnea (OSA) and the&#160;diagnosis is confirmed&#160;by&#160;<br/>polysomnography.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
13&#160;<br/>
<hr/>
<a name=14></a><b>ASPARLAS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Asparlas&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>Patient age&#160;21 years or&#160;less&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
14&#160;<br/>
<hr/>
<a name=15></a><b>AUSTEDO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Austedo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some&#160;Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Tourette's syndrome&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
15&#160;<br/>
<hr/>
<a name=16></a><b>AVONEX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Avonex&#160;INJ 30MCG/0.5ML&#160;<br/>
•&#160;&#160;Avonex Pen&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
16&#160;<br/>
<hr/>
<a name=17></a><b>AYVAKIT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ayvakit&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Myeloid&#160;and&#160;lymphoid neoplasms with eosinophilia, gastrointestinal&#160;<br/>stromal tumor (GIST) for unresectable, recurrent,&#160;or metastatic disease&#160;<br/>without&#160;platelet-derived&#160;growth factor receptor&#160;alpha (PDGFRA) exon 18&#160;<br/>mutation&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For myeloid&#160;and lymphoid neoplasms with eosinophilia, the&#160;patient meets&#160;<br/>
<b>Medical&#160;</b><br/>
all&#160;of the&#160;following criteria: 1)&#160;the disease is FIP1L1-&#160;PDGFRA&#160;<br/>
<b>Information&#160;</b><br/>
rearrangement-positive,&#160;AND 2) The&#160;disease harbors&#160;a PDGFRA D842A&#160;<br/>mutation, AND&#160;3) The disease is resistant&#160;to imatinib. For GIST, the&#160;<br/>patient meets either&#160;of the following&#160;criteria:&#160;1) The disease harbors&#160;<br/>PDGFRA exon 18 mutation, including PDGFRA D842V mutations, OR&#160;<br/>2) The requested drug will be used after failure on at least&#160;two Food and&#160;<br/>Drug&#160;Administration (FDA)-approved therapies&#160;in unresectable,&#160;<br/>recurrent, or&#160;metastatic&#160;disease without PDGFRA exon 18 mutation. For&#160;<br/>advanced systemic mastocytosis (AdvSM):&#160;1) the&#160;patient has&#160;a diagnosis&#160;<br/>of advanced systemic mastocytosis&#160;including aggressive systemic&#160;<br/>mastocytosis (ASM), systemic mastocytosis with associated&#160;<br/>hematological neoplasm&#160;(SM-AHN), and mast cell leukemia&#160;(MCL) AND&#160;<br/>2) the patient has&#160;a platelet count of greater than or equal to 50,000/mcL.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
17&#160;<br/>
<hr/>
<a name=18></a><b>BALVERSA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Balversa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
18&#160;<br/>
<hr/>
<a name=19></a><b>BANZEL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Banzel&#160;TABS&#160;<br/>
•&#160;&#160;Rufinamide&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>1 year&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
19&#160;<br/>
<hr/>
<a name=20></a><b>BELEODAQ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Beleodaq&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Adult T-cell&#160;leukemia/lymphoma,&#160;mycosis fungoides/Sezary&#160;syndrome,&#160;<br/>extranodal NK/T-cell&#160;lymphoma&#160;(nasal&#160;type), hepatosplenic&#160;gamma-delta&#160;<br/>T-cell lymphoma, and primary&#160;cutaneous anaplastic&#160;large&#160;cell&#160;lymphoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
20&#160;<br/>
<hr/>
<a name=21></a><b>BENLYSTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Benlysta&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
For patients&#160;new to therapy: severe active&#160;central nervous system&#160;lupus.&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For systemic&#160;lupus&#160;erythematosus (SLE):&#160;1) Patient&#160;is currently receiving&#160;<br/>
<b>Medical&#160;</b><br/>
a stable standard therapy&#160;regimen (e.g., corticosteroid or antimalarial)&#160;for&#160;<br/>
<b>Information&#160;</b><br/>
SLE&#160;OR&#160;2)&#160;patient is not currently receiving stable standard&#160;therapy&#160;<br/>regimen for&#160;SLE&#160;because patient tried and had an&#160;inadequate response&#160;or&#160;<br/>intolerance to stable standard therapy&#160;regimen. For lupus nephritis: 1)&#160;<br/>Patient is currently receiving a&#160;stable&#160;standard&#160;therapy regimen (e.g.,&#160;<br/>corticosteroid) for&#160;lupus&#160;nephritis OR 2) patient&#160;is not&#160;currently receiving&#160;<br/>a stable standard therapy&#160;regimen for lupus nephritis because&#160;patient tried&#160;<br/>and had an&#160;inadequate&#160;response or&#160;intolerance to a&#160;stable standard&#160;therapy&#160;<br/>regimen.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
21&#160;<br/>
<hr/>
<a name=22></a><b>BESREMI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Besremi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
22&#160;<br/>
<hr/>
<a name=23></a><b>BETASERON</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Betaseron&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
23&#160;<br/>
<hr/>
<a name=24></a><b>BEVACIZUMAB</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zirabev&#160;<br/>
24&#160;<br/>
<hr/>
<a name=25></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Breast&#160;cancer, central&#160;nervous system&#160;(CNS) tumor types: adult low-grade&#160;<br/>(WHO&#160;Grade II)&#160;infiltrative supratentorial&#160;<br/>astrocytoma/oligodendroglioma, adult intracranial&#160;and spinal&#160;<br/>ependymoma, anaplastic&#160;gliomas, adult medulloblastoma, primary central&#160;<br/>nervous system lymphoma, meningiomas, limited and extensive brain&#160;<br/>metastases,&#160;and metastatic spine tumors, malignant pleural&#160;mesothelioma,&#160;<br/>ovarian cancer/fallopian&#160;tube cancer/primary peritoneal&#160;cancer types:&#160;<br/>carcinosarcoma (malignant mixed Mullerian&#160;tumors), clear cell&#160;<br/>carcinoma,&#160;mucinous&#160;carcinoma, grade 1 endometrioid carcinoma, low-<br/>grade serous&#160;carcinoma,&#160;ovarian borderline&#160;epithelial tumors&#160;(low&#160;<br/>malignant&#160;potential) with invasive implants, and&#160;malignant sex cord-<br/>stromal tumors, soft tissue sarcoma types: angiosarcoma and&#160;solitary&#160;<br/>fibrous&#160;tumor/hemangiopericytoma,&#160;uterine neoplasms, endometrial&#160;<br/>cancer, vulvar&#160;squamous&#160;cell&#160;carcinoma, and ophthalmic-related&#160;<br/>disorders: diabetic macular edema, neovascular (wet)&#160;age-related macular&#160;<br/>degeneration including&#160;polypoidal choroidopathy and retinal angiomatous&#160;<br/>proliferation&#160;subtypes, macular edema following&#160;retinal vein&#160;occlusion,&#160;<br/>proliferative&#160;diabetic retinopathy, choroidal neovascularization,&#160;<br/>neovascular glaucoma and retinopathy of prematurity, small bowel&#160;<br/>adenocarcinoma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
25&#160;<br/>
<hr/>
<a name=26></a><b>BEXAROTENE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Bexarotene&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Mycosis fungoides, Sezary syndrome, CD30-positive primary cutaneous&#160;<br/>anaplastic&#160;large cell lymphoma, CD30-positive&#160;lymphomatoid&#160;papulosis.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
26&#160;<br/>
<hr/>
<a name=27></a><b>BLENREP</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Blenrep&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
27&#160;<br/>
<hr/>
<a name=28></a><b>BOSENTAN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Bosentan&#160;<br/>
•&#160;&#160;Tracleer&#160;TBSO&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;pulmonary&#160;arterial hypertension&#160;(PAH) (World Health Organization&#160;<br/>
<b>Medical&#160;</b><br/>
[WHO] Group 1): Diagnosis was confirmed by right heart catheterization.&#160;<br/>
<b>Information&#160;</b><br/>
For PAH&#160;new starts only: 1)&#160;Pretreatment mean&#160;pulmonary arterial&#160;<br/>pressure is greater than 20 mmHg, 2)&#160;Pretreatment pulmonary capillary&#160;<br/>wedge pressure&#160;is less than or&#160;equal to 15 mmHg, and 3)&#160;Pretreatment&#160;<br/>pulmonary vascular resistance&#160;is greater&#160;than or&#160;equal to 3 Wood units.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
28&#160;<br/>
<hr/>
<a name=29></a><b>BOSULIF</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Bosulif&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Philadelphia&#160;chromosome&#160;positive acute lymphoblastic leukemia&#160;(Ph+&#160;<br/>ALL)&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;myeloid leukemia&#160;(CML) or&#160;acute lymphoblastic leukemia&#160;<br/>
<b>Medical&#160;</b><br/>
(ALL): Diagnosis was confirmed by&#160;detection of&#160;the Philadelphia&#160;<br/>
<b>Information&#160;</b><br/>
chromosome or&#160;BCR-ABL gene. For CML, including patients newly&#160;<br/>diagnosed with CML and patients who have received a&#160;hematopoietic&#160;<br/>stem&#160;cell transplant: patient has experienced resistance or intolerance to&#160;<br/>imatinib or&#160;dasatinib. If&#160;patient experienced resistance to an alternative&#160;<br/>tyrosine kinase inhibitor for CML, patient is negative&#160;for&#160;all&#160;of the&#160;<br/>following&#160;mutations:&#160;T315I, G250E, V299L, and F317L.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
29&#160;<br/>
<hr/>
<a name=30></a><b>BRAFTOVI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Braftovi&#160;CAPS 75MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Adjuvant systemic&#160;therapy for&#160;cutaneous melanoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For colorectal&#160;cancer: The patient must meet both of the following&#160;<br/>
<b>Medical&#160;</b><br/>
criteria:&#160;1) Tumor&#160;is positive&#160;for&#160;BRAF&#160;V600E&#160;mutation, 2)&#160;The&#160;<br/>
<b>Information&#160;</b><br/>
requested drug will&#160;be used for either of&#160;the following: a) as&#160;subsequent&#160;<br/>therapy&#160;for&#160;advanced or&#160;metastatic&#160;disease, or&#160;b)&#160;as primary&#160;treatment for&#160;<br/>unresectable&#160;metachronous metastases. For cutaneous melanoma:&#160;The&#160;<br/>patient must&#160;meet&#160;all&#160;of the following&#160;criteria: 1)&#160;Tumor&#160;is positive for&#160;<br/>BRAF&#160;V600 activating&#160;mutation (e.g., V600E&#160;or V600K), 2) The&#160;<br/>requested drug will&#160;be used in combination with&#160;binimetinib,&#160;and 3)&#160;The&#160;<br/>requested drug will&#160;be used for either of&#160;the following: a) unresectable or&#160;<br/>metastatic&#160;disease, or&#160;b)&#160;adjuvant&#160;systemic therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
30&#160;<br/>
<hr/>
<a name=31></a><b>BRIVIACT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Briviact&#160;ORAL&#160;SOLN&#160;<br/>
•&#160;&#160;Briviact&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient has&#160;experienced an inadequate&#160;treatment response,&#160;<br/>
<b>Medical&#160;</b><br/>
intolerance,&#160;or contraindication to a&#160;generic anticonvulsant&#160;AND 2) If&#160;the&#160;<br/>
<b>Information&#160;</b><br/>
patient is 4&#160;years of&#160;age&#160;or older,&#160;the patient has&#160;experienced an&#160;<br/>inadequate treatment response, intolerance, or contraindication to any of&#160;<br/>the following: Aptiom,&#160;Vimpat, Xcopri, Spritam.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>1 month&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
31&#160;<br/>
<hr/>
<a name=32></a><b>BRIVIACT&#160;INJ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Briviact&#160;INJ&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient has&#160;experienced an inadequate&#160;treatment response,&#160;<br/>
<b>Medical&#160;</b><br/>
intolerance,&#160;or contraindication to a&#160;generic anticonvulsant&#160;AND 2) If&#160;the&#160;<br/>
<b>Information&#160;</b><br/>
patient is 4&#160;years of&#160;age&#160;or older,&#160;the patient has&#160;experienced an&#160;<br/>inadequate treatment response, intolerance, or contraindication to any of&#160;<br/>the following: Aptiom,&#160;Vimpat, Xcopri, Spritam.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>1 month&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
32&#160;<br/>
<hr/>
<a name=33></a><b>BRUKINSA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Brukinsa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age&#160;Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
33&#160;<br/>
<hr/>
<a name=34></a><b>BUPRENORPHINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Buprenorphine Hcl&#160;SUBL&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The requested&#160;drug is being prescribed for the treatment&#160;of&#160;opioid use&#160;<br/>
<b>Medical&#160;</b><br/>
disorder AND&#160;patient meets one of the following: 1)&#160;The patient is&#160;<br/>
<b>Information&#160;</b><br/>
pregnant or&#160;breastfeeding, and the&#160;requested drug is being prescribed for&#160;<br/>induction therapy and/or subsequent&#160;maintenance&#160;therapy&#160;for treatment of&#160;<br/>opioid use disorder OR 2) The requested drug&#160;is being prescribed for&#160;<br/>induction therapy for transition&#160;from&#160;opioid use&#160;to&#160;treatment&#160;of opioid use&#160;<br/>disorder OR 3) The requested drug&#160;is being prescribed for maintenance&#160;<br/>therapy&#160;for&#160;treatment of&#160;opioid use disorder in a&#160;patient who is&#160;intolerant&#160;<br/>to naloxone.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
12 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
34&#160;<br/>
<hr/>
<a name=35></a><b>BUPRENORPHINE&#160;PATCH</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Buprenorphine&#160;PTWK&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being prescribed for pain&#160;associated&#160;with cancer,&#160;<br/>
<b>Medical&#160;</b><br/>
sickle cell disease, a&#160;terminal condition, or pain&#160;being managed through&#160;<br/>
<b>Information&#160;</b><br/>
palliative&#160;care&#160;OR&#160;2) The requested&#160;drug is being prescribed&#160;for&#160;pain&#160;<br/>severe&#160;enough to require&#160;daily, around-the-clock,&#160;long-term&#160;treatment in&#160;a&#160;<br/>patient who has been taking an opioid&#160;AND 3) The patient can safely take&#160;<br/>the requested dose based&#160;on their history of&#160;opioid use [Note: This drug&#160;<br/>should be prescribed only by healthcare&#160;professionals&#160;who are&#160;<br/>knowledgeable in&#160;the use of potent opioids for the management of chronic&#160;<br/>pain.]&#160;AND 4) The patient has&#160;been&#160;evaluated and the patient&#160;will&#160;be&#160;<br/>monitored&#160;for the development of opioid use disorder&#160;AND 5) This&#160;<br/>request&#160;is for continuation of therapy&#160;for&#160;a patient&#160;who has been receiving&#160;<br/>an extended-release&#160;opioid agent&#160;for at least&#160;30 days OR the patient has&#160;<br/>taken an&#160;immediate-release opioid for at&#160;least one week.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
35&#160;<br/>
<hr/>
<a name=36></a><b>CABOMETYX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Cabometyx&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Non-small cell&#160;lung cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For renal&#160;cell carcinoma: The disease&#160;is advanced, relapsed, or stage&#160;IV.&#160;<br/>
<b>Medical&#160;</b><br/>
For non-small cell&#160;lung cancer: 1) The disease is&#160;rearranged during&#160;<br/>
<b>Information&#160;</b><br/>
transfection (RET) positive AND 2) the disease is recurrent,&#160;advanced, or&#160;<br/>metastatic. For hepatocellular carcinoma:&#160;the requested drug will be used&#160;<br/>as subsequent treatment.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
36&#160;<br/>
<hr/>
<a name=37></a><b>CALCIPOTRIENE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Calcipotriene&#160;CREA&#160;<br/>
•&#160;&#160;&#160;Calcipotriene&#160;OINT&#160;<br/>
•&#160;&#160;&#160;Calcipotriene&#160;SOLN&#160;<br/>
•&#160;&#160;&#160;Calcipotriene/betamethasone&#160;<br/>
Dipropionate&#160;OINT&#160;<br/>
•&#160;&#160;&#160;Calcitriol&#160;OINT&#160;<br/>
•&#160;&#160;&#160;Enstilar&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being prescribed for the&#160;treatment of&#160;psoriasis&#160;<br/>
<b>Medical&#160;</b><br/>
AND 2) The&#160;patient experienced an inadequate&#160;treatment response,&#160;<br/>
<b>Information&#160;</b><br/>
intolerance,&#160;or the patient has&#160;a contraindication&#160;to&#160;a topical steroid.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
37&#160;<br/>
<hr/>
<a name=38></a><b>CALQUENCE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Calquence&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Waldenstrom macroglobulinemia/lymphoplasmacytic&#160;lymphoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;lymphocytic&#160;leukemia or small lymphocytic&#160;lymphoma:&#160;the&#160;<br/>
<b>Medical&#160;</b><br/>
patient has&#160;experienced an intolerable adverse&#160;event with ibrutinib.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
38&#160;<br/>
<hr/>
<a name=39></a><b>CAPLYTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Caplyta&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;experienced&#160;an inadequate treatment response, intolerance, or&#160;<br/>
<b>Medical&#160;</b><br/>
contraindication to one of the following generic products: A)&#160;aripiprazole,&#160;<br/>
<b>Information&#160;</b><br/>
B) asenapine, C) olanzapine, D) quetiapine, E)&#160;risperidone, F) ziprasidone&#160;<br/>AND the patient&#160;experienced an inadequate&#160;treatment&#160;response,&#160;<br/>intolerance,&#160;or contraindication to one of&#160;the following brand&#160;products: A)&#160;<br/>Latuda, B) Rexulti, C)&#160;Secuado.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
39&#160;<br/>
<hr/>
<a name=40></a><b>CAPRELSA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Caprelsa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Differentiated thyroid&#160;carcinoma: papillary, follicular, and Hurthle cell.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
40&#160;<br/>
<hr/>
<a name=41></a><b>CARAC</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fluorouracil&#160;CREA&#160;0.5%&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
Patients who&#160;are&#160;pregnant or&#160;may become&#160;pregnant. Patients with&#160;<br/>
<b>Criteria&#160;</b><br/>
dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.&#160;<br/>
<b>Required&#160;</b><br/>
If&#160;being&#160;used as part&#160;of&#160;a compounded product, all active ingredients in&#160;<br/>
<b>Medical&#160;</b><br/>
the compounded product are FDA&#160;approved for topical use.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
3 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
41&#160;<br/>
<hr/>
<a name=42></a><b>CARBAGLU</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Carbaglu&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For N-acetylglutamate&#160;synthase (NAGS) deficiency: Diagnosis of NAGS&#160;<br/>
<b>Medical&#160;</b><br/>
deficiency&#160;was confirmed by enzymatic or genetic testing.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
42&#160;<br/>
<hr/>
<a name=43></a><b>CAYSTON</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Cayston&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;treatment&#160;of respiratory symptoms in cystic&#160;fibrosis patients: 1)&#160;<br/>
<b>Medical&#160;</b><br/>
Pseudomonas aeruginosa&#160;is present in&#160;the patient's&#160;airway cultures&#160;OR&#160;2)&#160;<br/>
<b>Information&#160;</b><br/>
The patient&#160;has a&#160;history&#160;of pseudomonas aeruginosa infection or&#160;<br/>colonization&#160;in the airways.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
43&#160;<br/>
<hr/>
<a name=44></a><b>CERDELGA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Cerdelga&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For Gaucher&#160;disease, the&#160;diagnosis was confirmed by an enzyme assay&#160;<br/>
<b>Medical&#160;</b><br/>
demonstrating a deficiency of&#160;beta-glucocerebrosidase&#160;enzyme activity&#160;or&#160;<br/>
<b>Information&#160;</b><br/>
by genetic testing. The patient's CYP2D6 metabolizer status has been&#160;<br/>established&#160;using&#160;an FDA-cleared&#160;test. The patient is a CYP2D6 extensive&#160;<br/>metabolizer, an intermediate&#160;metabolizer, or a&#160;poor metabolizer.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
44&#160;<br/>
<hr/>
<a name=45></a><b>CHANTIX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Apo-varenicline&#160;<br/>
•&#160;&#160;Chantix&#160;TABS&#160;0.5MG,&#160;1MG&#160;<br/>
•&#160;&#160;Chantix Continuing Month Pak&#160;<br/>
•&#160;&#160;Chantix Starting Month&#160;Pak&#160;<br/>
•&#160;&#160;Varenicline&#160;Tartrate&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
6 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;applies after the member has&#160;<br/>received a&#160;cumulative 24 weeks of therapy in a&#160;Plan Year.&#160;<br/>
45&#160;<br/>
<hr/>
<a name=46></a><b>CHLORDIAZEPOXIDE&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Chlordiazepoxide Hcl&#160;CAPS 10MG,&#160;<br/>
5MG&#160;<br/>
•&#160;&#160;&#160;Chlordiazepoxide Hydrochloride&#160;<br/>
CAPS 25MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For all&#160;indications: the prescriber must acknowledge the benefit&#160;of&#160;<br/>
<b>Medical&#160;</b><br/>
therapy with&#160;the prescribed medication outweighs the potential risks for&#160;<br/>
<b>Information&#160;</b><br/>
the patient. &#160;(Note: The&#160;American Geriatrics&#160;Society&#160;identifies the&#160;use of&#160;<br/>this medication as potentially inappropriate in&#160;older&#160;adults, meaning it is&#160;<br/>best&#160;avoided, prescribed&#160;at reduced dosage, or used with caution or&#160;<br/>carefully&#160;monitored.) &#160;For the&#160;management of anxiety disorders: 1) the&#160;<br/>requested drug is&#160;being used concurrently with a selective&#160;serotonin&#160;<br/>reuptake inhibitor&#160;(SSRI) or&#160;serotonin-norepinephrine reuptake inhibitor&#160;<br/>(SNRI)&#160;until&#160;SSRI/SNRI&#160;is effective&#160;for&#160;the symptoms of&#160;anxiety, OR 2)&#160;<br/>the patient has experienced an inadequate treatment response,&#160;intolerance,&#160;<br/>or has a contraindication&#160;to AT LEAST TWO&#160;agents from the&#160;following&#160;<br/>classes: a) selective&#160;serotonin reuptake inhibitors&#160;(SSRIs), OR&#160;b)&#160;<br/>serotonin-norepinephrine reuptake inhibitors&#160;(SNRIs).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Short-term relief&#160;anxiety-preop apprehens and anx-1 mo, Anxiety&#160;<br/>
<b>Duration&#160;</b><br/>
Disorder-4&#160;mo, Alc&#160;Withdrawal-PlanYR&#160;<br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older.&#160;<br/>
46&#160;<br/>
<hr/>
<a name=47></a><b>CLOBAZAM</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Clobazam&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age&#160;Restrictions&#160;&#160;</b>2 years&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
47&#160;<br/>
<hr/>
<a name=48></a><b>CLOMIPRAMINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Clomipramine Hcl&#160;CAPS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Depression,&#160;Panic Disorder&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being prescribed for one&#160;of the following:&#160;<br/>
<b>Medical&#160;</b><br/>
Obsessive-Compulsive&#160;Disorder&#160;(OCD) or&#160;Panic&#160;Disorder&#160;AND 2) The&#160;<br/>
<b>Information&#160;</b><br/>
patient has&#160;experienced an inadequate treatment response, intolerance, or&#160;<br/>the patient has a contraindication to&#160;any of the following: a serotonin&#160;and&#160;<br/>norepinephrine reuptake&#160;inhibitor&#160;(SNRI)&#160;or a&#160;selective serotonin&#160;<br/>reuptake inhibitor (SSRI) OR 3) The requested drug is&#160;being prescribed&#160;<br/>for&#160;Depression AND 4)&#160;The patient&#160;has experienced an inadequate&#160;<br/>treatment response, intolerance, or the patient has&#160;a contraindication&#160;to&#160;<br/>two of the following:&#160;serotonin&#160;and&#160;norepinephrine reuptake&#160;inhibitors&#160;<br/>(SNRIs), selective serotonin reuptake inhibitors&#160;(SSRIs), mirtazapine,&#160;<br/>bupropion.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
48&#160;<br/>
<hr/>
<a name=49></a><b>CLORAZEPATE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Clorazepate&#160;Dipotassium&#160;TABS&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For all&#160;indications: the prescriber must acknowledge the benefit&#160;of&#160;<br/>
<b>Medical&#160;</b><br/>
therapy with&#160;the requested drug outweighs the potential risks&#160;for the&#160;<br/>
<b>Information&#160;</b><br/>
patient. (Note: The&#160;American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.) For the management of&#160;anxiety disorders: 1)&#160;the&#160;requested&#160;<br/>drug is being used concurrently with a selective&#160;serotonin reuptake&#160;<br/>inhibitor&#160;(SSRI) or&#160;serotonin-norepinephrine reuptake&#160;inhibitor (SNRI)&#160;<br/>until&#160;the SSRI/SNRI becomes effective for the symptoms of&#160;anxiety OR&#160;<br/>2) the patient has&#160;experienced an inadequate&#160;treatment&#160;response,&#160;<br/>intolerance,&#160;or has a contraindication&#160;to AT LEAST TWO&#160;agents from the&#160;<br/>following&#160;classes:&#160;a)&#160;selective serotonin reuptake inhibitors&#160;(SSRIs) OR&#160;<br/>b) serotonin-norepinephrine reuptake inhibitors (SNRIs).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Short-term relief&#160;anxiety-1 month, Anxiety Disorders-4&#160;months, All other&#160;<br/>
<b>Duration&#160;</b><br/>
Diagnoses-Plan Year&#160;<br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older.&#160;<br/>
49&#160;<br/>
<hr/>
<a name=50></a><b>CLOZAPINE&#160;ODT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Clozapine Odt&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
50&#160;<br/>
<hr/>
<a name=51></a><b>COLY-MYCIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Colistimethate Sodium&#160;INJ&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Intravenous&#160;(IV) or&#160;intramuscular&#160;(IM) use only. Administration will not&#160;<br/>
<b>Medical&#160;</b><br/>
be via&#160;nebulizer.&#160;(Note:&#160;CMS endorsed compendia do not support&#160;<br/>
<b>Information&#160;</b><br/>
inhalation/nebulization&#160;of colistimethate.). The&#160;infection is proven or&#160;<br/>strongly&#160;suspected&#160;to be caused by susceptible bacteria based&#160;on: 1)&#160;<br/>culture&#160;and susceptibility&#160;information&#160;OR&#160;2) local epidemiology and&#160;<br/>susceptibility patterns.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
Prescribed by&#160;or in consultation with an infectious disease specialist&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Initial&#160;approval:&#160;3&#160;months, Renewal:&#160;Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
51&#160;<br/>
<hr/>
<a name=52></a><b>COMETRIQ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Cometriq&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Non-small cell&#160;lung cancer&#160;(NSCLC), differentiated thyroid carcinoma:&#160;<br/>papillary, follicular, and&#160;Hurthle cell.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For NSCLC: The requested medication is used for NSCLC when the&#160;<br/>
<b>Medical&#160;</b><br/>
patient's disease expresses rearranged during transfection (RET) gene&#160;<br/>
<b>Information&#160;</b><br/>
rearrangements.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
52&#160;<br/>
<hr/>
<a name=53></a><b>COPIKTRA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Copiktra&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Gastric MALT&#160;lymphoma, non-gastric MALT lymphoma, nodal marginal&#160;<br/>zone lymphoma, splenic marginal&#160;zone lymphoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For follicular&#160;lymphoma, gastric MALT lymphoma, non-gastric MALT&#160;<br/>
<b>Medical&#160;</b><br/>
lymphoma,&#160;nodal marginal zone&#160;lymphoma, and splenic marginal zone&#160;<br/>
<b>Information&#160;</b><br/>
lymphoma: the requested&#160;drug will be&#160;used as subsequent therapy after at&#160;<br/>least 2 prior&#160;therapies.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
53&#160;<br/>
<hr/>
<a name=54></a><b>COTELLIC</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Cotellic&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Central nervous&#160;system (CNS) cancer&#160;(i.e., glioma, meningioma,&#160;<br/>astrocytoma)&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For adjuvant&#160;treatment of melanoma, and central&#160;nervous system (CNS)&#160;<br/>
<b>Medical&#160;</b><br/>
cancer&#160;(i.e.,&#160;glioma, meningioma, astrocytoma):&#160;The patient&#160;must&#160;meet&#160;<br/>
<b>Information&#160;</b><br/>
both of&#160;the following criteria: 1) The&#160;tumor is positive for BRAF V600&#160;<br/>activating&#160;mutation (e.g.,&#160;V600E&#160;or V600K), and 2)&#160;The requested drug&#160;<br/>will&#160;be used&#160;in combination with vemurafenib. For&#160;unresectable or&#160;<br/>metastatic&#160;melanoma: The patient must meet both&#160;of the following&#160;<br/>criteria:&#160;1) The tumor is&#160;positive for&#160;BRAF&#160;V600 activating&#160;mutation&#160;<br/>(e.g., V600E&#160;or V600K), and 2)&#160;The requested&#160;drug will be used in&#160;<br/>combination&#160;with vemurafenib&#160;(with&#160;or without&#160;atezolizumab).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
54&#160;<br/>
<hr/>
<a name=55></a><b>CYSTAGON</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Cystagon&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;nephropathic&#160;cystinosis: Diagnosis of&#160;nephropathic&#160;cystinosis&#160;was&#160;<br/>
<b>Medical&#160;</b><br/>
confirmed by the presence of&#160;increased cystine&#160;concentration&#160;in&#160;<br/>
<b>Information&#160;</b><br/>
leukocytes or by genetic&#160;testing.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
55&#160;<br/>
<hr/>
<a name=56></a><b>CYSTARAN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Cystaran&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For cystinosis: 1)&#160;Diagnosis&#160;of cystinosis was confirmed by the presence&#160;<br/>
<b>Medical&#160;</b><br/>
of increased&#160;cystine concentration&#160;in leukocytes or by genetic testing,&#160;and&#160;<br/>
<b>Information&#160;</b><br/>
2) Patient has corneal cystine&#160;crystal&#160;accumulation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
56&#160;<br/>
<hr/>
<a name=57></a><b>DALFAMPRIDINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Dalfampridine Er&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For multiple&#160;sclerosis, patient must&#160;meet&#160;the following: For&#160;new starts,&#160;<br/>
<b>Medical&#160;</b><br/>
prior to initiating&#160;therapy, patient meets&#160;the following: patient&#160;<br/>
<b>Information&#160;</b><br/>
demonstrates sustained walking impairment. For continuation of therapy,&#160;<br/>patient meets the following: patient&#160;must&#160;have experienced an&#160;<br/>improvement in walking&#160;speed OR other&#160;objective measure&#160;of walking&#160;<br/>ability since&#160;starting&#160;the requested drug.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
57&#160;<br/>
<hr/>
<a name=58></a><b>DAURISMO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Daurismo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Post&#160;induction&#160;therapy&#160;following response to previous therapy with the&#160;<br/>same regimen for acute myeloid leukemia&#160;(AML). Relapsed/refractory&#160;<br/>AML as a component of&#160;repeating the initial successful&#160;induction&#160;<br/>regimen.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For acute&#160;myeloid&#160;leukemia: 1)&#160;the requested&#160;medication must be used&#160;in&#160;<br/>
<b>Medical&#160;</b><br/>
combination&#160;with cytarabine, 2)&#160;the patient is 75&#160;years of&#160;age&#160;or older&#160;OR&#160;<br/>
<b>Information&#160;</b><br/>
has comorbidities that preclude&#160;intensive&#160;chemotherapy, and&#160;3) the&#160;<br/>requested medication will&#160;be used as&#160;treatment for induction therapy,&#160;<br/>post-induction therapy,&#160;or relapsed&#160;or refractory&#160;disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
58&#160;<br/>
<hr/>
<a name=59></a><b>DEFERASIROX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Deferasirox&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;iron overload due to blood transfusions: pretreatment serum&#160;<br/>
<b>Medical&#160;</b><br/>
ferritin level is greater than 1000 mcg/L.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
59&#160;<br/>
<hr/>
<a name=60></a><b>DEMSER</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Metyrosine&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
60&#160;<br/>
<hr/>
<a name=61></a><b>DESVENLAFAXINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Desvenlafaxine Er&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Patient has&#160;experienced an inadequate treatment response, intolerance, or&#160;<br/>
<b>Medical&#160;</b><br/>
the patient has a contraindication to TWO of the following:&#160;serotonin&#160;and&#160;<br/>
<b>Information&#160;</b><br/>
norepinephrine reuptake&#160;inhibitors&#160;(SNRIs), selective serotonin&#160;reuptake&#160;<br/>inhibitors&#160;(SSRIs), mirtazapine, bupropion.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
61&#160;<br/>
<hr/>
<a name=62></a><b>DHE&#160;NASAL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Dihydroergotamine Mesylate&#160;<br/>
NASAL&#160;SOLN&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient has&#160;experienced an inadequate&#160;treatment response to one&#160;<br/>
<b>Medical&#160;</b><br/>
triptan 5-HT1 receptor&#160;agonist OR 2) The patient has experienced an&#160;<br/>
<b>Information&#160;</b><br/>
intolerance to one triptan 5-HT1 receptor&#160;agonist&#160;OR&#160;3) The patient has&#160;a&#160;<br/>contraindication that would prohibit&#160;a trial of triptan 5-HT1 receptor&#160;<br/>agonists.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
62&#160;<br/>
<hr/>
<a name=63></a><b>DIACOMIT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Diacomit&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
63&#160;<br/>
<hr/>
<a name=64></a><b>DIAZEPAM</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Diazepam&#160;CONC&#160;<br/>
•&#160;&#160;Diazepam&#160;INJ 5MG/ML&#160;<br/>
•&#160;&#160;Diazepam&#160;ORAL SOLN 5MG/5ML&#160;<br/>
•&#160;&#160;Diazepam&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For all&#160;indications: the prescriber must acknowledge the benefit&#160;of&#160;<br/>
<b>Medical&#160;</b><br/>
therapy with&#160;the requested drug outweighs the potential risks&#160;for the&#160;<br/>
<b>Information&#160;</b><br/>
patient. (Note: The&#160;American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.) For the management of&#160;anxiety disorders: 1)&#160;the&#160;requested&#160;<br/>drug is being used concurrently with a selective&#160;serotonin reuptake&#160;<br/>inhibitor&#160;(SSRI) or&#160;serotonin-norepinephrine reuptake&#160;inhibitor (SNRI)&#160;<br/>until&#160;the SSRI/SNRI becomes effective for the symptoms of&#160;anxiety, OR&#160;<br/>2) The patient has&#160;experienced an inadequate&#160;treatment response,&#160;<br/>intolerance,&#160;or has a contraindication&#160;to AT LEAST TWO&#160;agents from the&#160;<br/>following&#160;classes:&#160;a)&#160;selective serotonin reuptake inhibitors&#160;(SSRIs), b)&#160;<br/>serotonin-norepinephrine reuptake inhibitors&#160;(SNRIs).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Short-term relief&#160;anx-1&#160;mo, skeletal&#160;muscle spasm-3 mo, Anx Disorders-4&#160;<br/>
<b>Duration&#160;</b><br/>
mo, Other Diagnoses-PlanYR&#160;<br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older.&#160;<br/>
64&#160;<br/>
<hr/>
<a name=65></a><b>DICLOFENAC&#160;GEL&#160;1%</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Diclofenac&#160;Sodium&#160;GEL 1%&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has osteoarthritis pain in joints&#160;susceptible to topical treatment&#160;<br/>
<b>Medical&#160;</b><br/>
such as feet, ankles, knees, hands, wrists, or elbows.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
65&#160;<br/>
<hr/>
<a name=66></a><b>DICLOFENAC&#160;SOLN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pennsaid&#160;SOLN 2%&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
66&#160;<br/>
<hr/>
<a name=67></a><b>DOPTELET</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Doptelet&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;thrombocytopenia&#160;associated with chronic&#160;liver&#160;disease: Baseline&#160;<br/>
<b>Medical&#160;</b><br/>
platelet&#160;count prior to a&#160;scheduled procedure&#160;is less than 50,000/mcL. For&#160;<br/>
<b>Information&#160;</b><br/>
chronic immune thrombocytopenia (ITP): 1)&#160;For&#160;new starts: a) Patient has&#160;<br/>had an inadequate&#160;response or&#160;is intolerant&#160;to a prior therapy such as&#160;<br/>corticosteroids or immunoglobulins,&#160;AND b) Untransfused platelet count&#160;<br/>at any point&#160;prior to the&#160;initiation of the requested&#160;medication&#160;is less than&#160;<br/>30,000/mcL&#160;OR&#160;30,000 to 50,000/mcL&#160;with symptomatic bleeding or risk&#160;<br/>factor(s)&#160;for&#160;bleeding&#160;(e.g., undergoing a medical or dental procedure&#160;<br/>where blood&#160;loss&#160;is anticipated,&#160;comorbidities such as peptic ulcer&#160;disease&#160;<br/>and hypertension, anticoagulation therapy, profession or&#160;lifestyle&#160;that&#160;<br/>predisposes&#160;patient to&#160;trauma). 2) For continuation of therapy,&#160;platelet&#160;<br/>count response to the requested drug: a)&#160;Current platelet&#160;count is less than&#160;<br/>or equal to 200,000/mcL&#160;OR&#160;b) Current platelet count is greater than&#160;<br/>200,000/mcL and less&#160;than or&#160;equal to 400,000/mcL and dosing will be&#160;<br/>adjusted to a&#160;platelet&#160;count sufficient&#160;to avoid clinically important&#160;<br/>bleeding.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>18 years&#160;of age or older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Chronic&#160;liver&#160;disease:&#160;1&#160;month, ITP initial:&#160;6&#160;months, ITP reauthorization:&#160;<br/>
<b>Duration&#160;</b><br/>
Plan Year&#160;<br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
67&#160;<br/>
<hr/>
<a name=68></a><b>DRIZALMA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Drizalma Sprinkle&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Cancer&#160;pain,&#160;chemotherapy-induced&#160;neuropathic&#160;pain&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient has&#160;tried&#160;duloxetine capsules OR 2) The patient is unable to&#160;<br/>
<b>Medical&#160;</b><br/>
take&#160;duloxetine capsules&#160;for&#160;any reason (e.g., difficulty swallowing&#160;<br/>
<b>Information&#160;</b><br/>
capsules,&#160;requires nasogastric administration).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>Generalized&#160;Anxiety&#160;Disorder&#160;-&#160;7 years&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
68&#160;<br/>
<hr/>
<a name=69></a><b>DRONABINOL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Dronabinol&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chemotherapy-induced&#160;nausea and vomiting (CINV):&#160;The patient is&#160;<br/>
<b>Medical&#160;</b><br/>
receiving cancer&#160;chemotherapy AND&#160;has experienced an inadequate&#160;<br/>
<b>Information&#160;</b><br/>
treatment response, intolerance, or contraindication to one oral 5-HT3&#160;<br/>receptor&#160;antagonist.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
6 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
69&#160;<br/>
<hr/>
<a name=70></a><b>DUEXIS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Duexis&#160;<br/>
•&#160;&#160;Ibuprofen/famotidine&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has tried two different regimens containing any combination&#160;<br/>
<b>Medical&#160;</b><br/>
of a&#160;nonsteroidal anti-inflammatory&#160;drug (NSAID) and an acid blocker&#160;<br/>
<b>Information&#160;</b><br/>
from any of&#160;the following drug classes:&#160;H2-receptor&#160;antagonist&#160;(H2RA),&#160;<br/>proton pump inhibitor&#160;(PPI).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
70&#160;<br/>
<hr/>
<a name=71></a><b>EMSAM</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Emsam&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;Patient has experienced an inadequate treatment response, intolerance,&#160;<br/>
<b>Medical&#160;</b><br/>
or the patient has&#160;a contraindication&#160;to&#160;TWO of the&#160;following: serotonin&#160;<br/>
<b>Information&#160;</b><br/>
and norepinephrine&#160;reuptake&#160;inhibitors&#160;(SNRIs), selective&#160;serotonin&#160;<br/>reuptake inhibitors&#160;(SSRIs), mirtazapine, bupropion OR&#160;2) Patient is&#160;<br/>unable&#160;to&#160;swallow oral formulations.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
71&#160;<br/>
<hr/>
<a name=72></a><b>ENBREL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Enbrel&#160;<br/>
•&#160;&#160;Enbrel&#160;Mini&#160;<br/>
•&#160;&#160;Enbrel&#160;Sureclick&#160;<br/>
72&#160;<br/>
<hr/>
<a name=73></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Hidradenitis suppurativa&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For moderately&#160;to severely active rheumatoid arthritis (new&#160;starts&#160;only):&#160;<br/>
<b>Medical&#160;</b><br/>
1) Inadequate response,&#160;intolerance or contraindication to methotrexate&#160;<br/>
<b>Information&#160;</b><br/>
(MTX) OR 2) Inadequate response&#160;or intolerance to a prior biologic&#160;<br/>disease-modifying&#160;antirheumatic drug (DMARD) or&#160;a targeted synthetic&#160;<br/>DMARD. For&#160;active ankylosing spondylitis (new starts only):&#160;1)&#160;<br/>Inadequate response&#160;to a non-steroidal anti-inflammatory drug (NSAID)&#160;<br/>trial, OR&#160;2) Intolerance&#160;or contraindication to NSAIDs. For moderate to&#160;<br/>severe plaque psoriasis&#160;(new&#160;starts only): 1) At least&#160;3% of body surface&#160;<br/>area&#160;(BSA) is affected OR crucial body areas&#160;(e.g., feet, hands, face, neck,&#160;<br/>groin, intertriginous&#160;areas) are affected at&#160;the time of&#160;diagnosis, AND&#160;2)&#160;<br/>Patient meets any of the&#160;following: a) Patient has&#160;experienced&#160;an&#160;<br/>inadequate response&#160;or intolerance&#160;to&#160;either phototherapy&#160;(e.g., UVB,&#160;<br/>PUVA)&#160;or pharmacologic treatment with methotrexate, cyclosporine, or&#160;<br/>acitretin, OR b) Pharmacologic treatment&#160;with methotrexate,&#160;<br/>cyclosporine, or acitretin is contraindicated, OR c)&#160;Patient has&#160;severe&#160;<br/>psoriasis that warrants a&#160;biologic DMARD as first-line therapy (i.e. at&#160;<br/>least 10%&#160;of the BSA&#160;or crucial body&#160;areas&#160;(e.g.,&#160;hands, feet,&#160;face, neck,&#160;<br/>scalp, genitals/groin, intertriginous&#160;areas)&#160;are&#160;affected). For&#160;hidradenitis&#160;<br/>suppurativa&#160;(new starts only): patient has severe, refractory disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
73&#160;<br/>
<hr/>
<a name=74></a><b>ENHERTU</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Enhertu&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Non-small cell&#160;lung cancer&#160;with human epidermal growth factor receptor&#160;<br/>2 (HER2) mutations, HER2-amplified and RAS and BRAF&#160;wild-type&#160;<br/>colorectal cancer.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
74&#160;<br/>
<hr/>
<a name=75></a><b>EPCLUSA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Epclusa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For hepatitis&#160;C virus&#160;(HCV):&#160;Infection confirmed by presence of HCV&#160;<br/>
<b>Medical&#160;</b><br/>
RNA in the&#160;serum prior&#160;to starting treatment. Planned treatment regimen,&#160;<br/>
<b>Information&#160;</b><br/>
genotype, prior treatment history, presence&#160;or absence of&#160;cirrhosis&#160;<br/>(compensated or decompensated&#160;[Child Turcotte Pugh class&#160;B or C]),&#160;<br/>presence or&#160;absence of human immunodeficiency virus (HIV) coinfection,&#160;<br/>presence or&#160;absence of resistance-associated substitutions where&#160;<br/>applicable,&#160;liver and kidney transplantation status if&#160;applicable. Coverage&#160;<br/>conditions&#160;and specific durations of approval&#160;will&#160;be based on&#160;current&#160;<br/>AASLD treatment guidelines.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Criteria will&#160;be applied consistent with current AASLD-IDSA guidance.&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
75&#160;<br/>
<hr/>
<a name=76></a><b>EPIDIOLEX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Epidiolex&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
76&#160;<br/>
<hr/>
<a name=77></a><b>EPO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Procrit&#160;<br/>
77&#160;<br/>
<hr/>
<a name=78></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Anemia&#160;due&#160;to myelodysplastic syndromes (MDS), anemia in congestive&#160;<br/>heart&#160;failure&#160;(CHF), anemia in rheumatoid arthritis&#160;(RA), anemia due to&#160;<br/>hepatitis C treatment&#160;(ribavirin in combination with either interferon alfa&#160;<br/>or peginterferon alfa)&#160;<br/>
<b>Exclusion&#160;</b><br/>
Patients receiving&#160;chemotherapy with&#160;curative intent. Patients with&#160;<br/>
<b>Criteria&#160;</b><br/>
myeloid cancer.&#160;<br/>
<b>Required&#160;</b><br/>
Requirements regarding&#160;hemoglobin&#160;(Hgb) values exclude values&#160;due&#160;to a&#160;<br/>
<b>Medical&#160;</b><br/>
recent transfusion. For initial approval: 1)&#160;for&#160;all&#160;uses except anemia&#160;due&#160;<br/>
<b>Information&#160;</b><br/>
to chemotherapy or myelodysplastic&#160;syndrome (MDS): patient has&#160;<br/>adequate&#160;iron stores&#160;(defined as a transferrin saturation [TSAT] greater&#160;<br/>than or&#160;equal to 20%) AND&#160;2) for all uses except surgery: pretreatment&#160;<br/>(no erythropoietin treatment in previous month)&#160;Hgb is&#160;less than 10 g/dL&#160;<br/>(less than 9&#160;g/dL for anemia&#160;in congestive heart&#160;failure), AND&#160;3) for&#160;<br/>MDS: pretreatment serum erythropoietin level is&#160;500 international units/L&#160;<br/>or less. For reauthorizations (patient&#160;received erythropoietin&#160;treatment in&#160;<br/>previous&#160;month)&#160;in&#160;all&#160;uses except surgery: 1) patient&#160;has received at&#160;least&#160;<br/>12 weeks of&#160;erythropoietin therapy,&#160;AND 2) patient&#160;responded to&#160;<br/>erythropoietin therapy,&#160;AND 3) current Hgb is&#160;less than 12 g/dL, AND&#160;4)&#160;<br/>for&#160;all uses&#160;except&#160;anemia due to chemotherapy or MDS: patient has&#160;<br/>adequate&#160;iron stores&#160;(defined as a&#160;TSAT&#160;greater&#160;than or&#160;equal&#160;to 20%).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
16 weeks&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;includes&#160;use&#160;in&#160;anemia in&#160;patients whose religious&#160;beliefs&#160;forbid&#160;<br/>blood transfusions. Coverage under&#160;Part&#160;D will&#160;be denied&#160;if&#160;coverage&#160;is&#160;<br/>available under&#160;Part&#160;A or Part B as&#160;the medication is&#160;prescribed and&#160;<br/>dispensed or administered for&#160;the individual (e.g.,&#160;used for treatment of&#160;<br/>anemia for&#160;a&#160;patient with&#160;chronic renal failure&#160;who is undergoing dialysis,&#160;<br/>or furnished&#160;from physician's supply incident&#160;to a physician service).&#160;<br/>
78&#160;<br/>
<hr/>
<a name=79></a><b>ERIVEDGE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Erivedge&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Adult medulloblastoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For adult&#160;medulloblastoma:&#160;patient&#160;has received&#160;chemotherapy previously&#160;<br/>
<b>Medical&#160;</b><br/>
AND has tumor(s) with&#160;mutations&#160;in&#160;the sonic hedgehog pathway&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
79&#160;<br/>
<hr/>
<a name=80></a><b>ERLEADA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Erleada&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The requested&#160;drug will&#160;be used in combination with a gonadotropin-<br/>
<b>Medical&#160;</b><br/>
releasing hormone (GnRH) analog or&#160;after bilateral orchiectomy.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
80&#160;<br/>
<hr/>
<a name=81></a><b>ERLOTINIB</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Erlotinib Hydrochloride&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent or&#160;advanced non-small cell lung cancer (NSCLC), recurrent&#160;<br/>chordoma, relapsed or stage IV renal&#160;cell&#160;carcinoma (RCC), brain&#160;<br/>metastases from&#160;NSCLC.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For NSCLC&#160;(including brain&#160;metastases from NSCLC): 1)&#160;the disease&#160;is&#160;<br/>
<b>Medical&#160;</b><br/>
recurrent,&#160;advanced, or&#160;metastatic&#160;and 2) the patient has sensitizing EGFR&#160;<br/>
<b>Information&#160;</b><br/>
mutation-positive disease. For pancreatic cancer: the disease&#160;is locally&#160;<br/>advanced, unresectable,&#160;or&#160;metastatic.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
81&#160;<br/>
<hr/>
<a name=82></a><b>ESBRIET</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Esbriet&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For idiopathic&#160;pulmonary fibrosis (Initial Review Only): 1)&#160;a high-<br/>
<b>Medical&#160;</b><br/>
resolution computed&#160;tomography (HRCT) study of the chest or&#160;a&#160;lung&#160;<br/>
<b>Information&#160;</b><br/>
biopsy reveals the usual interstitial pneumonia&#160;(UIP) pattern,&#160;OR&#160;2)&#160;<br/>HRCT study&#160;of the chest&#160;reveals a&#160;result&#160;other&#160;than the UIP pattern&#160;(e.g.,&#160;<br/>probable UIP, indeterminate&#160;for UIP)&#160;and the&#160;diagnosis is&#160;supported either&#160;<br/>by a lung biopsy or by a&#160;multidisciplinary discussion between at least&#160;a&#160;<br/>radiologist and pulmonologist&#160;who are experienced in idiopathic&#160;<br/>pulmonary fibrosis if&#160;a lung biopsy&#160;has not&#160;been&#160;conducted.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
82&#160;<br/>
<hr/>
<a name=83></a><b>EVEROLIMUS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Afinitor&#160;TABS&#160;10MG&#160;<br/>
•&#160;&#160;&#160;Afinitor Disperz&#160;<br/>
•&#160;&#160;&#160;Everolimus&#160;TABS&#160;10MG, 2.5MG,&#160;<br/>
5MG, 7.5MG&#160;<br/>
•&#160;&#160;&#160;Everolimus&#160;TBSO&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Classic Hodgkin&#160;lymphoma, thymomas and thymic carcinomas,&#160;<br/>Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma, soft&#160;<br/>tissue sarcoma (perivascular&#160;epithelioid cell&#160;tumors (PEComa)&#160;and&#160;<br/>lymphangioleiomyomatosis&#160;subtypes), gastrointestinal stromal tumors,&#160;<br/>neuroendocrine tumors&#160;of the&#160;thymus, thyroid&#160;carcinoma&#160;(papillary,&#160;<br/>Hurthle cell,&#160;and follicular), endometrial carcinoma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For breast&#160;cancer: 1)&#160;The disease is&#160;recurrent or metastatic&#160;hormone&#160;<br/>
<b>Medical&#160;</b><br/>
receptor&#160;(HR)-positive,&#160;human epidermal growth factor receptor&#160;2&#160;<br/>
<b>Information&#160;</b><br/>
(HER2)-negative, AND&#160;2) The requested medication is prescribed in&#160;<br/>combination&#160;with exemestane, fulvestrant, or&#160;tamoxifen, AND&#160;3) The&#160;<br/>requested medication is&#160;used for subsequent&#160;treatment. For&#160;renal cell&#160;<br/>carcinoma:&#160;The disease&#160;is relapsed,&#160;advanced, or&#160;stage IV. For&#160;<br/>subependymal giant cell astrocytoma&#160;(SEGA):&#160;The requested drug is&#160;<br/>given as adjuvant treatment.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
83&#160;<br/>
<hr/>
<a name=84></a><b>EXKIVITY</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Exkivity&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
84&#160;<br/>
<hr/>
<a name=85></a><b>FANAPT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fanapt&#160;<br/>
•&#160;&#160;Fanapt Titration Pack&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;experienced&#160;an inadequate treatment response, intolerance, or&#160;<br/>
<b>Medical&#160;</b><br/>
contraindication to one of the following generic products: A)&#160;aripiprazole,&#160;<br/>
<b>Information&#160;</b><br/>
B) asenapine, C) olanzapine, D) quetiapine, E)&#160;risperidone, F) ziprasidone&#160;<br/>AND the patient&#160;experienced an inadequate&#160;treatment&#160;response,&#160;<br/>intolerance,&#160;or contraindication to one of&#160;the following brand&#160;products: A)&#160;<br/>Latuda, B) Rexulti, C)&#160;Secuado.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
85&#160;<br/>
<hr/>
<a name=86></a><b>FARYDAK</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Farydak&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
86&#160;<br/>
<hr/>
<a name=87></a><b>FASENRA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fasenra&#160;<br/>
•&#160;&#160;Fasenra Pen&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For severe&#160;asthma: For&#160;initial therapy: 1)&#160;Either&#160;a)&#160;Patient&#160;has baseline&#160;<br/>
<b>Medical&#160;</b><br/>
blood eosinophil count&#160;of at&#160;least 150 cells per&#160;microliter OR b) Patient&#160;is&#160;<br/>
<b>Information&#160;</b><br/>
dependent&#160;on systemic corticosteroids, and 2)&#160;Patient&#160;has a history of&#160;<br/>severe&#160;asthma despite current treatment&#160;with&#160;both of&#160;the following&#160;<br/>medications&#160;at optimized&#160;doses: a) inhaled corticosteroid and&#160;b) additional&#160;<br/>controller (long-acting beta2-agonist, leukotriene&#160;modifier, or sustained-<br/>release theophylline).&#160;For continuation of therapy: Asthma control has&#160;<br/>improved on&#160;treatment with the requested drug, as&#160;demonstrated by a&#160;<br/>reduction in&#160;the frequency and/or&#160;severity of&#160;symptoms and&#160;exacerbations&#160;<br/>or a&#160;reduction in the daily maintenance oral corticosteroid dose.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>12 years&#160;of age or older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
87&#160;<br/>
<hr/>
<a name=88></a><b>FENTANYL&#160;PATCH</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fentanyl&#160;PT72&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being prescribed for pain&#160;associated&#160;with cancer,&#160;<br/>
<b>Medical&#160;</b><br/>
sickle cell disease, a&#160;terminal condition, or pain&#160;being managed through&#160;<br/>
<b>Information&#160;</b><br/>
palliative&#160;care&#160;OR&#160;2) The requested&#160;drug is being prescribed&#160;for&#160;pain&#160;<br/>severe&#160;enough to require&#160;daily, around-the-clock,&#160;long-term&#160;treatment in&#160;a&#160;<br/>patient who has been taking an opioid&#160;AND 3) The patient can safely take&#160;<br/>the requested dose based&#160;on their history of&#160;opioid use [Note: This drug&#160;<br/>should be prescribed only by healthcare&#160;professionals&#160;who are&#160;<br/>knowledgeable&#160;in&#160;the use of potent opioids for the management of chronic&#160;<br/>pain.]&#160;AND 4) The patient has&#160;been&#160;evaluated and the patient&#160;will&#160;be&#160;<br/>monitored&#160;for the development of opioid use disorder&#160;AND 5) This&#160;<br/>request&#160;is for continuation of therapy&#160;for&#160;a patient&#160;who has been receiving&#160;<br/>an extended-release&#160;opioid agent&#160;for at least&#160;30 days OR the patient has&#160;<br/>taken an&#160;immediate-release opioid for at&#160;least one week.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
88&#160;<br/>
<hr/>
<a name=89></a><b>FETZIMA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fetzima&#160;<br/>
•&#160;&#160;Fetzima Titration Pack&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has experienced an inadequate&#160;treatment response,&#160;<br/>
<b>Medical&#160;</b><br/>
intolerance,&#160;or the patient has&#160;a contraindication&#160;to&#160;TWO of the&#160;following:&#160;<br/>
<b>Information&#160;</b><br/>
serotonin and norepinephrine reuptake inhibitors&#160;(SNRIs), selective&#160;<br/>serotonin reuptake&#160;inhibitors&#160;(SSRIs), mirtazapine, bupropion.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
89&#160;<br/>
<hr/>
<a name=90></a><b>FINTEPLA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fintepla&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
90&#160;<br/>
<hr/>
<a name=91></a><b>FLUOROURACIL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fluoroplex&#160;CREA&#160;<br/>
•&#160;&#160;Fluorouracil&#160;CREA&#160;5%&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
Patients who&#160;are&#160;pregnant or&#160;may become&#160;pregnant. Fluorouracil cream&#160;5&#160;<br/>
<b>Criteria&#160;</b><br/>
percent only: Patients with dihydropyrimidine dehydrogenase (DPD)&#160;<br/>enzyme deficiency.&#160;<br/>
<b>Required&#160;</b><br/>
Applies to&#160;new starts only. If&#160;being used as part of a&#160;compounded product,&#160;<br/>
<b>Medical&#160;</b><br/>
all&#160;active ingredients in&#160;the compounded product are FDA&#160;approved for&#160;<br/>
<b>Information&#160;</b><br/>
topical use.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
3 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
91&#160;<br/>
<hr/>
<a name=92></a><b>FORTAMET/GLUMETZA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Metformin&#160;Hydrochloride Er&#160;TB24&#160;<br/>
500MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has experienced an intolerance&#160;to generic&#160;Glucophage XR.&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
92&#160;<br/>
<hr/>
<a name=93></a><b>FORTEO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Forteo&#160;INJ 620MCG/2.48ML&#160;<br/>
93&#160;<br/>
<hr/>
<a name=94></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For postmenopausal&#160;osteoporosis: patient has&#160;ONE of the following (1 or&#160;<br/>
<b>Medical&#160;</b><br/>
2):&#160;1) a&#160;history of&#160;fragility fracture, OR 2) A pre-treatment T-score of&#160;less&#160;<br/>
<b>Information&#160;</b><br/>
than or&#160;equal to&#160;-2.5 or pre-treatment&#160;T-score greater&#160;than&#160;-2.5 and less&#160;<br/>than -1 with&#160;a high pre-treatment Fracture Risk Assessment Tool (FRAX)&#160;<br/>fracture probability AND&#160;patient has ANY of the following:&#160;a)&#160;indicators&#160;<br/>for&#160;higher fracture risk (e.g., advanced age, frailty, glucocorticoid therapy,&#160;<br/>very low T-scores, or&#160;increased&#160;fall&#160;risk), OR&#160;b) patient has&#160;failed prior&#160;<br/>treatment with or&#160;is intolerant&#160;to a previous&#160;injectable&#160;osteoporosis&#160;<br/>therapy OR&#160;c)&#160;patient has had an oral&#160;bisphosphonate&#160;trial of&#160;at least&#160;1-<br/>year&#160;duration or there is&#160;a clinical reason to avoid treatment with an oral&#160;<br/>bisphosphonate. For primary or hypogonadal&#160;osteoporosis&#160;in&#160;men:&#160;patient&#160;<br/>has one&#160;of the following: 1)&#160;a history of osteoporotic vertebral or hip&#160;<br/>fracture, OR&#160;2) pre-treatment T-score of less than or equal&#160;to&#160;-2.5, OR&#160;3)&#160;<br/>pre-treatment T-score greater&#160;than&#160;-2.5 and less&#160;than&#160;-1 with a&#160;high pre-<br/>treatment FRAX fracture probability. For glucocorticoid-induced&#160;<br/>osteoporosis: Patient has&#160;had an oral&#160;bisphosphonate&#160;trial of&#160;at&#160;least 1-<br/>year&#160;duration unless patient has a contraindication or intolerance to an&#160;<br/>oral bisphosphonate, AND patient&#160;meets ANY of the following: 1)&#160;patient&#160;<br/>has a&#160;history&#160;of fragility&#160;fracture, OR&#160;2) a&#160;pre-treatment T-score&#160;of less&#160;<br/>than or&#160;equal to&#160;-2.5, OR&#160;3) pre-treatment T-score greater&#160;than -2.5 and&#160;<br/>less than -1&#160;with a&#160;high&#160;pre-treatment FRAX&#160;fracture&#160;probability.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
24 months&#160;total&#160;unless&#160;the patient remains&#160;at high risk for fracture&#160;and&#160;<br/>
<b>Duration&#160;</b><br/>
benefit outweighs&#160;risk&#160;<br/>
<b>Other Criteria&#160;</b><br/>
Patient has&#160;high FRAX fracture probability if the&#160;10 year&#160;probability is&#160;<br/>either greater than or&#160;equal to 20 percent for any&#160;major osteoporotic&#160;<br/>fracture or greater than or equal to 3&#160;percent for hip fracture. If&#160;<br/>glucocorticoid treatment&#160;is greater than 7.5 mg (prednisone&#160;equivalent)&#160;<br/>per&#160;day, the&#160;estimated risk score generated with FRAX should&#160;be&#160;<br/>multiplied by 1.15 for major&#160;osteoporotic fracture and 1.2 for&#160;hip fracture.&#160;<br/>
94&#160;<br/>
<hr/>
<a name=95></a><b>FOTIVDA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fotivda&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For advanced&#160;renal cell&#160;carcinoma:&#160;The following criteria must be met:&#160;1)&#160;<br/>
<b>Medical&#160;</b><br/>
The disease&#160;is relapsed or refractory,&#160;2) The requested medication must&#160;be&#160;<br/>
<b>Information&#160;</b><br/>
used after at&#160;least two prior&#160;systemic therapies, and 3) The patient has&#160;<br/>experienced&#160;disease progression or an&#160;intolerable adverse&#160;event with a&#160;<br/>trial of&#160;cabozantinib.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
95&#160;<br/>
<hr/>
<a name=96></a><b>FYCOMPA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fycompa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For treatment&#160;of partial-onset&#160;seizures:&#160;1) The patient experienced an&#160;<br/>
<b>Medical&#160;</b><br/>
inadequate treatment response, intolerance, or contraindication to a&#160;<br/>
<b>Information&#160;</b><br/>
generic anticonvulsant&#160;AND 2) The&#160;patient has&#160;experienced&#160;an inadequate&#160;<br/>treatment response, intolerance, or contraindication to any of&#160;the&#160;<br/>following:&#160;Aptiom, Vimpat, Xcopri, Spritam. For adjunctive treatment&#160;of&#160;<br/>primary&#160;generalized&#160;tonic-clonic seizures: 1) The&#160;patient experienced an&#160;<br/>inadequate treatment response, intolerance, or contraindication to a&#160;<br/>generic anticonvulsant&#160;AND 2) The&#160;patient experienced an inadequate&#160;<br/>treatment response, intolerance, or contraindication to one of&#160;the&#160;<br/>following:&#160;Vimpat, Spritam.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>Partial-onset seizures: 4&#160;years of&#160;age&#160;or older. Primary generalized&#160;tonic-<br/>
clonic&#160;seizures: 12 years&#160;of&#160;age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
96&#160;<br/>
<hr/>
<a name=97></a><b>GATTEX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Gattex&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For short&#160;bowel syndrome (SBS) initial therapy:&#160;Adult patients were&#160;<br/>
<b>Medical&#160;</b><br/>
dependent&#160;on parenteral&#160;support for at least 12&#160;months. For SBS&#160;<br/>
<b>Information&#160;</b><br/>
continuation: Requirement for parenteral support&#160;has decreased from&#160;<br/>baseline&#160;while on therapy with the requested&#160;medication.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
97&#160;<br/>
<hr/>
<a name=98></a><b>GAVRETO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Gavreto&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent or&#160;advanced rearranged during transfection (RET)&#160;<br/>rearrangement-positive non-small cell lung cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For non-small&#160;cell&#160;lung cancer, patient must meet&#160;all&#160;of the&#160;following:&#160;1)&#160;<br/>
<b>Medical&#160;</b><br/>
The disease&#160;is recurrent,&#160;advanced, or metastatic,&#160;and 2)&#160;The tumor&#160;is&#160;<br/>
<b>Information&#160;</b><br/>
rearranged during transfection&#160;(RET) fusion-positive or&#160;RET&#160;<br/>rearrangement-positive.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>Non-small cell&#160;lung cancer:&#160;18 years&#160;of age or&#160;older.&#160;Medullary thyroid&#160;<br/>
cancer&#160;and thyroid cancer:&#160;12 years&#160;of age or&#160;older.&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
98&#160;<br/>
<hr/>
<a name=99></a><b>GILENYA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Gilenya&#160;CAPS 0.5MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
99&#160;<br/>
<hr/>
<a name=100></a><b>GILOTRIF</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Gilotrif&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For non-small&#160;cell&#160;lung cancer (NSCLC): Patient&#160;meets either of the&#160;<br/>
<b>Medical&#160;</b><br/>
following:&#160;<br/>
<b>Information&#160;</b><br/>
1) Patient has metastatic&#160;squamous NSCLC that progressed after&#160;<br/>platinum-based chemotherapy, OR&#160;2) Patient has&#160;sensitizing&#160;EGFR&#160;<br/>mutation-positive disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
100&#160;<br/>
<hr/>
<a name=101></a><b>GLATIRAMER</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Copaxone&#160;INJ 20MG/ML, 40MG/ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
101&#160;<br/>
<hr/>
<a name=102></a><b>GROWTH&#160;HORMONE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Genotropin&#160;<br/>
•&#160;&#160;Genotropin&#160;Miniquick&#160;<br/>
102&#160;<br/>
<hr/>
<a name=103></a><b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All Medically-accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
Pediatric patients&#160;with closed epiphyses (except in patients with PWS).&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Pediatric growth&#160;hormone deficiency (GHD):&#160;Patient (pt) meets&#160;any of&#160;the&#160;<br/>
<b>Medical&#160;</b><br/>
following: 1) younger than 2.5 years&#160;old (yo) with pre-treatment (pre-tx)&#160;<br/>
<b>Information&#160;</b><br/>
height&#160;(ht)&#160;more&#160;than 2 standard deviations&#160;(SD)&#160;below mean&#160;and slow&#160;<br/>growth velocity OR&#160;2) 2.5 yo or older AND&#160;one&#160;of the following: a) pre-<br/>tx 1-year ht&#160;velocity more than 2 SD below mean OR b) pre-tx&#160;ht more&#160;<br/>than 2 SD below mean and 1-year&#160;ht&#160;velocity more than 1 SD below&#160;<br/>mean, AND patient meets any of the&#160;following: 1) failed 2 pre-tx growth&#160;<br/>hormone (GH) stimulation tests (peak below 10 ng/mL), OR&#160;2)&#160;<br/>pituitary/central nervous&#160;system (CNS) disorder (e.g., genetic defects,&#160;<br/>CNS tumors, congenital&#160;structural abnormalities)&#160;and pre-tx insulin-like&#160;<br/>growth factor-1 (IGF-1) more&#160;than 2 SD below mean, OR&#160;3) pt&#160;is a&#160;<br/>neonate or&#160;was diagnosed with GHD&#160;as a neonate. Turner syndrome: 1)&#160;<br/>Confirmed by karyotyping AND 2) pre-tx ht is&#160;less than the 5th percentile&#160;<br/>for&#160;age. Small&#160;for gestational age&#160;(GA): 1)&#160;Birth&#160;weight (wt) less than&#160;<br/>2500g at GA greater than 37 weeks, OR birth wt or length below&#160;3rd&#160;<br/>percentile for GA or at&#160;least 2 SD below mean for GA, AND&#160;2) did not&#160;<br/>manifest&#160;catch-up growth by age 2.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>SGA:&#160;2 years of&#160;age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
Endocrinologist,&#160;pediatric endocrinologist, pediatric nephrologist,&#160;<br/>
<b>Restrictions&#160;</b><br/>
infectious disease specialist, gastroenterologist/nutritional support&#160;<br/>specialist, geneticist.&#160;<br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Adult GHD: Pt&#160;meets any of the following: 1) failed 2 pre-tx&#160;GH&#160;<br/>stimulation tests, OR&#160;2) pre-tx&#160;IGF-1&#160;more&#160;than 2 SD below mean AND&#160;<br/>failed 1 pre-tx GH stimulation test. (Note:&#160;Stimulation tests include: a)&#160;<br/>insulin&#160;tolerance test [ITT] [peak GH less&#160;than or&#160;equal&#160;to 5 ng/ml], or b)&#160;<br/>Macrelin-stimulation test [peak GH level&#160;less than 2.8ng/ml],&#160;or c)&#160;<br/>glucagon-stimulation test [GST] [peak GH&#160;level less than or equal to 3&#160;<br/>ng/ml] for pt with a body&#160;mass index&#160;[BMI] 25-30 kg/m2 and&#160;high pretest&#160;<br/>probability&#160;of GHD&#160;[e.g., acquired structural abnormalities] or BMI&#160;less&#160;<br/>than 25 kg/m2, or d)&#160;GST [peak GH level&#160;less than or equal to 1 ng/ml] in&#160;<br/>pt with BMI&#160;25-30 kg/m2 and low pretest probability of GHD or BMI&#160;<br/>
103&#160;<br/>
<hr/>
<a name=104></a>greater than&#160;30 kg/m2), OR 3) organic hypothalamic-pituitary disease&#160;<br/>(e.g., suprasellar mass with previous&#160;surgery and&#160;cranial irradiation)&#160;with&#160;<br/>3 or more&#160;pituitary hormone deficiencies AND pre-tx IGF-1&#160;more&#160;than 2&#160;<br/>SD&#160;below mean, OR&#160;4) genetic or structural hypothalamic-pituitary&#160;<br/>defects, OR 5) childhood-onset&#160;GHD with congenital (genetic&#160;or&#160;<br/>structural)&#160;abnormality&#160;of the hypothalamus/pituitary/CNS. Renewal for&#160;<br/>pediatric GHD, TS, SGA, and adult GHD: Patient is experiencing&#160;<br/>improvement.&#160;<br/>
104&#160;<br/>
<hr/>
<a name=105></a><b>HAEGARDA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Haegarda&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The requested&#160;drug is being used for the prevention of&#160;acute angioedema&#160;<br/>
<b>Medical&#160;</b><br/>
attacks. Patient has hereditary angioedema&#160;(HAE) with C1 inhibitor&#160;<br/>
<b>Information&#160;</b><br/>
deficiency or dysfunction confirmed by laboratory testing OR&#160;patient has&#160;<br/>hereditary angioedema&#160;with normal C1 inhibitor&#160;confirmed&#160;by laboratory&#160;<br/>testing. For&#160;patients with HAE with&#160;normal C1 inhibitor, EITHER 1)&#160;<br/>Patient tested positive for an F12, angiopoietin-1, plasminogen, or&#160;<br/>kininogen-1&#160;(KNG1) gene mutation&#160;OR&#160;2) Patient has a&#160;family history of&#160;<br/>angioedema and the angioedema was&#160;refractory to a trial of an&#160;<br/>antihistamine for at least one month.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
Immunologist,&#160;allergist,&#160;rheumatologist&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
105&#160;<br/>
<hr/>
<a name=106></a><b>HARVONI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Harvoni&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;hepatitis&#160;C virus&#160;(HCV):&#160;Infection confirmed by presence of HCV&#160;<br/>
<b>Medical&#160;</b><br/>
RNA in the&#160;serum prior&#160;to starting treatment. Planned treatment regimen,&#160;<br/>
<b>Information&#160;</b><br/>
genotype, prior treatment history, presence&#160;or absence of&#160;cirrhosis&#160;<br/>(compensated or decompensated&#160;[Child Turcotte&#160;Pugh&#160;class&#160;B or C]),&#160;<br/>presence or&#160;absence of human immunodeficiency virus (HIV) coinfection,&#160;<br/>presence or&#160;absence of resistance-associated substitutions where&#160;<br/>applicable,&#160;liver and kidney transplantation status if&#160;applicable. Coverage&#160;<br/>conditions&#160;and specific durations of approval&#160;will&#160;be based on&#160;current&#160;<br/>AASLD treatment guidelines.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Criteria applied&#160;consistent w/ current AASLD-IDSA&#160;guidance. Reminder&#160;<br/>
<b>Duration&#160;</b><br/>
for&#160;8wk option if appropriate.&#160;<br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
106&#160;<br/>
<hr/>
<a name=107></a><b>HERCEPTIN&#160;HYLECTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Herceptin Hylecta&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Neoadjuvant&#160;treatment&#160;for human epidermal growth factor&#160;receptor&#160;2&#160;<br/>(HER2)-positive breast cancer,&#160;recurrent or&#160;advanced unresectable HER2-<br/>positive breast&#160;cancer.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Neoadjuvant&#160;therapy&#160;for&#160;breast&#160;cancer: 6 months, Other: Plan&#160;Year.&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
107&#160;<br/>
<hr/>
<a name=108></a><b>HETLIOZ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Hetlioz&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For Non-24-Hour&#160;Sleep-Wake&#160;Disorder: 1)&#160;for&#160;initial therapy&#160;and&#160;<br/>
<b>Medical&#160;</b><br/>
continuation&#160;of therapy:&#160;a)&#160;diagnosis&#160;of total blindness in both eyes (e.g.,&#160;<br/>
<b>Information&#160;</b><br/>
nonfunctioning retinas)&#160;and b) unable to perceive&#160;light&#160;in either eye, AND&#160;<br/>2) if currently on therapy&#160;with the&#160;requested drug,&#160;patient must meet at&#160;<br/>least one of&#160;the following: a)&#160;increased total nighttime sleep or b)&#160;<br/>decreased daytime nap&#160;duration. For nighttime sleep disturbances&#160;in&#160;<br/>Smith-Magenis Syndrome (SMS): 1)&#160;for&#160;initial&#160;therapy and continuation&#160;<br/>therapy,&#160;the patient has&#160;a&#160;confirmed diagnosis of&#160;SMS AND&#160;2) if&#160;<br/>currently on&#160;therapy with&#160;the requested drug, the patient experiences&#160;<br/>improvement in the quality of&#160;sleep since starting&#160;therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>Non-24:&#160;18 years of&#160;age&#160;or older. SMS: 16 years&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
Sleep disorder&#160;specialist&#160;or neurologist&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Initiation:&#160;6&#160;Months, Renewal:&#160;Plan&#160;Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
108&#160;<br/>
<hr/>
<a name=109></a><b>HETLIOZ&#160;LQ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Hetlioz Lq&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;nighttime&#160;sleep disturbances in Smith-Magenis Syndrome (SMS):&#160;1)&#160;<br/>
<b>Medical&#160;</b><br/>
for&#160;initial&#160;therapy and continuation therapy, the patient has&#160;a&#160;confirmed&#160;<br/>
<b>Information&#160;</b><br/>
diagnosis of&#160;SMS AND&#160;2) if currently on therapy&#160;with the&#160;requested drug,&#160;<br/>the patient&#160;experiences improvement in the&#160;quality of sleep&#160;since starting&#160;<br/>therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>3 to&#160;15 years of age&#160;<br/>
<b>Prescriber&#160;</b><br/>
Sleep disorder&#160;specialist&#160;or neurologist&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Initiation:&#160;6&#160;Months, Renewal:&#160;Plan&#160;Year.&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
109&#160;<br/>
<hr/>
<a name=110></a><b>HIGH&#160;RISK&#160;MEDICATION&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Chlordiazepoxide/amitriptyline&#160;<br/>
•&#160;&#160;&#160;Dicyclomine Hcl&#160;SOLN&#160;<br/>
•&#160;&#160;&#160;Dicyclomine&#160;Hydrochloride&#160;CAPS&#160;<br/>
•&#160;&#160;&#160;Dicyclomine Hydrochloride&#160;INJ&#160;<br/>
•&#160;&#160;&#160;Dicyclomine Hydrochloride&#160;TABS&#160;<br/>
•&#160;&#160;&#160;Dihydroergotamine Mesylate&#160;INJ&#160;<br/>
•&#160;&#160;&#160;Diphenhydramine&#160;Hcl&#160;INJ 50MG/ML&#160;<br/>
•&#160;&#160;&#160;Dipyridamole&#160;TABS&#160;<br/>
•&#160;&#160;&#160;Disopyramide Phosphate&#160;CAPS&#160;<br/>
•&#160;&#160;&#160;Guanfacine Er&#160;TB24 1MG, 2MG,&#160;<br/>
4MG&#160;<br/>
•&#160;&#160;&#160;Guanfacine Hcl&#160;<br/>
•&#160;&#160;&#160;Guanfacine Hydrochloride&#160;TB24&#160;<br/>
3MG&#160;<br/>
•&#160;&#160;&#160;Ketorolac Tromethamine&#160;INJ&#160;<br/>
15MG/ML, 30MG/ML&#160;<br/>
•&#160;&#160;&#160;Ketorolac Tromethamine&#160;TABS&#160;<br/>
•&#160;&#160;&#160;Meprobamate&#160;<br/>
•&#160;&#160;&#160;Methscopolamine&#160;Bromide&#160;TABS&#160;<br/>
•&#160;&#160;&#160;Methyldopa&#160;TABS&#160;250MG, 500MG&#160;<br/>
•&#160;&#160;&#160;Perphenazine/amitriptyline&#160;<br/>
•&#160;&#160;&#160;Thioridazine Hcl&#160;TABS&#160;100MG,&#160;<br/>
10MG, 25MG, 50MG&#160;<br/>
•&#160;&#160;&#160;Trimethobenzamide Hydrochloride&#160;<br/>
110&#160;<br/>
<hr/>
<a name=111></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning&#160;it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
111&#160;<br/>
<hr/>
<a name=112></a><b>HRM&#160;-&#160;ANTICONVULSANTS&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Phenobarbital&#160;ELIX 20MG/5ML&#160;<br/>
•&#160;&#160;&#160;Phenobarbital&#160;TABS&#160;100MG, 15MG,&#160;<br/>
16.2MG, 30MG, 32.4MG, 60MG,&#160;<br/>64.8MG, 97.2MG&#160;<br/>
•&#160;&#160;&#160;Phenobarbital Sodium&#160;INJ&#160;<br/>
130MG/ML, 65MG/ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Epilepsy&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
112&#160;<br/>
<hr/>
<a name=113></a><b>HRM&#160;-&#160;HYPNOTICS&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Eszopiclone&#160;<br/>
•&#160;&#160;Zaleplon&#160;<br/>
•&#160;&#160;Zolpidem Tartrate&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient has&#160;a contraindication&#160;to the non-HRM (non-High Risk&#160;<br/>
<b>Medical&#160;</b><br/>
Medication) alternative&#160;drug doxepin (3 mg or 6&#160;mg)&#160;OR&#160;2) The non-<br/>
<b>Information&#160;</b><br/>
HRM (non-High Risk Medication)&#160;alternative&#160;drug doxepin (3 mg or 6&#160;<br/>mg)&#160;has been tried AND 3)&#160;The patient experienced an inadequate&#160;<br/>treatment response&#160;OR&#160;intolerance to the non-HRM (non-High Risk&#160;<br/>Medication) alternative&#160;drug doxepin (3 mg or 6&#160;mg)&#160;AND 4) If&#160;the&#160;<br/>patient is using two or more&#160;additional central nervous system (CNS)&#160;<br/>active medications&#160;(e.g.,&#160;lorazepam,&#160;quetiapine, sertraline, clonazepam,&#160;<br/>escitalopram, alprazolam) with the requested drug, the prescriber has&#160;<br/>determined&#160;that taking multiple central nervous&#160;system&#160;(CNS) active&#160;<br/>medications&#160;is medically necessary for the patient&#160;[Note: Use of multiple&#160;<br/>central nervous system&#160;(CNS) active&#160;medications&#160;in older adults is&#160;<br/>associated with an&#160;increased risk of falls.].&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.) Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;<br/>this prescribed medication outweighs the potential risks for this patient.&#160;<br/>
113&#160;<br/>
<hr/>
<a name=114></a>114&#160;<br/>
<hr/>
<a name=115></a><b>HRM&#160;-&#160;SCOPOLAMINE&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Scopolamine&#160;PT72 1MG/3DAYS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Excessive salivation&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
115&#160;<br/>
<hr/>
<a name=116></a><b>HRM-ANTIPARKINSON&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Benztropine&#160;Mesylate&#160;INJ&#160;<br/>
•&#160;&#160;Benztropine&#160;Mesylate&#160;TABS&#160;<br/>
•&#160;&#160;Trihexyphenidyl&#160;Hcl&#160;SOLN&#160;<br/>
•&#160;&#160;Trihexyphenidyl&#160;Hydrochloride&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
EPS&#160;(extrapyramidal&#160;symptoms): 1)&#160;The patient&#160;has not&#160;tried&#160;the non-<br/>
<b>Medical&#160;</b><br/>
HRM alternative drug amantadine AND&#160;2) The&#160;patient has&#160;a&#160;<br/>
<b>Information&#160;</b><br/>
contraindication to&#160;the non-HRM alternative drug amantadine OR 3) The&#160;<br/>patient has&#160;tried&#160;the non-HRM alternative drug amantadine AND&#160;4) The&#160;<br/>patient experienced an inadequate&#160;treatment response OR intolerance to&#160;<br/>the non-HRM alternative drug amantadine. Parkinson's:&#160;1) The patient has&#160;<br/>tried two of&#160;the following non-HRM alternative drugs: amantadine,&#160;<br/>carbidopa/levodopa, pramipexole, or ropinirole. AND&#160;2) The&#160;patient&#160;<br/>experienced&#160;an inadequate treatment response OR intolerance to two of&#160;<br/>the following non-HRM alternative drugs: amantadine,&#160;<br/>carbidopa/levodopa, pramipexole, or ropinirole.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning&#160;it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
116&#160;<br/>
<hr/>
<a name=117></a>117&#160;<br/>
<hr/>
<a name=118></a><b>HRM-CYPROHEPTADINE&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Cyproheptadine Hcl&#160;SYRP&#160;<br/>
•&#160;&#160;Cyproheptadine Hydrochloride&#160;TABS&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Pruritus,&#160;spasticity due&#160;to&#160;spinal cord injury&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For rhinitis:&#160;1) The patient has&#160;tried&#160;two of the following non-HRM&#160;<br/>
<b>Medical&#160;</b><br/>
alternative drugs: levocetirizine, azelastine nasal,&#160;fluticasone&#160;nasal, or&#160;<br/>
<b>Information&#160;</b><br/>
flunisolide nasal&#160;AND 2) The patient&#160;experienced&#160;an inadequate treatment&#160;<br/>response OR intolerance to two of&#160;the following non-HRM alternative&#160;<br/>drugs: levocetirizine, azelastine nasal, fluticasone&#160;nasal, or&#160;flunisolide&#160;<br/>nasal.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>The prescriber&#160;must acknowledge that the benefit&#160;of therapy with this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
118&#160;<br/>
<hr/>
<a name=119></a><b>HRM-DOXEPIN&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Doxepin Hcl&#160;CAPS 150MG, 75MG&#160;<br/>
•&#160;&#160;&#160;Doxepin Hcl&#160;CONC&#160;<br/>
•&#160;&#160;&#160;Doxepin Hydrochloride&#160;CAPS&#160;<br/>
100MG, 10MG, 25MG, 50MG&#160;<br/>
119&#160;<br/>
<hr/>
<a name=120></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For depression: 1)&#160;The patient tried&#160;two of the following alternative&#160;drugs:&#160;<br/>
<b>Medical&#160;</b><br/>
SSRIs&#160;(selective serotonin&#160;reuptake inhibitors), SNRIs&#160;(serotonin-<br/>
<b>Information&#160;</b><br/>
norepinephrine reuptake&#160;inhibitors), bupropion,&#160;mirtazapine, or trazodone&#160;<br/>AND 2) The&#160;patient experienced an inadequate&#160;treatment response OR&#160;<br/>intolerance to two of the following&#160;alternative drugs: SSRIs&#160;(selective&#160;<br/>serotonin reuptake&#160;inhibitors), SNRIs (serotonin-norepinephrine reuptake&#160;<br/>inhibitors), bupropion,&#160;mirtazapine, or trazodone. For anxiety: 1)&#160;The&#160;<br/>patient has&#160;tried&#160;two of the following alternative&#160;drugs: buspirone,&#160;<br/>duloxetine,&#160;escitalopram, sertraline, or venlafaxine extended-release&#160;AND&#160;<br/>2) The patient experienced an inadequate&#160;treatment response&#160;OR&#160;<br/>intolerance to two of the following&#160;alternative drugs: buspirone,&#160;<br/>duloxetine,&#160;escitalopram, sertraline, or venlafaxine extended-release.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
120&#160;<br/>
<hr/>
<a name=121></a><b>HRM-HYDROXYZINE&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Hydroxyzine Hcl&#160;SYRP&#160;<br/>
•&#160;&#160;&#160;Hydroxyzine Hcl&#160;TABS 50MG&#160;<br/>
•&#160;&#160;&#160;Hydroxyzine Hydrochloride&#160;TABS&#160;<br/>
10MG, 25MG&#160;<br/>
•&#160;&#160;&#160;Hydroxyzine Pamoate&#160;CAPS&#160;<br/>
121&#160;<br/>
<hr/>
<a name=122></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For anxiety:&#160;1) The patient has&#160;tried&#160;two of the&#160;following alternative&#160;<br/>
<b>Medical&#160;</b><br/>
drugs: buspirone, duloxetine, escitalopram, sertraline, or&#160;venlafaxine&#160;<br/>
<b>Information&#160;</b><br/>
extended-release AND 2) The patient experienced&#160;an inadequate&#160;<br/>treatment response&#160;OR&#160;intolerance to two of the&#160;following&#160;alternative&#160;<br/>drugs: buspirone, duloxetine, escitalopram, sertraline, or&#160;venlafaxine&#160;<br/>extended-release OR&#160;3) The patient&#160;has not&#160;tried&#160;two of the following&#160;<br/>alternative drugs: buspirone, duloxetine, escitalopram, sertraline or&#160;<br/>venlafaxine&#160;extended-release AND 4) The patient has acute anxiety.&#160;If&#160;the&#160;<br/>patient is&#160;taking one or more&#160;additional anticholinergic medications&#160;(e.g.,&#160;<br/>oxybutynin,&#160;meclizine, paroxetine, amitriptyline,&#160;dicyclomine,&#160;<br/>cyclobenzaprine)&#160;with the requested&#160;drug, the prescriber has determined&#160;<br/>that&#160;taking&#160;multiple&#160;anticholinergic&#160;medications&#160;is medically necessary&#160;<br/>for&#160;the patient [Note: Use of multiple anticholinergic medications in older&#160;<br/>adults&#160;is associated with&#160;an increased risk of&#160;cognitive decline.].&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed&#160;at reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
122&#160;<br/>
<hr/>
<a name=123></a><b>HRM-HYDROXYZINE&#160;INJ&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Hydroxyzine Hcl&#160;INJ 25MG/ML&#160;<br/>
•&#160;&#160;Hydroxyzine Hydrochloride&#160;INJ&#160;<br/>
123&#160;<br/>
<hr/>
<a name=124></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Alcohol Withdrawal&#160;Syndrome: 1)&#160;The patient has not&#160;tried one of&#160;the&#160;<br/>
<b>Medical&#160;</b><br/>
following&#160;alternative drugs: clorazepate&#160;or lorazepam AND&#160;2) The patient&#160;<br/>
<b>Information&#160;</b><br/>
has a&#160;contraindication to&#160;one of&#160;the following alternative&#160;drugs:&#160;<br/>clorazepate&#160;or lorazepam OR 3) The patient has&#160;tried one of&#160;the following&#160;<br/>alternative drugs: clorazepate or lorazepam&#160;AND 4) The patient&#160;<br/>experienced&#160;an inadequate treatment response OR intolerance to one of&#160;<br/>the following alternative&#160;drugs: clorazepate&#160;or lorazepam. Anxiety: 1)&#160;The&#160;<br/>patient has&#160;tried&#160;two of the following&#160;alternative&#160;drugs: buspirone,&#160;<br/>duloxetine,&#160;escitalopram, sertraline or venlafaxine extended-release AND&#160;<br/>2) The patient experienced an inadequate&#160;treatment response&#160;OR&#160;<br/>intolerance to two of the following&#160;alternative drugs: buspirone,&#160;<br/>duloxetine,&#160;escitalopram,&#160;sertraline or venlafaxine extended-release OR 3)&#160;<br/>The patient&#160;has not&#160;tried&#160;two of the following alternative drugs:&#160;<br/>buspirone, duloxetine, escitalopram,&#160;sertraline or&#160;venlafaxine&#160;extended-<br/>release AND&#160;4) The patient has acute anxiety.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
124&#160;<br/>
<hr/>
<a name=125></a><b>HRM-PROMETHAZINE&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Promethazine Hcl&#160;INJ&#160;<br/>
•&#160;&#160;&#160;Promethazine Hcl&#160;SUPP&#160;12.5MG,&#160;<br/>
25MG&#160;<br/>
•&#160;&#160;&#160;Promethazine Hcl&#160;TABS 12.5MG&#160;<br/>
•&#160;&#160;&#160;Promethazine Hcl Plain&#160;<br/>
•&#160;&#160;&#160;Promethazine Hydrochloride&#160;TABS&#160;<br/>
25MG, 50MG&#160;<br/>
•&#160;&#160;&#160;Promethegan&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Rhinitis:&#160;1) The patient&#160;has tried two of the following non-HRM&#160;<br/>
<b>Medical&#160;</b><br/>
alternative drugs: levocetirizine, azelastine nasal,&#160;fluticasone&#160;nasal, or&#160;<br/>
<b>Information&#160;</b><br/>
flunisolide nasal&#160;AND 2) The patient&#160;experienced&#160;an inadequate treatment&#160;<br/>response OR intolerance to two of&#160;the following non-HRM alternative&#160;<br/>drugs: levocetirizine, azelastine nasal, fluticasone&#160;nasal, or&#160;flunisolide&#160;<br/>nasal.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
125&#160;<br/>
<hr/>
<a name=126></a>126&#160;<br/>
<hr/>
<a name=127></a><b>HRMS&#160;-&#160;ANTIDEPRESSANTS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Amitriptyline Hcl&#160;TABS 100MG,&#160;<br/>
150MG, 75MG&#160;<br/>
•&#160;&#160;&#160;Amitriptyline Hydrochloride&#160;TABS&#160;<br/>
10MG, 25MG, 50MG&#160;<br/>
•&#160;&#160;&#160;Desipramine&#160;Hydrochloride&#160;<br/>
•&#160;&#160;&#160;Imipramine Hcl&#160;TABS&#160;25MG, 50MG&#160;<br/>
•&#160;&#160;&#160;Imipramine Hydrochloride&#160;TABS&#160;<br/>
10MG&#160;<br/>
•&#160;&#160;&#160;Imipramine Pamoate&#160;<br/>
127&#160;<br/>
<hr/>
<a name=128></a><b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Neuropathic&#160;pain&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
If&#160;the&#160;requested drug&#160;is being prescribed for the treatment&#160;of&#160;depression:&#160;<br/>
<b>Medical&#160;</b><br/>
1) The patient tried two&#160;of the following alternative&#160;drugs: SSRIs&#160;<br/>
<b>Information&#160;</b><br/>
(selective serotonin&#160;reuptake&#160;inhibitors), SNRIs&#160;(serotonin-norepinephrine&#160;<br/>reuptake inhibitors), bupropion, mirtazapine,&#160;or trazodone AND&#160;2) The&#160;<br/>patient experienced an inadequate&#160;treatment response OR intolerance to&#160;<br/>two of the following alternative drugs: SSRIs (selective&#160;serotonin&#160;<br/>reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake&#160;<br/>inhibitors), bupropion,&#160;mirtazapine, or trazodone.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
128&#160;<br/>
<hr/>
<a name=129></a><b>HRMS&#160;-&#160;CARBINOXAMINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Carbinoxamine Maleate&#160;SOLN&#160;<br/>
•&#160;&#160;Carbinoxamine Maleate&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Rhinitis:&#160;1) The patient&#160;has tried two of the following non-HRM&#160;<br/>
<b>Medical&#160;</b><br/>
alternative drugs: levocetirizine, azelastine nasal,&#160;fluticasone&#160;nasal, or&#160;<br/>
<b>Information&#160;</b><br/>
flunisolide nasal&#160;AND 2) The patient&#160;experienced&#160;an inadequate treatment&#160;<br/>response OR intolerance to two of&#160;the following non-HRM alternative&#160;<br/>drugs: levocetirizine, azelastine nasal, fluticasone&#160;nasal, or&#160;flunisolide&#160;<br/>nasal.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
129&#160;<br/>
<hr/>
<a name=130></a><b>HRMS&#160;-&#160;CLEMASTINE-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Clemastine&#160;Fumarate&#160;TABS 2.68MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Rhinitis:&#160;1) The patient&#160;has tried two of the following non-HRM&#160;<br/>
<b>Medical&#160;</b><br/>
alternative drugs: levocetirizine, azelastine nasal,&#160;fluticasone&#160;nasal, or&#160;<br/>
<b>Information&#160;</b><br/>
flunisolide nasal&#160;AND 2) The patient&#160;experienced&#160;an inadequate treatment&#160;<br/>response OR intolerance to two of&#160;the following non-HRM alternative&#160;<br/>drugs: levocetirizine, azelastine nasal, fluticasone&#160;nasal, or&#160;flunisolide&#160;<br/>nasal.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
130&#160;<br/>
<hr/>
<a name=131></a><b>HRMS&#160;-&#160;MECLIZINE&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Meclizine Hcl&#160;TABS&#160;12.5MG&#160;<br/>
•&#160;&#160;&#160;Meclizine Hydrochloride&#160;TABS&#160;<br/>
25MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;Medically-accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
131&#160;<br/>
<hr/>
<a name=132></a><b>HRMS&#160;-&#160;TCAS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Protriptyline&#160;Hcl&#160;<br/>
•&#160;&#160;Trimipramine Maleate&#160;CAPS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient tried two&#160;of the following alternative&#160;drugs: SSRIs&#160;<br/>
<b>Medical&#160;</b><br/>
(selective serotonin&#160;reuptake&#160;inhibitors), SNRIs&#160;(serotonin-norepinephrine&#160;<br/>
<b>Information&#160;</b><br/>
reuptake inhibitors),&#160;bupropion, mirtazapine, or trazodone AND&#160;2) The&#160;<br/>patient experienced an inadequate&#160;treatment response OR intolerance to&#160;<br/>two of the following alternative drugs: SSRIs (selective&#160;serotonin&#160;<br/>reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake&#160;<br/>inhibitors),&#160;bupropion,&#160;mirtazapine, or trazodone.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
132&#160;<br/>
<hr/>
<a name=133></a><b>HRM-SKELETAL&#160;MUSCLE&#160;RELAXANTS&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Chlorzoxazone&#160;TABS&#160;500MG&#160;<br/>
•&#160;&#160;&#160;Cyclobenzaprine Hydrochloride&#160;<br/>
TABS&#160;10MG, 5MG&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
If&#160;the&#160;patient is using one&#160;or more&#160;additional anticholinergic&#160;medications&#160;<br/>
<b>Medical&#160;</b><br/>
(e.g., oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine,&#160;<br/>
<b>Information&#160;</b><br/>
hydroxyzine) with the requested drug, the prescriber has determined that&#160;<br/>taking&#160;multiple anticholinergic medications&#160;is medically necessary for the&#160;<br/>patient [Note: Use&#160;of multiple anticholinergic&#160;medications&#160;in&#160;older&#160;adults&#160;<br/>is associated with an increased risk of cognitive decline.].&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
3 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older. (The American Geriatrics Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed&#160;at reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.)&#160;<br/>Prescriber must acknowledge that the&#160;benefit of&#160;therapy with&#160;this&#160;<br/>prescribed&#160;medication&#160;outweighs&#160;the potential&#160;risks&#160;for&#160;this patient.&#160;<br/>
133&#160;<br/>
<hr/>
<a name=134></a><b>HUMIRA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Humira&#160;INJ&#160;10MG/0.1ML,&#160;<br/>
20MG/0.2ML, 40MG/0.4ML,&#160;<br/>40MG/0.8ML&#160;<br/>
•&#160;&#160;&#160;Humira Pediatric Crohns&#160;Disease&#160;<br/>
Starter Pack&#160;INJ 0, 80MG/0.8ML&#160;<br/>
•&#160;&#160;&#160;Humira Pen&#160;<br/>
•&#160;&#160;&#160;Humira Pen-cd/uc/hs Starter&#160;<br/>
•&#160;&#160;&#160;Humira Pen-pediatric Uc Starter&#160;Pack&#160;<br/>
•&#160;&#160;&#160;Humira Pen-ps/uv&#160;Starter&#160;<br/>
134&#160;<br/>
<hr/>
<a name=135></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Axial spondyloarthritis,&#160;Behcet's syndrome&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;moderately&#160;to severely active rheumatoid arthritis (new&#160;starts&#160;only):&#160;<br/>
<b>Medical&#160;</b><br/>
1) Inadequate response,&#160;intolerance or contraindication to methotrexate&#160;<br/>
<b>Information&#160;</b><br/>
(MTX) OR 2) Inadequate response or intolerance to a prior biologic&#160;<br/>disease-modifying&#160;antirheumatic drug (DMARD) or&#160;a targeted synthetic&#160;<br/>DMARD. For&#160;active ankylosing spondylitis and&#160;axial&#160;spondyloarthritis&#160;<br/>(new starts only): 1) Inadequate&#160;response to a non-steroidal anti-<br/>inflammatory drug (NSAID) trial OR&#160;2) Intolerance or contraindication&#160;to&#160;<br/>NSAIDs. For&#160;moderate&#160;to&#160;severe plaque psoriasis (new starts&#160;only): 1) At&#160;<br/>least 3%&#160;of body surface area&#160;(BSA) is affected&#160;OR&#160;crucial body areas&#160;<br/>(e.g., feet, hands, face, neck, groin,&#160;intertriginous areas) are affected at the&#160;<br/>time of&#160;diagnosis, AND 2) Patient meets any of the following: a)&#160;Patient&#160;<br/>has experienced an inadequate&#160;response or&#160;intolerance to either&#160;<br/>phototherapy (e.g., UVB, PUVA) or&#160;pharmacologic treatment with&#160;<br/>methotrexate, cyclosporine, or&#160;acitretin, OR b) Pharmacologic&#160;treatment&#160;<br/>with methotrexate, cyclosporine, or acitretin is contraindicated, OR c)&#160;<br/>Patient has&#160;severe psoriasis&#160;that warrants a biologic DMARD as first-line&#160;<br/>therapy&#160;(i.e.&#160;at least&#160;10%&#160;of the BSA&#160;or crucial&#160;body areas&#160;(e.g., hands,&#160;<br/>feet,&#160;face, neck, scalp, genitals/groin,&#160;intertriginous areas) are&#160;affected).&#160;<br/>For moderately to severely active Crohn's disease (new starts&#160;only): 1)&#160;<br/>Inadequate response&#160;to at least one&#160;conventional&#160;therapy&#160;(e.g.,&#160;<br/>corticosteroids), OR 2) Intolerance or contraindication to conventional&#160;<br/>therapy. For&#160;moderately to severely active ulcerative colitis (new starts&#160;<br/>only): 1) Inadequate&#160;response to at least&#160;one conventional therapy (e.g.,&#160;<br/>corticosteroids), OR 2) Intolerance or contraindication to conventional&#160;<br/>therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
135&#160;<br/>
<hr/>
<a name=136></a><b>HYPNOTIC-BENZODIAZEPINES&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Temazepam&#160;CAPS 15MG, 22.5MG,&#160;<br/>
7.5MG&#160;<br/>
•&#160;&#160;&#160;Triazolam&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Prescriber must&#160;acknowledge the benefit of&#160;therapy with the requested&#160;<br/>
<b>Medical&#160;</b><br/>
drug outweighs the potential risks for the patient.&#160; (Note:&#160;The&#160;American&#160;<br/>
<b>Information&#160;</b><br/>
Geriatrics Society identifies&#160;the use&#160;of this medication as potentially&#160;<br/>inappropriate in older adults, meaning it&#160;is best&#160;avoided, prescribed&#160;at&#160;<br/>reduced dosage, or used&#160;with caution&#160;or carefully&#160;monitored.) &#160;The patient&#160;<br/>has experienced an inadequate&#160;treatment response, intolerance, or has a&#160;<br/>contraindication to doxepin (3 mg or&#160;6 mg).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older.&#160;<br/>
136&#160;<br/>
<hr/>
<a name=137></a><b>IBRANCE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ibrance&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Unresectable well-differentiated/dedifferentiated liposarcoma of&#160;the&#160;<br/>retroperitoneum.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
137&#160;<br/>
<hr/>
<a name=138></a><b>ICATIBANT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Icatibant Acetate&#160;<br/>
•&#160;&#160;Sajazir&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For hereditary&#160;angioedema (HAE):&#160;The requested drug is being used for&#160;<br/>
<b>Medical&#160;</b><br/>
the treatment of&#160;acute angioedema attacks. Patient has&#160;HAE with C1&#160;<br/>
<b>Information&#160;</b><br/>
inhibitor&#160;deficiency or dysfunction confirmed by&#160;laboratory&#160;testing OR&#160;<br/>patient has&#160;HAE with normal C1 inhibitor confirmed by&#160;laboratory&#160;<br/>testing. For&#160;patients with HAE with&#160;normal C1 inhibitor, EITHER 1)&#160;<br/>Patient tested positive for an F12, angiopoietin-1, plasminogen, or&#160;<br/>kininogen-1&#160;(KNG1) gene mutation&#160;OR&#160;2) Patient has a&#160;family history of&#160;<br/>angioedema and the angioedema was&#160;refractory to&#160;a trial of an&#160;<br/>antihistamine for at least one month.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>18 years&#160;of age or older&#160;<br/>
<b>Prescriber&#160;</b><br/>
Immunologist,&#160;allergist,&#160;rheumatologist&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
138&#160;<br/>
<hr/>
<a name=139></a><b>ICLUSIG</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Iclusig&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Therapy after&#160;hematopoietic&#160;stem cell transplant (HSCT) for chronic&#160;<br/>myeloid leukemia&#160;(CML) and acute&#160;lymphoblastic&#160;leukemia (ALL)&#160;<br/>patients&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;myeloid leukemia&#160;(CML) or&#160;acute lymphoblastic leukemia&#160;<br/>
<b>Medical&#160;</b><br/>
(ALL): diagnosis was confirmed by&#160;detection of&#160;the Philadelphia&#160;<br/>
<b>Information&#160;</b><br/>
chromosome or&#160;BCR-ABL gene. For CML, including patients who have&#160;<br/>received a&#160;hematopoietic stem cell transplant:&#160;1) patient has&#160;accelerated or&#160;<br/>blast phase CML and no other kinase inhibitor is&#160;indicated,&#160;OR 2) patient&#160;<br/>has chronic&#160;phase&#160;CML and has experienced resistance&#160;or intolerance to&#160;<br/>at least&#160;2 prior kinase inhibitors&#160;AND at least one of&#160;those&#160;was imatinib&#160;or&#160;<br/>dasatinib, OR 3) patient&#160;is positive&#160;for the T315I mutation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
139&#160;<br/>
<hr/>
<a name=140></a><b>IDHIFA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Idhifa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Newly-diagnosed acute&#160;myeloid leukemia&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For acute&#160;myeloid&#160;leukemia&#160;(AML) with an isocitrate dehydrogenase-2&#160;<br/>
<b>Medical&#160;</b><br/>
(IDH2) mutation: 1)&#160;patient has a physiologic age of&#160;60 years or older&#160;<br/>
<b>Information&#160;</b><br/>
with newly-diagnosed AML and meets one&#160;of the&#160;following: a) patient&#160;is&#160;<br/>not a candidate&#160;for intensive induction therapy,&#160;or b)&#160;patient&#160;declines&#160;<br/>intensive induction chemotherapy,&#160;OR&#160;2) patient has&#160;a physiologic age of&#160;<br/>60 years or&#160;older&#160;and&#160;the requested&#160;drug will be&#160;used as post-induction&#160;<br/>therapy&#160;following response to induction therapy&#160;with the&#160;requested drug&#160;<br/>OR&#160;3) patient has&#160;relapsed or&#160;refractory AML.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
140&#160;<br/>
<hr/>
<a name=141></a><b>IMATINIB</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Imatinib&#160;Mesylate&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Desmoid tumors, pigmented villonodular synovitis/tenosynovial&#160;giant&#160;cell&#160;<br/>tumor (PVNS/TGCT), recurrent chordoma, melanoma, AIDS-related&#160;<br/>Kaposi sarcoma, chronic myelomonocytic&#160;leukemia, chronic&#160;graft&#160;versus&#160;<br/>host&#160;disease&#160;(cGVHD), T-cell acute lymphoblastic leukemia,&#160;aggressive&#160;<br/>systemic&#160;mastocytosis when eosinophilia is present with FIP1L1-<br/>PDGFRA fusion gene&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;myeloid leukemia&#160;(CML) or&#160;Philadelphia&#160;chromosome&#160;<br/>
<b>Medical&#160;</b><br/>
positive acute lymphoblastic&#160;leukemia (Ph+ ALL):&#160;diagnosis&#160;was&#160;<br/>
<b>Information&#160;</b><br/>
confirmed by detection&#160;of the Philadelphia&#160;chromosome or&#160;BCR-ABL&#160;<br/>gene. For&#160;CML: patient&#160;did not&#160;fail&#160;(excluding&#160;failure due to&#160;intolerance)&#160;<br/>prior therapy with a&#160;tyrosine kinase inhibitor. For melanoma:&#160;c-Kit&#160;<br/>mutation is&#160;positive.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
141&#160;<br/>
<hr/>
<a name=142></a><b>IMBRUVICA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Imbruvica&#160;<br/>
142&#160;<br/>
<hr/>
<a name=143></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Hairy cell&#160;leukemia,&#160;lymphoplasmacytic&#160;lymphoma, follicular lymphoma,&#160;<br/>primary&#160;central nervous system&#160;lymphoma, AIDS-related B-cell&#160;<br/>lymphoma,&#160;histologic transformation of nodal&#160;marginal zone&#160;lymphoma&#160;<br/>to diffuse&#160;large B-cell lymphoma, diffuse large B-cell lymphoma, post-<br/>transplant&#160;lymphoproliferative&#160;disorders, high-grade B-cell lymphoma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For mantle&#160;cell&#160;lymphoma: 1)&#160;the requested drug&#160;will&#160;be used&#160;in a patient&#160;<br/>
<b>Medical&#160;</b><br/>
who has received at least one prior&#160;therapy, OR&#160;2) the requested drug will&#160;<br/>
<b>Information&#160;</b><br/>
be used in combination with rituximab as pretreatment to induction&#160;<br/>therapy with&#160;RHyperCVAD&#160;(rituximab, cyclophosphamide, vincristine,&#160;<br/>doxorubicin,&#160;and dexamethasone)&#160;regimen. For&#160;marginal zone&#160;lymphoma&#160;<br/>(including gastric mucosa-associated&#160;lymphoid&#160;tissue [MALT]&#160;<br/>lymphoma,&#160;non-gastric&#160;MALT&#160;lymphoma, nodal marginal&#160;zone&#160;<br/>lymphoma,&#160;and splenic marginal&#160;zone lymphoma):&#160;the patient has&#160;<br/>received at&#160;least one prior therapy. For hairy cell&#160;leukemia:&#160;the requested&#160;<br/>drug will be&#160;used as a single agent for disease&#160;progression. For primary&#160;<br/>central nervous system lymphoma: 1) the disease&#160;is relapsed&#160;or refractory&#160;<br/>OR&#160;2) the requested drug&#160;is used for induction therapy as&#160;a single agent.&#160;<br/>For histologic transformation of nodal marginal&#160;zone lymphoma to diffuse&#160;<br/>large B-cell&#160;lymphoma: the requested&#160;drug will be&#160;used in patients&#160;who&#160;<br/>have received prior chemoimmunotherapy. For diffuse large B-cell&#160;<br/>lymphoma: the requested&#160;drug will be&#160;used as second-line or&#160;subsequent&#160;<br/>therapy. For&#160;AIDS-related B-cell lymphoma: the requested&#160;drug will be&#160;<br/>used as a single agent and as second-line or subsequent therapy for&#160;<br/>relapsed disease. For post-transplant lymphoproliferative disorders: the&#160;<br/>requested drug will&#160;be used in patients who have received prior&#160;<br/>chemoimmunotherapy. For high-grade B-cell lymphoma:&#160;the requested&#160;<br/>drug will be&#160;used as second-line or&#160;subsequent&#160;therapy. For follicular&#160;<br/>lymphoma: the requested&#160;drug will&#160;be&#160;used as a single agent.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
143&#160;<br/>
<hr/>
<a name=144></a>144&#160;<br/>
<hr/>
<a name=145></a><b>IMLYGIC</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Imlygic&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Limited resectable&#160;or incompletely&#160;resectable melanoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For melanoma: The&#160;requested drug&#160;will&#160;be used&#160;for&#160;the treatment&#160;of&#160;<br/>
<b>Medical&#160;</b><br/>
unresectable, limited&#160;resectable, or&#160;incompletely&#160;resectable cutaneous,&#160;<br/>
<b>Information&#160;</b><br/>
subcutaneous, and nodal&#160;lesions.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
145&#160;<br/>
<hr/>
<a name=146></a><b>INCRELEX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Increlex&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
Pediatric patients&#160;with closed epiphyses&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For growth&#160;failure&#160;due to severe&#160;primary&#160;insulin-like growth factor-1&#160;<br/>
<b>Medical&#160;</b><br/>
(IGF-1) deficiency or growth hormone gene deletion in patients who have&#160;<br/>
<b>Information&#160;</b><br/>
developed neutralizing antibodies to&#160;growth hormone, must&#160;meet&#160;all&#160;of&#160;<br/>the following prior to beginning therapy with the requested drug (new&#160;<br/>starts only):&#160;1) height 3 or more&#160;standard&#160;deviations (SD) below the mean&#160;<br/>for&#160;children&#160;of the same&#160;age and gender&#160;AND 2) basal&#160;IGF-1&#160;level 3 or&#160;<br/>more SD below the mean&#160;for&#160;children&#160;of the same&#160;age and gender&#160;AND 3)&#160;<br/>provocative&#160;growth hormone&#160;test showing a normal or elevated growth&#160;<br/>hormone&#160;level. For renewal, patient&#160;is experiencing improvement.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
146&#160;<br/>
<hr/>
<a name=147></a><b>INLYTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Inlyta&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Thyroid carcinoma&#160;(papillary, Hurthle cell, or follicular).&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For renal&#160;cell carcinoma: the disease&#160;is advanced,&#160;relapsed, or&#160;stage IV.&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
147&#160;<br/>
<hr/>
<a name=148></a><b>INQOVI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Inqovi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
148&#160;<br/>
<hr/>
<a name=149></a><b>INREBIC</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Inrebic&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Myeloid,&#160;lymphoid, or&#160;mixed&#160;lineage neoplasms with eosinophilia and&#160;<br/>janus&#160;kinase 2 (JAK2) rearrangement&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For myeloid, lymphoid,&#160;or mixed lineage neoplasms&#160;with eosinophilia and&#160;<br/>
<b>Medical&#160;</b><br/>
JAK2 rearrangement: the disease is&#160;in&#160;chronic or&#160;blast phase.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
149&#160;<br/>
<hr/>
<a name=150></a><b>IR&#160;BEFORE&#160;ER</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Hydrocodone&#160;Bitartrate Er&#160;T24A&#160;<br/>
•&#160;&#160;Hysingla Er&#160;<br/>
•&#160;&#160;Methadone&#160;Hcl&#160;INJ&#160;<br/>
•&#160;&#160;Methadone&#160;Hcl&#160;ORAL&#160;SOLN&#160;<br/>
•&#160;&#160;Methadone&#160;Hcl&#160;TABS&#160;<br/>
•&#160;&#160;Methadone&#160;Hydrochloride&#160;CONC&#160;<br/>
•&#160;&#160;Morphine Sulfate Er&#160;CP24&#160;<br/>
•&#160;&#160;Morphine Sulfate Er&#160;TBCR&#160;<br/>
•&#160;&#160;Tramadol Hcl Er&#160;TB24&#160;<br/>
150&#160;<br/>
<hr/>
<a name=151></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being prescribed for pain&#160;associated&#160;with cancer,&#160;<br/>
<b>Medical&#160;</b><br/>
sickle cell disease, a&#160;terminal condition, or pain&#160;being managed through&#160;<br/>
<b>Information&#160;</b><br/>
palliative&#160;care&#160;OR&#160;2) The requested&#160;drug is being prescribed&#160;for&#160;pain&#160;<br/>severe&#160;enough to require&#160;daily, around-the-clock,&#160;long-term&#160;treatment in&#160;a&#160;<br/>patient who has been taking an opioid&#160;AND 3) The patient can safely take&#160;<br/>the requested dose based&#160;on their history of&#160;opioid use [Note: This drug&#160;<br/>should be prescribed only by healthcare&#160;professionals&#160;who are&#160;<br/>knowledgeable in&#160;the use of potent opioids for the management of chronic&#160;<br/>pain.]&#160;AND 4) The patient has&#160;been&#160;evaluated and the patient&#160;will&#160;be&#160;<br/>monitored&#160;for the&#160;development of opioid use disorder&#160;AND 5) This&#160;<br/>request&#160;is for continuation of therapy&#160;for&#160;a patient&#160;who has been receiving&#160;<br/>an extended-release&#160;opioid agent&#160;for at least&#160;30 days OR the patient has&#160;<br/>taken an&#160;immediate-release opioid for at&#160;least one week.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
151&#160;<br/>
<hr/>
<a name=152></a><hr/>
<a name=153></a><b>ISOTRETINOIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Accutane&#160;<br/>•&#160;&#160;Amnesteem&#160;<br/>
•&#160;&#160;Claravis&#160;<br/>
•&#160;&#160;Isotretinoin&#160;CAPS&#160;<br/>
•&#160;&#160;Myorisan&#160;<br/>
•&#160;&#160;Zenatane&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved&#160;Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Refractory acne&#160;vulgaris, severe&#160;refractory rosacea, neuroblastoma,&#160;<br/>cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides,&#160;Sezary&#160;<br/>syndrome),&#160;high risk for&#160;developing&#160;skin cancer&#160;(squamous cell&#160;cancers),&#160;<br/>transient&#160;acantholytic dermatosis (Grover's Disease), keratosis&#160;follicularis&#160;<br/>(Darier Disease), lamellar ichthyosis, pityriasis rubra pilaris.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
153&#160;<br/>
<hr/>
<a name=154></a><b>ITRACONAZOLE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Itraconazole&#160;CAPS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Coccidioidomycosis,&#160;Coccidioidomycosis prophylaxis&#160;in HIV infection,&#160;<br/>Cryptococcosis, Histoplasmosis prophylaxis&#160;in HIV infection,&#160;invasive&#160;<br/>fungal&#160;infection prophylaxis in liver transplant patients, Microsporidiosis,&#160;<br/>Talaromycosis (formerly&#160;Penicilliosis), Pityriasis versicolor/Tinea&#160;<br/>versicolor, Sporotrichosis, Tinea&#160;corporis, Tinea&#160;cruris, Tinea capitis,&#160;<br/>Tinea&#160;manuum, Tinea&#160;pedis&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
If&#160;for&#160;the treatment of&#160;onychomycosis due to dermatophytes&#160;(Tinea&#160;<br/>
<b>Medical&#160;</b><br/>
unguium), the diagnosis has been confirmed by a&#160;fungal diagnostic&#160;test&#160;<br/>
<b>Information&#160;</b><br/>
(e.g., potassium hydroxide [KOH] preparation, fungal culture,&#160;or nail&#160;<br/>biopsy).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Disseminated/CNS&#160;histoplasmosis,&#160;Histoplasmosis/Coccidioidomycosis&#160;<br/>
<b>Duration&#160;</b><br/>
ppx: 12 mths. Others: 6 mths&#160;<br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
154&#160;<br/>
<hr/>
<a name=155></a><b>IVERMECTIN&#160;TAB</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ivermectin&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Ascariasis,&#160;Cutaneous larva&#160;migrans, Mansonelliasis, Scabies,&#160;<br/>Gnathostomiasis, Pediculosis&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The requested&#160;drug is not being prescribed&#160;for&#160;the prevention or treatment&#160;<br/>
<b>Medical&#160;</b><br/>
of coronavirus disease 2019 (COVID-19).&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age&#160;Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
1 month&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
155&#160;<br/>
<hr/>
<a name=156></a><b>IVIG</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Bivigam&#160;INJ 10%, 5GM/50ML&#160;<br/>
•&#160;&#160;&#160;Flebogamma Dif&#160;<br/>
•&#160;&#160;&#160;Gammagard Liquid&#160;<br/>
•&#160;&#160;&#160;Gammagard S/d Iga Less Than&#160;<br/>
1mcg/ml&#160;<br/>
•&#160;&#160;&#160;Gammaked&#160;INJ 10GM/100ML,&#160;<br/>
1GM/10ML, 20GM/200ML,&#160;<br/>5GM/50ML&#160;<br/>
•&#160;&#160;&#160;Gammaplex&#160;INJ 10GM/100ML,&#160;<br/>
10GM/200ML, 20GM/200ML,&#160;<br/>20GM/400ML, 5GM/100ML,&#160;<br/>5GM/50ML&#160;<br/>
•&#160;&#160;&#160;Gamunex-c&#160;<br/>
•&#160;&#160;&#160;Octagam&#160;INJ 10GM/100ML,&#160;<br/>
10GM/200ML, 2.5GM/50ML,&#160;<br/>20GM/200ML, 25GM/500ML,&#160;<br/>2GM/20ML, 30GM/300ML,&#160;<br/>5GM/100ML, 5GM/50ML&#160;<br/>
•&#160;&#160;&#160;Panzyga&#160;<br/>
•&#160;&#160;&#160;Privigen&#160;<br/>
156&#160;<br/>
<hr/>
<a name=157></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All Medically-accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For B-cell&#160;chronic&#160;lymphocytic&#160;leukemia&#160;(CLL):&#160;1) serum IgG less&#160;than&#160;<br/>
<b>Medical&#160;</b><br/>
500 mg/dL&#160;OR&#160;2) a&#160;history of&#160;recurrent bacterial infections.&#160;For bone&#160;<br/>
<b>Information&#160;</b><br/>
marrow transplant/hematopoietic stem cell transplant&#160;(BMT/HSCT):&#160;1)&#160;<br/>IVIG is requested within&#160;the first 100&#160;days post-transplant OR 2) serum&#160;<br/>IgG less than 400 mg/dL. For pediatric human&#160;immunodeficiency virus&#160;<br/>(HIV) infection:&#160;1) serum IgG less&#160;than 400 mg/dL, OR 2) history of&#160;<br/>recurrent bacterial&#160;infections. For dermatomyositis and polymyositis: 1) at&#160;<br/>least one standard first-line&#160;treatment (corticosteroid or&#160;<br/>immunosuppressant) has been tried&#160;but was unsuccessful or&#160;not tolerated&#160;<br/>OR&#160;2) patient is unable to receive&#160;standard therapy because&#160;of a&#160;<br/>contraindication or other clinical&#160;reason. For pure&#160;red cell&#160;aplasia&#160;<br/>(PRCA): PRCA&#160;is secondary to parvovirus B19 infection.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
157&#160;<br/>
<hr/>
<a name=158></a><b>JAKAFI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Jakafi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Lower-risk&#160;myelofibrosis, accelerated phase myelofibrosis, blast&#160;phase&#160;<br/>myelofibrosis/acute myeloid leukemia, acute&#160;lymphoblastic&#160;leukemia&#160;<br/>(ALL), chronic myelomonocytic&#160;leukemia&#160;(CMML)-2, BCR-ABL&#160;<br/>negative atypical&#160;chronic myeloid leukemia&#160;(aCML), essential&#160;<br/>thrombocythemia,&#160;and myeloid,&#160;lymphoid or&#160;mixed lineage neoplasms&#160;<br/>with eosinophilia and JAK2 rearrangement&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For polycythemia&#160;vera:&#160;patient had an inadequate&#160;response&#160;or&#160;intolerance&#160;<br/>
<b>Medical&#160;</b><br/>
to interferon therapy or hydroxyurea.&#160;For acute lymphoblastic&#160;leukemia:&#160;<br/>
<b>Information&#160;</b><br/>
patient has&#160;a&#160;cytokine&#160;receptor-like factor 2 (CRLF2) mutation or a&#160;<br/>mutation associated with&#160;activation of the Janus kinase/signal&#160;transducers&#160;<br/>and activators&#160;of transcription (JAK/STAT) pathway. For CMML-2: the&#160;<br/>requested drug is&#160;used in&#160;combination with a&#160;hypomethylating agent. For&#160;<br/>BCR-ABL negative aCML: the&#160;requested drug&#160;is used as a&#160;single&#160;agent&#160;or&#160;<br/>in combination with a&#160;hypomethylating agent. For essential&#160;<br/>thrombocythemia: patient had an inadequate&#160;response or&#160;loss&#160;of response&#160;<br/>to hydroxyurea, interferon therapy,&#160;or anagrelide. For myeloid, lymphoid,&#160;<br/>or mixed lineage neoplasms&#160;with eosinophilia and JAK2 rearrangement:&#160;<br/>the disease&#160;is in chronic or blast phase.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
158&#160;<br/>
<hr/>
<a name=159></a><b>KALYDECO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Kalydeco&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For cystic&#160;fibrosis (CF):&#160;The requested medication will&#160;not be used in&#160;<br/>
<b>Medical&#160;</b><br/>
combination&#160;with other&#160;medications&#160;containing ivacaftor.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>4 months&#160;of age or older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
159&#160;<br/>
<hr/>
<a name=160></a><b>KESIMPTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Kesimpta&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
160&#160;<br/>
<hr/>
<a name=161></a><b>KETOCONAZOLE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ketoconazole&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Cushing's syndrome&#160;<br/>
<b>Exclusion&#160;</b><br/>
Acute or&#160;chronic liver disease. Concurrent use with drugs&#160;that are&#160;<br/>
<b>Criteria&#160;</b><br/>
contraindicated with ketoconazole&#160;tablets: dofetilide, quinidine, pimozide,&#160;<br/>cisapride,&#160;methadone, disopyramide,&#160;dronedarone, ranolazine, ergot&#160;<br/>alkaloids, irinotecan,&#160;lurasidone, oral&#160;midazolam,&#160;alprazolam,&#160;triazolam,&#160;<br/>felodipine, nisoldipine, tolvaptan,&#160;eplerenone, lovastatin, simvastatin, or&#160;<br/>colchicine.&#160;<br/>
<b>Required&#160;</b><br/>
The potential&#160;benefits&#160;outweigh the&#160;risks of&#160;treatment with oral&#160;<br/>
<b>Medical&#160;</b><br/>
ketoconazole. For systemic&#160;fungal&#160;infections, the patient has&#160;any of&#160;the&#160;<br/>
<b>Information&#160;</b><br/>
following diagnoses: blastomycosis, coccidioidomycosis, histoplasmosis,&#160;<br/>chromomycosis, or&#160;paracoccidioidomycosis. For Cushing's&#160;syndrome: the&#160;<br/>requested drug is&#160;being prescribed&#160;for a patient&#160;who cannot tolerate&#160;<br/>surgery or where surgery&#160;has not&#160;been curative.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
6 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
161&#160;<br/>
<hr/>
<a name=162></a><b>KEYTRUDA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Keytruda&#160;INJ 100MG/4ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All Medically-accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
162&#160;<br/>
<hr/>
<a name=163></a><b>KISQALI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Kisqali&#160;<br/>
•&#160;&#160;Kisqali Femara&#160;200 Dose&#160;<br/>
•&#160;&#160;Kisqali Femara&#160;400 Dose&#160;<br/>
•&#160;&#160;Kisqali Femara&#160;600 Dose&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
For treatment&#160;of breast&#160;cancer using&#160;Kisqali&#160;(ribociclib)&#160;in combination&#160;<br/>with an aromatase inhibitor or Kisqali Femara&#160;Co-Pack (ribociclib and&#160;<br/>letrozole) as&#160;initial&#160;endocrine-based therapy: if the patient is&#160;<br/>postmenopausal&#160;OR&#160;male, the&#160;patient has&#160;experienced an intolerable&#160;<br/>adverse&#160;event to Ibrance (palbociclib) AND&#160;Verzenio (abemaciclib)&#160;or&#160;<br/>has a&#160;contraindication to&#160;Ibrance (palbociclib) AND&#160;Verzenio&#160;<br/>(abemaciclib). For&#160;treatment of breast cancer&#160;with Kisqali&#160;(ribociclib)&#160;in&#160;<br/>combination&#160;with fulvestrant, one of the following&#160;criteria must met: 1)&#160;<br/>the requested drug is being used with&#160;fulvestrant&#160;as initial endocrine-<br/>based therapy in a postmenopausal patient or&#160;in a male, OR&#160;2) the&#160;<br/>requested drug is&#160;being used following disease progression on endocrine&#160;<br/>therapy&#160;in a postmenopausal&#160;patient&#160;or in a&#160;male&#160;and the&#160;patient has&#160;<br/>experienced&#160;an intolerable adverse event to&#160;Ibrance (palbociclib) AND&#160;<br/>Verzenio&#160;(abemaciclib) OR has a contraindication to Ibrance&#160;(palbociclib)&#160;<br/>AND Verzenio (abemaciclib).&#160;<br/>
163&#160;<br/>
<hr/>
<a name=164></a>164&#160;<br/>
<hr/>
<a name=165></a><b>KORLYM</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Korlym&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
Endocrinologist&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
165&#160;<br/>
<hr/>
<a name=166></a><b>KRISTALOSE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Kristalose&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient has&#160;experienced an inadequate&#160;treatment response to a one&#160;<br/>
<b>Medical&#160;</b><br/>
month trial&#160;of generic lactulose solution OR&#160;2) The patient has&#160;<br/>
<b>Information&#160;</b><br/>
experienced&#160;an intolerance that would prohibit a&#160;one month&#160;trial&#160;of&#160;<br/>generic lactulose&#160;solution.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
166&#160;<br/>
<hr/>
<a name=167></a><b>KUVAN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Sapropterin&#160;Dihydrochloride&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For phenylketonuria: For patients&#160;who have not&#160;yet received&#160;a therapeutic&#160;<br/>
<b>Medical&#160;</b><br/>
trial of&#160;the requested drug, the patient's pretreatment, including before&#160;<br/>
<b>Information&#160;</b><br/>
dietary management, phenylalanine&#160;level&#160;is greater than 6&#160;mg/dL (360&#160;<br/>micromol/L). For patients who completed a&#160;therapeutic&#160;trial of the&#160;<br/>requested drug, the&#160;patient must have&#160;experienced&#160;improvement (for&#160;<br/>example, reduction&#160;in blood phenylalanine&#160;levels, improvement in&#160;<br/>neuropsychiatric symptoms).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Initial:&#160;2 months. All others: Plan Year.&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
167&#160;<br/>
<hr/>
<a name=168></a><b>KYNMOBI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Kynmobi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For continuation&#160;treatment of&#160;off episodes in Parkinson's&#160;disease:&#160;The&#160;<br/>
<b>Medical&#160;</b><br/>
patient is&#160;experiencing improvement on the requested drug.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
168&#160;<br/>
<hr/>
<a name=169></a><b>LAPATINIB</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lapatinib Ditosylate&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Brain metastases&#160;from human epidermal&#160;growth&#160;factor receptor 2&#160;<br/>(HER2)-positive breast cancer,&#160;recurrent epidermal growth factor&#160;receptor&#160;<br/>(EGFR)-positive chordoma, HER2-amplified&#160;and&#160;RAS and BRAF wild-<br/>type colorectal&#160;cancer&#160;in&#160;combination with trastuzumab.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For HER2-positive&#160;breast cancer, the&#160;requested drug will&#160;be used in&#160;<br/>
<b>Medical&#160;</b><br/>
combination&#160;with any of&#160;the following: 1)&#160;aromatase inhibitor, 2)&#160;<br/>
<b>Information&#160;</b><br/>
capecitabine, OR&#160;3) trastuzumab.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
169&#160;<br/>
<hr/>
<a name=170></a><b>LENVIMA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lenvima 10&#160;Mg Daily Dose&#160;<br/>
•&#160;&#160;Lenvima 12mg Daily Dose&#160;<br/>
•&#160;&#160;Lenvima 14&#160;Mg Daily Dose&#160;<br/>
•&#160;&#160;Lenvima 18&#160;Mg Daily Dose&#160;<br/>
•&#160;&#160;Lenvima 20&#160;Mg Daily Dose&#160;<br/>
•&#160;&#160;Lenvima 24&#160;Mg Daily Dose&#160;<br/>
•&#160;&#160;Lenvima 4&#160;Mg Daily Dose&#160;<br/>
•&#160;&#160;Lenvima 8&#160;Mg Daily Dose&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Medullary thyroid&#160;carcinoma, recurrent endometrial carcinoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For differentiated&#160;thyroid&#160;cancer&#160;(follicular, papillary, or Hurthle cell):&#160;<br/>
<b>Medical&#160;</b><br/>
disease is not amenable&#160;to&#160;radioactive iodine&#160;therapy and unresectable,&#160;<br/>
<b>Information&#160;</b><br/>
locally recurrent, persistent, or&#160;metastatic. For hepatocellular&#160;carcinoma:&#160;<br/>disease is unresectable or inoperable, local,&#160;metastatic or with&#160;extensive&#160;<br/>liver tumor&#160;burden. For&#160;renal cell carcinoma:&#160;disease is&#160;advanced,&#160;<br/>relapsed, or&#160;stage IV. For endometrial carcinoma,&#160;the patient&#160;meets ALL&#160;<br/>of the following: 1)&#160;The disease is&#160;advanced or recurrent, 2) The disease&#160;<br/>is not&#160;microsatellite instability-high&#160;(MSI-H) or&#160;mismatch&#160;repair deficient&#160;<br/>(dMMR), 3)&#160;The patient&#160;experienced&#160;disease progression following prior&#160;<br/>systemic&#160;therapy, AND 4)&#160;The patient is not&#160;a candidate&#160;for&#160;curative&#160;<br/>surgery or radiation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
170&#160;<br/>
<hr/>
<a name=171></a><b>LEUPROLIDE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Leuprolide&#160;Acetate&#160;INJ&#160;1MG/0.2ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Use in&#160;combination with growth hormone for children with growth failure&#160;<br/>and advancing puberty,&#160;recurrent&#160;androgen receptor&#160;positive&#160;salivary&#160;<br/>gland tumors.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
171&#160;<br/>
<hr/>
<a name=172></a><b>LIBTAYO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Libtayo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Inoperable or&#160;incompletely resected&#160;cutaneous squamous cell carcinoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For cutaneous&#160;squamous cell carcinoma:&#160;patient&#160;meets both&#160;of the&#160;<br/>
<b>Medical&#160;</b><br/>
following: 1) disease is one of the&#160;following:&#160;a) metastatic, b) locally&#160;<br/>
<b>Information&#160;</b><br/>
advanced, or&#160;c)&#160;regional and inoperable or&#160;incompletely resected, and 2)&#160;<br/>patient is not a candidate&#160;for&#160;curative surgery or curative radiation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
172&#160;<br/>
<hr/>
<a name=173></a><b>LIDOCAINE&#160;PATCHES</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lidocaine&#160;PTCH&#160;5%&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Pain associated&#160;with diabetic neuropathy, pain&#160;associated with cancer-<br/>related neuropathy (including treatment-related neuropathy&#160;[e.g.,&#160;<br/>neuropathy associated with radiation&#160;treatment or&#160;chemotherapy]).&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age&#160;Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
173&#160;<br/>
<hr/>
<a name=174></a><b>LINEZOLID</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Linezolid&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The infection&#160;is proven&#160;or strongly suspected&#160;to&#160;be caused by susceptible&#160;<br/>
<b>Medical&#160;</b><br/>
bacteria. The patient will be using&#160;the requested&#160;drug orally&#160;or&#160;<br/>
<b>Information&#160;</b><br/>
intravenously.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
Prescribed or&#160;directed by&#160;an Infectious Disease specialist when being&#160;<br/>
<b>Restrictions&#160;</b><br/>
converted from intravenous (IV) linezolid&#160;(Zyvox)&#160;<br/>
<b>Coverage&#160;</b><br/>
28 days&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
174&#160;<br/>
<hr/>
<a name=175></a><b>LONSURF</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lonsurf&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For colorectal&#160;cancer: The disease is&#160;advanced or metastatic.&#160;For gastric&#160;<br/>
<b>Medical&#160;</b><br/>
or gastroesophageal&#160;junction adenocarcinoma, all&#160;of the following criteria&#160;<br/>
<b>Information&#160;</b><br/>
must&#160;be&#160;met: 1)&#160;The disease is unresectable locally advanced,&#160;recurrent, or&#160;<br/>metastatic,&#160;and 2) The patient has&#160;been previously&#160;treated with&#160;at least&#160;<br/>two prior lines of&#160;chemotherapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
175&#160;<br/>
<hr/>
<a name=176></a><b>LORBRENA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lorbrena&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Anaplastic lymphoma&#160;kinase (ALK)-positive recurrent or advanced non-<br/>small cell&#160;lung cancer&#160;(NSCLC). Repressor of silencing (ROS)-1&#160;<br/>rearrangement-positive recurrent, advanced, or&#160;metastatic&#160;NSCLC&#160;<br/>following progression on&#160;crizotinib, entrectinib, or ceritinib.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
176&#160;<br/>
<hr/>
<a name=177></a><b>LUMAKRAS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lumakras&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
177&#160;<br/>
<hr/>
<a name=178></a><b>LUMOXITI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lumoxiti&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For hairy&#160;cell leukemia,&#160;the patient will not receive more&#160;than 6 cycles of&#160;<br/>
<b>Medical&#160;</b><br/>
treatment with the&#160;requested drug.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
6 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
178&#160;<br/>
<hr/>
<a name=179></a><b>LUPRON&#160;PED</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lupron Depot-ped (1-month)&#160;<br/>
•&#160;&#160;Lupron Depot-ped (3-month)&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For central&#160;precocious puberty (CPP),&#160;patients not currently&#160;receiving&#160;<br/>
<b>Medical&#160;</b><br/>
therapy&#160;must meet all of&#160;the following criteria: 1)&#160;Diagnosis of CPP was&#160;<br/>
<b>Information&#160;</b><br/>
confirmed by a pubertal&#160;response&#160;to&#160;a gonadotropin releasing hormone&#160;<br/>(GnRH) agonist test&#160;OR&#160;a pubertal level of&#160;a&#160;third generation luteinizing&#160;<br/>hormone (LH) assay, 2)&#160;Assessment&#160;of bone&#160;age&#160;versus chronological age&#160;<br/>supports the&#160;diagnosis of&#160;CPP, and 3) The onset of secondary sexual&#160;<br/>characteristics occurred&#160;prior to 8 years&#160;of age for female patients&#160;OR&#160;<br/>prior to 9 years&#160;of age for male patients.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>CPP:&#160;Patient must&#160;be&#160;less than 12 years&#160;old&#160;if&#160;female&#160;and less than 13&#160;<br/>
years old&#160;if&#160;male.&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
179&#160;<br/>
<hr/>
<a name=180></a><b>LUPRON-ENDOMETRIOSIS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Lupron Depot (1-month)&#160;INJ&#160;<br/>
3.75MG&#160;<br/>
•&#160;&#160;&#160;Lupron Depot (3-month)&#160;INJ&#160;<br/>
11.25MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Breast&#160;cancer, malignant&#160;sex cord-stromal&#160;tumors, epithelial ovarian&#160;<br/>cancer/fallopian tube&#160;cancer/primary peritoneal&#160;cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For uterine&#160;fibroids, patient must meet one&#160;of the&#160;following:&#160;1) Diagnosis&#160;<br/>
<b>Medical&#160;</b><br/>
of anemia (e.g., hematocrit&#160;less&#160;than or equal&#160;to 30 percent and/or&#160;<br/>
<b>Information&#160;</b><br/>
hemoglobin&#160;less than or&#160;equal&#160;to 10g/dL), OR&#160;2) the requested medication&#160;<br/>will&#160;be used&#160;prior to surgery&#160;for&#160;uterine fibroids.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Fibroids:&#160;3&#160;months (mo), max 6&#160;mo&#160;total. Endometriosis:&#160;6&#160;mo, max 12&#160;<br/>
<b>Duration&#160;</b><br/>
mo total. Others:&#160;Plan Year&#160;<br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
180&#160;<br/>
<hr/>
<a name=181></a><b>LYNPARZA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Lynparza&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent HER2-negative,&#160;BRCA&#160;1/2-germline&#160;mutated breast&#160;cancer,&#160;<br/>recurrent or&#160;metastatic&#160;HER2-positive, BRCA&#160;1/2-germline&#160;mutated&#160;<br/>breast&#160;cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For breast&#160;cancer&#160;the disease must be: 1)&#160;BRCA&#160;1/2-germline&#160;mutated,&#160;<br/>
<b>Medical&#160;</b><br/>
and 2)&#160;recurrent or&#160;metastatic. For prostate cancer: The patient has&#160;<br/>
<b>Information&#160;</b><br/>
progressed on prior treatment with an androgen receptor-directed therapy.&#160;<br/>For epithelial ovarian, fallopian&#160;tube, or primary peritoneal cancer: 1) The&#160;<br/>requested drug is&#160;used for maintenance therapy for stage&#160;II-IV&#160;or&#160;<br/>recurrent disease who are in complete or&#160;partial response to chemotherapy&#160;<br/>OR&#160;2) The patient has&#160;deleterious or&#160;suspected deleterious germline&#160;<br/>BRCA-mutated advanced, recurrent,&#160;or persistent&#160;disease after two or&#160;<br/>more prior&#160;chemotherapy regimens.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
181&#160;<br/>
<hr/>
<a name=182></a><b>LYRICA&#160;CR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pregabalin&#160;Er&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has experienced an inadequate&#160;treatment response&#160;to&#160;<br/>
<b>Medical&#160;</b><br/>
gabapentin,&#160;or the patient has&#160;experienced an intolerance to gabapentin, or&#160;<br/>
<b>Information&#160;</b><br/>
the patient has a contraindication to gabapentin.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
182&#160;<br/>
<hr/>
<a name=183></a><b>MAVYRET</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Mavyret&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
Decompensated cirrhosis/moderate&#160;or severe hepatic&#160;impairment&#160;(Child&#160;<br/>
<b>Criteria&#160;</b><br/>
Turcotte Pugh [CTP] class B or C).&#160;<br/>
<b>Required&#160;</b><br/>
For hepatitis&#160;C virus&#160;(HCV):&#160;Infection confirmed by presence of HCV&#160;<br/>
<b>Medical&#160;</b><br/>
RNA in the&#160;serum prior&#160;to starting treatment. Planned treatment regimen,&#160;<br/>
<b>Information&#160;</b><br/>
genotype, prior treatment history, presence&#160;or absence of&#160;cirrhosis&#160;<br/>(compensated or decompensated&#160;[CTP class B or&#160;C]), presence&#160;or absence&#160;<br/>of human&#160;immunodeficiency virus&#160;(HIV) coinfection, presence or&#160;absence&#160;<br/>of resistance-associated substitutions&#160;where applicable, liver&#160;and kidney&#160;<br/>transplantation status&#160;if&#160;applicable. Coverage conditions&#160;and specific&#160;<br/>durations of approval&#160;will be&#160;based on current American Association for&#160;<br/>the Study of&#160;Liver&#160;Diseases (AASLD) treatment&#160;guidelines.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Criteria will&#160;be applied consistent with current AASLD-IDSA guidance&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
183&#160;<br/>
<hr/>
<a name=184></a><b>MEKINIST</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Mekinist&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Brain metastases&#160;from melanoma, uveal&#160;melanoma, central&#160;nervous&#160;<br/>system (CNS) cancer (i.e., glioma, meningioma, astrocytoma), low grade&#160;<br/>serous ovarian cancer.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For brain&#160;metastasis from melanoma, adjuvant treatment of&#160;melanoma,&#160;<br/>
<b>Medical&#160;</b><br/>
and central&#160;nervous system (CNS) cancer&#160;(i.e., glioma, meningioma,&#160;<br/>
<b>Information&#160;</b><br/>
astrocytoma):&#160;1) The&#160;tumor&#160;is positive for&#160;a BRAF&#160;V600 activating&#160;<br/>mutation (e.g., V600E&#160;or V600K), and 2)&#160;The requested drug will&#160;be used&#160;<br/>in combination with dabrafenib. For&#160;unresectable&#160;or metastatic melanoma:&#160;<br/>1) The tumor is positive&#160;for&#160;a BRAF&#160;V600 activating mutation (e.g.,&#160;<br/>V600E&#160;or V600K), and 2) The&#160;requested drug will be used as&#160;a single&#160;<br/>agent&#160;or in combination&#160;with dabrafenib. For non-small cell&#160;lung cancer,&#160;<br/>and anaplastic thyroid cancer: 1) The&#160;tumor is positive for a&#160;BRAF&#160;<br/>V600E&#160;mutation, and 2)&#160;The requested drug will&#160;be used in combination&#160;<br/>with dabrafenib. For&#160;uveal melanoma, the&#160;requested drug will be used as&#160;a&#160;<br/>single&#160;agent.&#160;For low grade serous&#160;ovarian&#160;cancer: The requested drug&#160;<br/>will&#160;be used&#160;to treat persistent&#160;or recurrent disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
184&#160;<br/>
<hr/>
<a name=185></a><b>MEKTOVI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Mektovi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Adjuvant systemic&#160;therapy for&#160;cutaneous melanoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For cutaneous&#160;melanoma: The patient must meet all of&#160;the following&#160;<br/>
<b>Medical&#160;</b><br/>
criteria:&#160;1) Tumor&#160;is positive&#160;for&#160;BRAF&#160;V600 activating mutation&#160;(e.g.,&#160;<br/>
<b>Information&#160;</b><br/>
V600E&#160;or V600K), 2) The requested&#160;drug will be&#160;used in combination&#160;<br/>with encorafenib, and 3)&#160;The requested drug will&#160;be used for&#160;either of&#160;the&#160;<br/>following: a) unresectable or&#160;metastatic&#160;disease,&#160;or b)&#160;adjuvant systemic&#160;<br/>therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
185&#160;<br/>
<hr/>
<a name=186></a><b>MEMANTINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Memantine&#160;Hcl Titration Pak&#160;<br/>
•&#160;&#160;&#160;Memantine&#160;Hydrochloride&#160;SOLN&#160;<br/>
2MG/ML&#160;<br/>
•&#160;&#160;&#160;Memantine&#160;Hydrochloride&#160;TABS&#160;<br/>
•&#160;&#160;&#160;Memantine&#160;Hydrochloride Er&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This edit&#160;only applies to patients less than 30 years of&#160;age.&#160;<br/>
186&#160;<br/>
<hr/>
<a name=187></a><b>MEPRON</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Atovaquone&#160;SUSP&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Babesiosis,&#160;Toxoplasmosis, Pneumocystis&#160;jirovecii&#160;pneumonia&#160;<br/>prophylaxis in pediatric&#160;patients, mild-to-moderate Pneumocystis&#160;jirovecii&#160;<br/>pneumonia&#160;treatment in&#160;pediatric patients.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For the&#160;treatment of mild-to-moderate Pneumocystis&#160;jiroveci pneumonia&#160;<br/>
<b>Medical&#160;</b><br/>
(PCP): the patient had an&#160;intolerance&#160;or has a contraindication&#160;to&#160;<br/>
<b>Information&#160;</b><br/>
sulfamethoxazole/trimethoprim&#160;(SMX-TMP). For the prevention of&#160;PCP&#160;<br/>and primary&#160;toxoplasmosis prophylaxis indications: A)&#160;the patient had&#160;an&#160;<br/>intolerance&#160;or has a contraindication&#160;to SMX-TMP, AND B) the patient&#160;<br/>has had a CD4 cell count of less than&#160;200 cells per cubic millimeter&#160;<br/>within the past&#160;3 months. For secondary&#160;toxoplasmosis prophylaxis: the&#160;<br/>patient has&#160;had a CD4 cell&#160;count&#160;of less than 200&#160;cells per cubic&#160;<br/>millimeter within the past&#160;6 months. &#160;For babesiosis treatment: the&#160;<br/>requested drug is&#160;used concurrently&#160;with azithromycin OR&#160;clindamycin.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Secondary toxoplasmosis&#160;prophylaxis: 6 months,&#160;All other indications: 3&#160;<br/>
<b>Duration&#160;</b><br/>
months&#160;<br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
187&#160;<br/>
<hr/>
<a name=188></a><b>MODAFINIL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Modafinil&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The patient has&#160;a diagnosis of&#160;narcolepsy and&#160;the diagnosis is&#160;<br/>
<b>Medical&#160;</b><br/>
confirmed by sleep&#160;lab evaluation OR&#160;2) The patient has a diagnosis of&#160;<br/>
<b>Information&#160;</b><br/>
Shift Work&#160;Disorder&#160;(SWD) OR 3) The patient&#160;has a&#160;diagnosis of&#160;<br/>obstructive&#160;sleep apnea (OSA) and the&#160;diagnosis is confirmed&#160;by&#160;<br/>polysomnography.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
188&#160;<br/>
<hr/>
<a name=189></a><b>MONJUVI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Monjuvi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
189&#160;<br/>
<hr/>
<a name=190></a><b>MYLOTARG</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Mylotarg&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Acute promyelocytic&#160;leukemia&#160;(APL)&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
190&#160;<br/>
<hr/>
<a name=191></a><b>NAPROXEN-ESOMEPRAZOLE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Naproxen/esomeprazole&#160;Magnesium&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has tried two different regimens containing any combination&#160;<br/>
<b>Medical&#160;</b><br/>
of a&#160;nonsteroidal anti-inflammatory&#160;drug (NSAID) and an acid blocker&#160;<br/>
<b>Information&#160;</b><br/>
from any of&#160;the following drug classes:&#160;H2-receptor&#160;antagonist&#160;(H2RA),&#160;<br/>proton pump inhibitor&#160;(PPI).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
191&#160;<br/>
<hr/>
<a name=192></a><b>NATPARA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Natpara&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
Acute postsurgical&#160;hypoparathyroidism (within 6&#160;months of&#160;surgery)&#160;and&#160;<br/>
<b>Criteria&#160;</b><br/>
expected&#160;recovery from&#160;hypoparathyroidism.&#160;<br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
192&#160;<br/>
<hr/>
<a name=193></a><b>NAYZILAM</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Nayzilam&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>12 years&#160;of age or older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
193&#160;<br/>
<hr/>
<a name=194></a><b>NERLYNX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Nerlynx&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent human&#160;epidermal&#160;growth&#160;factor receptor 2 (HER2)-positive&#160;<br/>breast&#160;cancer, Brain&#160;metastases from&#160;HER2-positive breast&#160;cancer.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan&#160;Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
194&#160;<br/>
<hr/>
<a name=195></a><b>NEXAVAR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Nexavar&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Acute myeloid&#160;leukemia, soft&#160;tissue&#160;sarcoma (angiosarcoma,&#160;desmoid&#160;<br/>tumors/aggressive fibromatosis, and&#160;solitary&#160;fibrous tumor&#160;subtypes),&#160;<br/>gastrointestinal&#160;stromal tumor, medullary&#160;thyroid&#160;carcinoma,&#160;<br/>osteosarcoma, recurrent&#160;chordoma, epithelial ovarian cancer,&#160;fallopian&#160;<br/>tube cancer,&#160;primary&#160;peritoneal&#160;cancer.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For thyroid&#160;carcinoma:&#160;Histology&#160;is follicular, papillary, Hurthle cell or&#160;<br/>
<b>Medical&#160;</b><br/>
medullary. For acute myeloid&#160;leukemia, any of the following&#160;criteria must&#160;<br/>
<b>Information&#160;</b><br/>
be met: 1) The requested&#160;drug is used&#160;in combination with azacitidine or&#160;<br/>decitabine&#160;for low-intensity treatment induction&#160;or post-induction&#160;therapy&#160;<br/>AND the patient&#160;is 60&#160;years&#160;of age or older&#160;with&#160;FLT3-ITD mutation, OR&#160;<br/>2) The disease is relapsed/refractory&#160;AND the requested drug is a&#160;<br/>component&#160;of repeating&#160;the initial successful induction&#160;if&#160;late relapse&#160;<br/>(greater&#160;than or&#160;equal&#160;to&#160;12 months),&#160;OR&#160;3) The disease&#160;is&#160;<br/>relapsed/refractory AND&#160;the requested drug is used in combination with&#160;<br/>azacitidine or decitabine&#160;if&#160;the patient is FLT3-ITD mutation&#160;positive. For&#160;<br/>renal cell carcinoma, the&#160;patient meets ALL of the following:&#160;1) The&#160;<br/>disease is advanced, AND&#160;2) The patient has experienced disease&#160;<br/>progression&#160;or an intolerable adverse&#160;event&#160;with&#160;a trial of cabozantinib or&#160;<br/>axitinib.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
195&#160;<br/>
<hr/>
<a name=196></a><b>NINLARO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ninlaro&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Systemic light&#160;chain&#160;amyloidosis, Waldenstrom&#160;<br/>macroglobulinemia/lymphoplasmacytic lymphoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For multiple&#160;myeloma:&#160;The requested&#160;drug will be&#160;used in combination&#160;<br/>
<b>Medical&#160;</b><br/>
with lenalidomide and dexamethasone OR&#160;pomalidomide and&#160;<br/>
<b>Information&#160;</b><br/>
dexamethasone OR&#160;dexamethasone&#160;OR&#160;cyclophosphamide and&#160;<br/>dexamethasone OR&#160;as a single&#160;agent.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
196&#160;<br/>
<hr/>
<a name=197></a><b>NITISINONE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Nitisinone&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For hereditary&#160;tyrosinemia type 1: Diagnosis of&#160;hereditary&#160;tyrosinemia&#160;<br/>
<b>Medical&#160;</b><br/>
type 1 is&#160;confirmed by one of&#160;the following:&#160;1) biochemical testing&#160;(e.g.,&#160;<br/>
<b>Information&#160;</b><br/>
detection of&#160;succinylacetone in urine) or 2)&#160;DNA testing&#160;(mutation&#160;<br/>analysis).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
197&#160;<br/>
<hr/>
<a name=198></a><b>NORTHERA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Droxidopa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For neurogenic&#160;orthostatic hypotension (nOH):&#160;Prior to initial&#160;therapy,&#160;<br/>
<b>Medical&#160;</b><br/>
patient has&#160;a&#160;persistent, consistent decrease in systolic blood pressure of at&#160;<br/>
<b>Information&#160;</b><br/>
least 20 mmHg OR decrease in diastolic blood pressure of at&#160;least 10&#160;<br/>mmHg within 3 minutes&#160;of standing&#160;or head-up&#160;tilt&#160;test. For&#160;continuation&#160;<br/>of therapy for nOH, patient experienced benefit&#160;from therapy&#160;(e.g., a&#160;<br/>sustained decrease in dizziness,&#160;lightheadedness,&#160;or feeling&#160;faint). For&#160;<br/>both initial and continuation of&#160;therapy for&#160;nOH, the requested&#160;drug will&#160;<br/>be used for&#160;patients with neurogenic orthostatic&#160;hypotension associated&#160;<br/>with one&#160;of the following diagnoses:&#160;1) Primary autonomic failure due&#160;to&#160;<br/>Parkinson's&#160;disease, multiple system&#160;atrophy, or&#160;pure&#160;autonomic failure,&#160;<br/>OR&#160;2) Dopamine beta-hydroxylase deficiency,&#160;OR&#160;3) Non-diabetic&#160;<br/>autonomic neuropathy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
3 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
198&#160;<br/>
<hr/>
<a name=199></a><b>NUBEQA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Nubeqa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The requested&#160;drug will&#160;be used in combination with a gonadotropin-<br/>
<b>Medical&#160;</b><br/>
releasing hormone (GnRH) analog or&#160;after bilateral orchiectomy.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
199&#160;<br/>
<hr/>
<a name=200></a><b>NUEDEXTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Nuedexta&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
200&#160;<br/>
<hr/>
<a name=201></a><b>NUPLAZID</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Nuplazid&#160;CAPS&#160;<br/>
•&#160;&#160;Nuplazid&#160;TABS 10MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For hallucinations&#160;and delusions associated with&#160;Parkinson's&#160;disease&#160;<br/>
<b>Medical&#160;</b><br/>
psychosis, the diagnosis of Parkinson's disease&#160;must&#160;be&#160;made prior to the&#160;<br/>
<b>Information&#160;</b><br/>
onset&#160;of psychotic&#160;symptoms.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
201&#160;<br/>
<hr/>
<a name=202></a><b>OCTREOTIDE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Octreotide&#160;Acetate&#160;INJ&#160;<br/>
1000MCG/ML, 100MCG/ML,&#160;<br/>200MCG/ML, 500MCG/ML,&#160;<br/>50MCG/ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Tumor&#160;control&#160;of thymomas&#160;and&#160;thymic carcinomas.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For acromegaly&#160;(initial):&#160;1) patient has a high pretreatment insulin-like&#160;<br/>
<b>Medical&#160;</b><br/>
growth factor-1 (IGF-1) level for age&#160;and/or&#160;gender&#160;based on the&#160;<br/>
<b>Information&#160;</b><br/>
laboratory&#160;reference range, and 2)&#160;patient had an&#160;inadequate or partial&#160;<br/>response&#160;to&#160;surgery or radiotherapy&#160;OR&#160;there is&#160;a clinical&#160;reason for why&#160;<br/>the patient has not had surgery or&#160;radiotherapy.&#160;For acromegaly&#160;<br/>(continuation of therapy):&#160;patient's IGF-1 level has decreased&#160;or&#160;<br/>normalized&#160;since&#160;initiation of therapy. For tumor control of&#160;thymomas&#160;and&#160;<br/>thymic carcinomas, the requested drug&#160;will&#160;be used as second-line&#160;<br/>systemic&#160;therapy in patients with unresectable or&#160;extrathoracic metastatic&#160;<br/>disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
202&#160;<br/>
<hr/>
<a name=203></a><b>ODOMZO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Odomzo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age&#160;Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
203&#160;<br/>
<hr/>
<a name=204></a><b>OFEV</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ofev&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
204&#160;<br/>
<hr/>
<a name=205></a><b>ONCASPAR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Oncaspar&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Extranodal&#160;natural&#160;killer/T-cell&#160;lymphoma (nasal type), hepatosplenic&#160;<br/>gamma-delta T-cell lymphoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For extranodal&#160;natural killer/T-cell&#160;lymphoma&#160;(nasal&#160;type), acute&#160;<br/>
<b>Medical&#160;</b><br/>
lymphoblastic leukemia,&#160;and hepatosplenic gamma-delta T-cell&#160;<br/>
<b>Information&#160;</b><br/>
lymphoma: the requested&#160;drug must be used in conjunction with multi-<br/>agent&#160;chemotherapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
205&#160;<br/>
<hr/>
<a name=206></a><b>ONUREG</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Onureg&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age&#160;Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
206&#160;<br/>
<hr/>
<a name=207></a><b>OPSUMIT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Opsumit&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For pulmonary&#160;arterial hypertension&#160;(PAH) (World Health Organization&#160;<br/>
<b>Medical&#160;</b><br/>
[WHO] Group 1): Diagnosis was confirmed by right heart catheterization.&#160;<br/>
<b>Information&#160;</b><br/>
For PAH&#160;new starts only: 1)&#160;Pretreatment mean&#160;pulmonary arterial&#160;<br/>pressure is greater than 20 mmHg, 2)&#160;Pretreatment pulmonary capillary&#160;<br/>wedge pressure&#160;is less than or&#160;equal to 15 mmHg, and 3)&#160;Pretreatment&#160;<br/>pulmonary vascular resistance&#160;is greater&#160;than or&#160;equal to 3 Wood units.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
207&#160;<br/>
<hr/>
<a name=208></a><b>ORACEA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Doxycycline&#160;CPDR&#160;<br/>
•&#160;&#160;Oracea&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Patient must&#160;have experienced an inadequate&#160;treatment response,&#160;<br/>
<b>Medical&#160;</b><br/>
intolerance,&#160;or has a contraindication&#160;to formulary&#160;generic topical&#160;<br/>
<b>Information&#160;</b><br/>
metronidazole.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
208&#160;<br/>
<hr/>
<a name=209></a><b>ORAL-INTRANASAL&#160;FENTANYL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Fentanyl&#160;Citrate Oral Transmucosal&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is indicated for the treatment of&#160;breakthrough&#160;<br/>
<b>Medical&#160;</b><br/>
CANCER-related pain only. The requested drug&#160;is being prescribed&#160;for&#160;<br/>
<b>Information&#160;</b><br/>
the management&#160;of breakthrough pain&#160;in a CANCER patient&#160;with&#160;<br/>underlying&#160;CANCER pain AND&#160;2) The International&#160;Classification of&#160;<br/>Diseases (ICD) diagnosis code provided supports the CANCER-<br/>RELATED diagnosis.&#160;[Note:&#160;For drug coverage&#160;approval, ICD&#160;diagnosis&#160;<br/>code provided MUST support the CANCER-RELATED diagnosis.]&#160;AND&#160;<br/>3) The patient is currently receiving,&#160;and will continue&#160;to receive, around-<br/>the-clock opioid therapy&#160;for&#160;underlying CANCER pain AND 4)&#160;The&#160;<br/>requested drug is&#160;intended only for use in opioid tolerant patients. The&#160;<br/>patient can safely&#160;take&#160;the requested&#160;dose based on their current opioid&#160;<br/>use history.&#160;[Note: Patients considered opioid&#160;tolerant&#160;are&#160;those who are&#160;<br/>taking around-the-clock&#160;medicine consisting of at least 60 mg of oral&#160;<br/>morphine per day, at least 25 mcg per hour of&#160;transdermal fentanyl, at&#160;<br/>least 30 mg&#160;of oral oxycodone per&#160;day, at&#160;least 60 mg of&#160;oral&#160;hydrocodone&#160;<br/>per&#160;day, at least&#160;8&#160;mg of oral&#160;hydromorphone per&#160;day, at least 25&#160;mg of&#160;<br/>oral oxymorphone per&#160;day, or&#160;an equianalgesic&#160;dose of&#160;another opioid&#160;<br/>medication&#160;daily&#160;for&#160;one&#160;week or longer.].&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
209&#160;<br/>
<hr/>
<a name=210></a><b>ORGOVYX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Orgovyx&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
210&#160;<br/>
<hr/>
<a name=211></a><b>ORKAMBI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Orkambi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For cystic&#160;fibrosis (CF):&#160;The requested medication will&#160;not be used in&#160;<br/>
<b>Medical&#160;</b><br/>
combination&#160;with other&#160;medications&#160;containing ivacaftor.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>2 years&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
211&#160;<br/>
<hr/>
<a name=212></a><b>OXANDROLONE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Oxandrolone&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Cachexia&#160;associated&#160;with AIDS (HIV&#160;wasting), To enhance&#160;growth in&#160;<br/>patients with Turners Syndrome&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Turners Syndrome: Plan&#160;Year, All&#160;other&#160;diagnoses: 6 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;will&#160;be denied if request&#160;is for an indication excluded from&#160;<br/>Medicare&#160;Part&#160;D.&#160;<br/>
212&#160;<br/>
<hr/>
<a name=213></a><b>OXAZEPAM&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Oxazepam&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For all&#160;indications: the prescriber must acknowledge the benefit&#160;of&#160;<br/>
<b>Medical&#160;</b><br/>
therapy with&#160;the requested drug outweighs the potential risks&#160;for the&#160;<br/>
<b>Information&#160;</b><br/>
patient. &#160;(Note:&#160;The American Geriatrics&#160;Society identifies&#160;the use of this&#160;<br/>medication&#160;as potentially inappropriate&#160;in older&#160;adults,&#160;meaning it&#160;is best&#160;<br/>avoided, prescribed at&#160;reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.) &#160;For the management of&#160;anxiety disorders, anxiety associated&#160;<br/>with depression, and the&#160;management of anxiety, tension, agitation and&#160;<br/>irritability&#160;in&#160;older&#160;patients:&#160;1) the&#160;requested drug&#160;is being used&#160;<br/>concurrently&#160;with a&#160;selective&#160;serotonin&#160;reuptake inhibitor (SSRI) or&#160;<br/>serotonin-norepinephrine reuptake inhibitor (SNRI) until the SSRI/SNRI&#160;<br/>becomes&#160;effective for the symptoms of anxiety,&#160;OR&#160;2) the patient has&#160;<br/>experienced&#160;an inadequate treatment response, intolerance, or&#160;a has a&#160;<br/>contraindication to AT LEAST TWO&#160;agents from&#160;the following classes:&#160;<br/>a)&#160;selective&#160;serotonin reuptake&#160;inhibitors&#160;(SSRIs), b)&#160;serotonin-<br/>norepinephrine reuptake&#160;inhibitors&#160;(SNRIs).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Short-term relief&#160;anxiety-1 month, Anxiety Disorders-4&#160;months, Alcohol&#160;<br/>
<b>Duration&#160;</b><br/>
Withdrawal-Plan Year&#160;<br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age&#160;or older.&#160;<br/>
213&#160;<br/>
<hr/>
<a name=214></a><b>PADCEV</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Padcev&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent primary&#160;carcinoma of&#160;the urethra, recurrent or&#160;persistent&#160;<br/>urothelial carcinoma of&#160;the bladder.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For urothelial&#160;carcinoma, the&#160;requested drug will be used as&#160;subsequent&#160;<br/>
<b>Medical&#160;</b><br/>
therapy&#160;for&#160;any of the following: a) locally&#160;advanced or metastatic&#160;<br/>
<b>Information&#160;</b><br/>
urothelial carcinoma, b)&#160;urothelial carcinoma of&#160;the bladder&#160;with muscle&#160;<br/>invasive local recurrence or&#160;persistent disease in&#160;a preserved&#160;bladder, c)&#160;<br/>urothelial carcinoma of&#160;the bladder&#160;with metastatic or local recurrence&#160;<br/>post&#160;cystectomy, or d)&#160;recurrent primary carcinoma of&#160;the urethra.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
214&#160;<br/>
<hr/>
<a name=215></a><b>PEGASYS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pegasys&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Myeloproliferative neoplasm&#160;(essential&#160;thrombocythemia, polycythemia&#160;<br/>vera, symptomatic low risk myelofibrosis), systemic&#160;mastocytosis, adult&#160;<br/>T-cell leukemia/lymphoma, mycosis&#160;fungoides/Sezary syndrome,&#160;primary&#160;<br/>cutaneous CD30+ T-cell&#160;lymphoproliferative disorders.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;hepatitis C:&#160;Hepatitis C&#160;virus (HCV)&#160;confirmed by presence&#160;<br/>
<b>Medical&#160;</b><br/>
of hepatitis C&#160;virus HCV RNA in serum prior&#160;to&#160;starting&#160;treatment and the&#160;<br/>
<b>Information&#160;</b><br/>
planned treatment regimen.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
HCV:&#160;12-48 weeks&#160;depending on regimen. HBV: 48 weeks. All&#160;Other:&#160;<br/>
<b>Duration&#160;</b><br/>
Plan Year.&#160;<br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
215&#160;<br/>
<hr/>
<a name=216></a><b>PEMAZYRE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pemazyre&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
216&#160;<br/>
<hr/>
<a name=217></a><b>PEPAXTO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pepaxto&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
217&#160;<br/>
<hr/>
<a name=218></a><b>PHENYLBUTYRATE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Sodium&#160;Phenylbutyrate&#160;POWD&#160;<br/>
3GM/TSP&#160;<br/>
•&#160;&#160;&#160;Sodium&#160;Phenylbutyrate&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For urea&#160;cycle disorder:&#160;Diagnosis of urea cycle disorder (UCD) was&#160;<br/>
<b>Medical&#160;</b><br/>
confirmed by enzymatic,&#160;biochemical or&#160;genetic&#160;testing.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
218&#160;<br/>
<hr/>
<a name=219></a><b>PHESGO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Phesgo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent human&#160;epidermal&#160;growth&#160;factor receptor 2 (HER2)-positive&#160;<br/>breast&#160;cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Neoadjuvant&#160;therapy&#160;for&#160;breast&#160;cancer: 6 months. Other: Plan&#160;Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
219&#160;<br/>
<hr/>
<a name=220></a><b>PIQRAY</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Piqray 200mg Daily Dose&#160;<br/>
•&#160;&#160;Piqray 250mg Daily Dose&#160;<br/>
•&#160;&#160;Piqray 300mg Daily Dose&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent hormone&#160;receptor&#160;(HR)-positive, human epidermal growth&#160;<br/>factor receptor 2 (HER2)-negative, PIK3CA-mutated breast cancer&#160;in&#160;<br/>combination&#160;with fulvestrant.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
220&#160;<br/>
<hr/>
<a name=221></a><b>POLIVY</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Polivy&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
High-grade&#160;B-cell&#160;lymphomas, histologic&#160;transformation of&#160;follicular to&#160;<br/>diffuse large B-cell&#160;lymphoma without translocations of MYC and BCL2&#160;<br/>and/or&#160;BCL6, monomorphic post-transplant&#160;lymphoproliferative disorders&#160;<br/>(B-cell type), acquired immunodeficiency syndrome (AIDS)-related B-<br/>cell&#160;lymphomas&#160;(AIDS-related diffuse large B-cell&#160;lymphoma, primary&#160;<br/>effusion lymphoma, and&#160;human herpesvirus-8 (HHV8)-positive diffuse&#160;<br/>large B-cell&#160;lymphoma),&#160;histologic transformation of nodal&#160;marginal zone&#160;<br/>lymphoma to diffuse large B-cell lymphoma, follicular&#160;lymphoma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For diffuse&#160;large B-cell&#160;lymphomas&#160;and high-grade B-cell lymphomas: 1)&#160;<br/>
<b>Medical&#160;</b><br/>
The requested drug is used as a single agent or in&#160;combination with&#160;<br/>
<b>Information&#160;</b><br/>
bendamustine with or&#160;without a rituximab product,&#160;AND 2) Patient has&#160;<br/>received at&#160;least&#160;two prior therapies.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
221&#160;<br/>
<hr/>
<a name=222></a><b>POMALYST</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pomalyst&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Systemic light&#160;chain&#160;amyloidosis, primary central nervous system&#160;(CNS)&#160;<br/>lymphoma,&#160;POEMS syndrome.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For multiple&#160;myeloma:&#160;The patient has previously&#160;received at&#160;least&#160;two&#160;<br/>
<b>Medical&#160;</b><br/>
prior therapies for multiple myeloma,&#160;including&#160;an immunomodulatory&#160;<br/>
<b>Information&#160;</b><br/>
agent&#160;AND a proteasome inhibitor. For Kaposi&#160;sarcoma, patient meets&#160;<br/>one of&#160;the following: 1)&#160;patient has&#160;acquired&#160;immunodeficiency syndrome&#160;<br/>(AIDS), or 2) patient&#160;is negative for human immunodeficiency virus&#160;<br/>(HIV).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
222&#160;<br/>
<hr/>
<a name=223></a><b>POTELIGEO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Poteligeo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Adult T-cell&#160;leukemia/lymphoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
223&#160;<br/>
<hr/>
<a name=224></a><b>PRALUENT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Praluent&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
224&#160;<br/>
<hr/>
<a name=225></a><b>PREGABALIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pregabalin&#160;CAPS&#160;<br/>
•&#160;&#160;Pregabalin&#160;SOLN&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Cancer-Related Neuropathic&#160;Pain, Cancer&#160;Treatment-Related Neuropathic&#160;<br/>Pain&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being prescribed for the&#160;management of&#160;<br/>
<b>Medical&#160;</b><br/>
postherpetic&#160;neuralgia, the management of&#160;neuropathic&#160;pain associated&#160;<br/>
<b>Information&#160;</b><br/>
with diabetic peripheral&#160;neuropathy, cancer-related neuropathic pain, or&#160;<br/>cancer&#160;treatment-related&#160;neuropathic&#160;pain AND&#160;2) The&#160;patient has&#160;<br/>experienced&#160;an inadequate treatment response, intolerance, or&#160;<br/>contraindication to gabapentin OR&#160;3) The requested drug&#160;is being&#160;<br/>prescribed as adjunctive&#160;therapy&#160;for&#160;the treatment of partial onset&#160;seizures&#160;<br/>OR&#160;4) The requested drug is being prescribed for&#160;the management&#160;of&#160;<br/>fibromyalgia or the management of&#160;neuropathic&#160;pain associated with&#160;<br/>spinal&#160;cord injury.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
225&#160;<br/>
<hr/>
<a name=226></a><b>PRETOMANID</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pretomanid&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
226&#160;<br/>
<hr/>
<a name=227></a><b>PROMACTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Promacta&#160;<br/>
227&#160;<br/>
<hr/>
<a name=228></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;or persistent&#160;immune thrombocytopenia (ITP): 1)&#160;For new&#160;<br/>
<b>Medical&#160;</b><br/>
starts:&#160;a)&#160;Patient&#160;has had&#160;an inadequate response&#160;or is intolerant to a prior&#160;<br/>
<b>Information&#160;</b><br/>
therapy such&#160;as corticosteroids or immunoglobulins, b)&#160;Untransfused&#160;<br/>platelet&#160;(plt) count at&#160;any point&#160;prior&#160;to the&#160;initiation of the requested&#160;<br/>medication&#160;is less than 30,000/mcL&#160;OR&#160;30,000-50,000/mcL&#160;with&#160;<br/>symptomatic bleeding or risk&#160;factor(s)&#160;for&#160;bleeding (e.g., undergoing a&#160;<br/>medical or&#160;dental procedure&#160;where blood loss is&#160;anticipated,&#160;comorbidities&#160;<br/>such as peptic ulcer&#160;disease and hypertension, anticoagulation therapy,&#160;<br/>profession or lifestyle&#160;that predisposes patient&#160;to&#160;trauma)&#160;AND c) For&#160;<br/>chronic ITP only: patient&#160;has had an inadequate&#160;response or&#160;intolerance to&#160;<br/>avatrombopag. 2)&#160;For continuation of therapy, plt count&#160;response&#160;to the&#160;<br/>requested drug: a)&#160;Current plt&#160;count is less than or equal to 200,000/mcL&#160;<br/>OR&#160;b) Current plt&#160;count is greater&#160;than 200,000/mcL to less than or&#160;equal&#160;<br/>to 400,000/mcL and dosing will&#160;be&#160;adjusted to a&#160;plt&#160;count sufficient to&#160;<br/>avoid clinically&#160;important bleeding.&#160;For thrombocytopenia associated&#160;<br/>with chronic&#160;hepatitis C:&#160;1) For&#160;new starts:&#160;the requested drug&#160;is used for&#160;<br/>initiation and maintenance of&#160;interferon-based therapy. 2) For&#160;<br/>continuation&#160;of therapy:&#160;patient is&#160;receiving&#160;interferon-based therapy. For&#160;<br/>severe&#160;aplastic anemia (AA): For&#160;continuation of therapy following the&#160;<br/>initial 6&#160;month approval for severe aplastic anemia: The patient&#160;must&#160;meet&#160;<br/>one of&#160;the following: 1)&#160;Current plt&#160;count is 50,000-200,000/mcL OR&#160;2)&#160;<br/>Current plt&#160;count is less&#160;than 50,000/mcL and patient&#160;has not&#160;received&#160;<br/>appropriately titrated therapy for at&#160;least 16 weeks, OR&#160;3) Current plt&#160;<br/>count is&#160;less&#160;than 50,000/mcL and patient is&#160;transfusion-independent, OR&#160;<br/>4) Current plt count is greater than 200,000/mcL&#160;to less than&#160;or equal to&#160;<br/>400,000/mcL and dosing will be adjusted to&#160;achieve and maintain an&#160;<br/>appropriate&#160;target&#160;plt&#160;count.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
HCV:&#160;6mo, ITP/AA&#160;initial:&#160;6mo, ITP&#160;reauth: Plan Year, AA&#160;reauth:&#160;APR-<br/>
<b>Duration&#160;</b><br/>
Plan Year, IPR-16 wks&#160;<br/>
228&#160;<br/>
<hr/>
<a name=229></a><b>Other Criteria&#160;</b><br/>
APR:&#160;adequate platelet&#160;response (greater&#160;than 50,000/mcL),&#160;IPR:&#160;<br/>inadequate platelet&#160;response (less than 50,000/mcL).&#160;<br/>
229&#160;<br/>
<hr/>
<a name=230></a><b>PULMOZYME</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Pulmozyme&#160;SOLN&#160;2.5MG/2.5ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For cystic&#160;fibrosis: Diagnosis of&#160;cystic fibrosis was confirmed by&#160;<br/>
<b>Medical&#160;</b><br/>
appropriate&#160;diagnostic or genetic testing.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available&#160;under&#160;Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
230&#160;<br/>
<hr/>
<a name=231></a><b>QINLOCK</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Qinlock&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
231&#160;<br/>
<hr/>
<a name=232></a><b>QUETIAPINE&#160;XR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Quetiapine&#160;Fumarate Er&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Maintenance monotherapy&#160;treatment&#160;in bipolar&#160;I&#160;disorder, monotherapy&#160;<br/>treatment of&#160;generalized&#160;anxiety disorder, monotherapy treatment of&#160;<br/>major depressive&#160;disorder&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For schizophrenia,&#160;acute&#160;treatment of manic or mixed episodes associated&#160;<br/>
<b>Medical&#160;</b><br/>
with bipolar I disorder, both as&#160;monotherapy&#160;and&#160;as an adjunct to lithium&#160;<br/>
<b>Information&#160;</b><br/>
or divalproex, the acute treatment of&#160;depressive episodes associated with&#160;<br/>bipolar disorder, maintenance treatment of&#160;bipolar I disorder,&#160;as an&#160;<br/>adjunct&#160;to lithium or&#160;divalproex, adjunctive&#160;treatment of major depressive&#160;<br/>disorder, or&#160;maintenance&#160;monotherapy treatment in bipolar I disorder: The&#160;<br/>patient experienced an inadequate&#160;treatment&#160;response, intolerance, or&#160;<br/>contraindication to one of the following generic products: A)&#160;aripiprazole,&#160;<br/>B) asenapine, C) olanzapine, D) quetiapine immediate-release, E)&#160;<br/>risperidone,&#160;F) ziprasidone. For all indications:&#160;If&#160;the patient&#160;is 65 years of&#160;<br/>age or&#160;older AND&#160;is using two or more&#160;additional&#160;central nervous system&#160;<br/>(CNS) active medications (e.g., lorazepam, sertraline,&#160;clonazepam,&#160;<br/>escitalopram, alprazolam, zolpidem)&#160;with the&#160;requested drug,&#160;the&#160;<br/>prescriber determined&#160;that taking multiple central&#160;nervous system&#160;(CNS)&#160;<br/>active medications&#160;is medically necessary. [Note:&#160;Use of multiple central&#160;<br/>nervous system (CNS) active&#160;medications in older adults is&#160;associated&#160;<br/>with an increased risk of falls.].&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
232&#160;<br/>
<hr/>
<a name=233></a><b>QUININE&#160;SULFATE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Quinine&#160;Sulfate&#160;CAPS 324MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Babesiosis,&#160;uncomplicated Plasmodium vivax&#160;malaria&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
1 month&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
233&#160;<br/>
<hr/>
<a name=234></a><b>REGRANEX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Regranex&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For the&#160;treatment of lower&#160;extremity diabetic neuropathic ulcers&#160;that&#160;<br/>
<b>Medical&#160;</b><br/>
extend into the subcutaneous tissue or beyond and have an&#160;adequate blood&#160;<br/>
<b>Information&#160;</b><br/>
supply.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
20 weeks&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
234&#160;<br/>
<hr/>
<a name=235></a><b>RETEVMO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Retevmo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent or&#160;advanced rearranged during transfection (RET)-<br/>rearrangement positive non-small cell lung cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For non-small&#160;cell&#160;lung cancer, patient must meet&#160;all&#160;of the&#160;following:&#160;1)&#160;<br/>
<b>Medical&#160;</b><br/>
The disease&#160;is recurrent,&#160;advanced or metastatic,&#160;and 2) Tumor is RET&#160;<br/>
<b>Information&#160;</b><br/>
fusion-positive or&#160;RET&#160;rearrangement-positive.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>Non-small cell&#160;lung cancer:&#160;18 years&#160;of age or&#160;older.&#160;Medullary thyroid&#160;<br/>
cancer&#160;and thyroid cancer:&#160;12 years&#160;of age or&#160;older.&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
235&#160;<br/>
<hr/>
<a name=236></a><b>REVLIMID</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Revlimid&#160;<br/>
236&#160;<br/>
<hr/>
<a name=237></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Systemic light&#160;chain&#160;amyloidosis, classical Hodgkin lymphoma,&#160;<br/>myelodysplastic&#160;syndrome without the 5q deletion cytogenetic&#160;<br/>abnormality,&#160;myelofibrosis-associated anemia, POEMS syndrome,&#160;<br/>myeloproliferative neoplasms, non-Hodgkin's lymphoma with&#160;the&#160;<br/>following subtypes:&#160;acquired&#160;immunodeficiency&#160;syndrome (AIDS)-<br/>related non-germinal&#160;center&#160;diffuse large B-cell&#160;lymphoma, primary&#160;<br/>central nervous system (CNS) lymphoma, monomorphic post-transplant&#160;<br/>lymphoproliferative disorder, chronic&#160;lymphocytic leukemia&#160;(CLL)/small&#160;<br/>lymphocytic&#160;lymphoma (SLL), diffuse large B-cell lymphoma,&#160;<br/>multicentric&#160;Castleman's&#160;disease, adult T-cell&#160;leukemia/lymphoma,&#160;<br/>mycosis fungoides&#160;(MF)/Sezary syndrome (SS),&#160;angioimmunoblastic T-<br/>cell&#160;lymphoma (AITL),&#160;peripheral T-cell lymphoma not&#160;otherwise&#160;<br/>specified&#160;(PTCL NOS), enteropathy-associated T-cell lymphoma,&#160;<br/>monomorphic epitheliotropic intestinal T-cell&#160;lymphoma, nodal peripheral&#160;<br/>T-cell lymphoma, primary cutaneous&#160;anaplastic&#160;large cell&#160;lymphoma&#160;<br/>(ALCL), hepatosplenic&#160;T-cell lymphoma, high-grade B-cell lymphomas,&#160;<br/>histologic transformation of nodal&#160;marginal zone&#160;lymphoma to diffuse&#160;<br/>large B-cell&#160;lymphoma,&#160;histologic transformation of follicular lymphoma&#160;<br/>to diffuse&#160;large B-cell lymphoma, AIDS-related&#160;Kaposi sarcoma,&#160;<br/>smoldering&#160;myeloma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For myelodysplastic&#160;syndrome (MDS):&#160;Lower&#160;risk MDS with&#160;<br/>
<b>Medical&#160;</b><br/>
symptomatic anemia per the Revised International Prognostic&#160;Scoring&#160;<br/>
<b>Information&#160;</b><br/>
System (IPSS-R), International Prognostic Scoring System (IPSS), or&#160;<br/>World Health organization (WHO) classification-based Prognostic&#160;<br/>Scoring System (WPSS).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
237&#160;<br/>
<hr/>
<a name=238></a><b>REZUROCK</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Rezurock&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>12 years&#160;of age or older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
238&#160;<br/>
<hr/>
<a name=239></a><b>RINVOQ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Rinvoq&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For moderately&#160;to severely active rheumatoid arthritis (new&#160;starts&#160;only):&#160;<br/>
<b>Medical&#160;</b><br/>
1) inadequate response,&#160;intolerance or contraindication to methotrexate&#160;<br/>
<b>Information&#160;</b><br/>
(MTX) OR 2) inadequate response or intolerance to a prior biologic&#160;<br/>disease-modifying&#160;antirheumatic drug (DMARD) or&#160;a targeted synthetic&#160;<br/>DMARD.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
239&#160;<br/>
<hr/>
<a name=240></a><b>RITUXAN&#160;HYCELA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Rituxan Hycela&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Castleman's&#160;disease&#160;(CD), high-grade B-cell lymphoma, histologic&#160;<br/>transformation of nodal&#160;marginal&#160;zone lymphoma to diffuse&#160;large B-cell&#160;<br/>lymphoma,&#160;marginal&#160;zone lymphomas (nodal marginal zone&#160;lymphoma,&#160;<br/>gastric mucosa-associated lymphoid&#160;tissue (MALT) lymphoma,&#160;<br/>nongastric&#160;MALT&#160;lymphoma, and&#160;splenic marginal&#160;zone lymphoma),&#160;<br/>mantle&#160;cell&#160;lymphoma, post-transplant lymphoproliferative disorder&#160;<br/>(PTLD), primary cutaneous B-cell lymphoma (e.g., cutaneous marginal&#160;<br/>zone lymphoma or cutaneous follicle center lymphomas), hairy cell&#160;<br/>leukemia, small lymphocytic&#160;lymphoma (SLL).&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Malignancies must&#160;be CD20 positive. Patient must receive&#160;at least one&#160;<br/>
<b>Medical&#160;</b><br/>
full dose of&#160;a rituximab&#160;product by&#160;intravenous infusion without&#160;<br/>
<b>Information&#160;</b><br/>
experiencing severe adverse reactions.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
240&#160;<br/>
<hr/>
<a name=241></a><b>RITUXIMAB</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Rituxan&#160;<br/>
•&#160;&#160;Ruxience&#160;<br/>
241&#160;<br/>
<hr/>
<a name=242></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Non-Hodgkin's lymphoma&#160;subtypes&#160;[small&#160;lymphocytic&#160;lymphoma&#160;<br/>(SLL), mantle cell lymphoma, marginal zone&#160;lymphomas&#160;(nodal, splenic,&#160;<br/>gastric mucosa-associated lymphoid&#160;tissue [MALT], nongastric MALT),&#160;<br/>Burkitt&#160;lymphoma, primary cutaneous B-cell lymphoma, high-grade B-<br/>cell&#160;lymphoma&#160;with&#160;translocations of MYC and BCL2 and/or BCL6&#160;<br/>(double/triple hit&#160;lymphoma), high-grade B-cell lymphoma not&#160;otherwise&#160;<br/>specified, histological&#160;transformation from&#160;follicular&#160;lymphoma to diffuse&#160;<br/>large B-cell&#160;lymphoma,&#160;histological&#160;transformation from nodal&#160;marginal&#160;<br/>zone lymphoma to diffuse large B-cell&#160;lymphoma, Castleman's disease,&#160;<br/>acquired immunodeficiency syndrome (AIDS)-related B-cell&#160;lymphoma,&#160;<br/>hairy cell&#160;leukemia, post-transplant lymphoproliferative disorder&#160;(PTLD),&#160;<br/>B-cell&#160;lymphoblastic lymphoma], refractory&#160;immune or&#160;idiopathic&#160;<br/>thrombocytopenic&#160;purpura (ITP), autoimmune hemolytic anemia,&#160;<br/>Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma,&#160;<br/>chronic graft-versus-host disease (GVHD), Sjogren&#160;syndrome, thrombotic&#160;<br/>thrombocytopenic&#160;purpura, refractory&#160;myasthenia&#160;gravis, Hodgkin's&#160;<br/>lymphoma (nodular&#160;lymphocyte-predominant), primary&#160;central nervous&#160;<br/>system (CNS) lymphoma, leptomeningeal&#160;metastases from lymphomas,&#160;<br/>acute&#160;lymphoblastic leukemia, prevention of Epstein-Barr&#160;virus (EBV)-<br/>related PTLD, multiple sclerosis, and immune checkpoint&#160;inhibitor-<br/>related toxicities&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For moderately&#160;to severely active rheumatoid arthritis (new&#160;starts&#160;only):&#160;<br/>
<b>Medical&#160;</b><br/>
1) patient&#160;meets ANY of the following: a)&#160;requested drug will&#160;be used&#160;in&#160;<br/>
<b>Information&#160;</b><br/>
combination&#160;with methotrexate (MTX) OR&#160;b) patient has&#160;intolerance or&#160;<br/>contraindication to MTX, AND 2) patient meets ANY&#160;of the following: a)&#160;<br/>inadequate response, intolerance, or&#160;contraindication to MTX&#160;OR&#160;b)&#160;<br/>inadequate response&#160;or intolerance&#160;to&#160;a prior&#160;biologic disease-modifying&#160;<br/>antirheumatic drug (DMARD) or a targeted synthetic DMARD.&#160;<br/>Hematologic malignancies&#160;must be&#160;CD20-positive. For multiple sclerosis:&#160;<br/>1) patient has a diagnosis of relapsing&#160;remitting multiple sclerosis&#160;and 2)&#160;<br/>patient has&#160;had an inadequate&#160;response to two or&#160;more disease-modifying&#160;<br/>drugs&#160;indicated for multiple sclerosis despite adequate duration of&#160;<br/>treatment.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
242&#160;<br/>
<hr/>
<a name=243></a><b>Coverage&#160;</b><br/>
Immune checkpoint&#160;inhibitor-related&#160;toxicities: 3&#160;months, All&#160;other: Plan&#160;<br/>
<b>Duration&#160;</b><br/>
Year&#160;<br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
243&#160;<br/>
<hr/>
<a name=244></a><b>ROZLYTREK</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Rozlytrek&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent or&#160;advanced ROS1-positive non-small cell&#160;lung cancer&#160;<br/>(NSCLC), advanced, recurrent, or persistent&#160;neurotrophic tyrosine&#160;<br/>receptor&#160;kinase (NTRK) gene fusion-positive solid tumors, first-line&#160;<br/>treatment of&#160;NTRK&#160;gene&#160;fusion-positive solid&#160;tumors.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For all&#160;neurotrophic tyrosine&#160;receptor kinase&#160;(NTRK) gene fusion-<br/>
<b>Medical&#160;</b><br/>
positive solid tumors,&#160;the disease is&#160;without&#160;a known acquired resistance&#160;<br/>
<b>Information&#160;</b><br/>
mutation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
244&#160;<br/>
<hr/>
<a name=245></a><b>RUBRACA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Rubraca&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For metastatic&#160;castration-resistant prostate cancer with a deleterious breast&#160;<br/>
<b>Medical&#160;</b><br/>
cancer&#160;susceptibility gene (BRCA) mutation (germline and/or somatic): 1)&#160;<br/>
<b>Information&#160;</b><br/>
patient has&#160;been treated&#160;with androgen receptor-directed therapy, 2)&#160;<br/>patient&#160;has been treated&#160;with a&#160;taxane-based chemotherapy or the patient&#160;<br/>is not&#160;fit&#160;for&#160;chemotherapy, 3) the requested drug will&#160;be used in&#160;<br/>combination&#160;with a&#160;gonadotropin-releasing hormone (GnRH) analog or&#160;<br/>after bilateral orchiectomy, and 4)&#160;patient experienced&#160;an unacceptable&#160;<br/>toxicity with a trial&#160;of Lynparza&#160;(olaparib). For maintenance treatment of&#160;<br/>patients with recurrent&#160;epithelial ovarian, fallopian tube, or primary&#160;<br/>peritoneal cancer&#160;who are&#160;in a complete or partial response to&#160;platinum-<br/>based chemotherapy, patient experienced an unacceptable toxicity with a&#160;<br/>trial of Lynparza&#160;(olaparib). For treatment&#160;of patients&#160;with&#160;a deleterious&#160;<br/>breast&#160;cancer susceptibility gene&#160;(BRCA) mutation (germline&#160;and/or&#160;<br/>somatic)-associated epithelial ovarian, fallopian tube, or&#160;primary&#160;<br/>peritoneal cancer&#160;who have been treated with&#160;two or more&#160;<br/>chemotherapies:&#160;if&#160;prescribed for deleterious germline BRCA-mutated&#160;<br/>advanced ovarian&#160;cancer&#160;treated with&#160;two or more prior&#160;chemotherapies,&#160;<br/>the patient&#160;experienced an unacceptable toxicity&#160;with a&#160;trial of Lynparza&#160;<br/>(olaparib).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
245&#160;<br/>
<hr/>
<a name=246></a><b>RYDAPT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Rydapt&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Relapsed or&#160;refractory acute myeloid&#160;leukemia (AML), myeloid,&#160;<br/>lymphoid, or mixed lineage neoplasms with eosinophilia and&#160;FGFR1 or&#160;<br/>FLT3 rearrangements, post-remission maintenance therapy for acute&#160;<br/>myeloid leukemia&#160;(AML), re-induction in residual disease&#160;for acute&#160;<br/>myeloid leukemia&#160;(AML)&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For acute&#160;myeloid&#160;leukemia&#160;(AML): AML must&#160;be FLT3 mutation-<br/>
<b>Medical&#160;</b><br/>
positive. For&#160;myeloid, lymphoid, or&#160;mixed&#160;lineage neoplasms with&#160;<br/>
<b>Information&#160;</b><br/>
eosinophilia and FGFR1&#160;or FLT3 rearrangements: the disease&#160;is in&#160;<br/>chronic or blast&#160;phase.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
246&#160;<br/>
<hr/>
<a name=247></a><b>SANDOSTATIN&#160;LAR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Sandostatin&#160;Lar Depot&#160;<br/>
247&#160;<br/>
<hr/>
<a name=248></a><b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Tumor&#160;control&#160;of thymomas&#160;and&#160;thymic carcinomas, neuroendocrine&#160;<br/>tumors&#160;(NETs) of the gastrointestinal (GI)&#160;tract, lung, thymus&#160;(carcinoid&#160;<br/>tumors), unresected primary&#160;gastrinoma, NETs of&#160;the pancreas, and&#160;<br/>pheochromocytoma/paraganglioma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For acromegaly&#160;(initial):&#160;1) patient has a high pretreatment insulin-like&#160;<br/>
<b>Medical&#160;</b><br/>
growth factor-1 (IGF-1) level for age&#160;and/or&#160;gender&#160;based on the&#160;<br/>
<b>Information&#160;</b><br/>
laboratory&#160;reference range, and 2)&#160;patient had an&#160;inadequate or partial&#160;<br/>response&#160;to&#160;surgery or radiotherapy&#160;OR&#160;there is&#160;a clinical reason for why&#160;<br/>the patient has not had surgery or&#160;radiotherapy.&#160;For acromegaly&#160;<br/>(continuation of therapy):&#160;patient's IGF-1 level has decreased&#160;or&#160;<br/>normalized&#160;since&#160;initiation of therapy. For tumor control, the&#160;requested&#160;<br/>drug will&#160;be&#160;used for any&#160;of the following: 1)&#160;neuroendocrine&#160;tumors&#160;of&#160;<br/>the gastrointestinal tract&#160;or pancreas in patients with locoregional&#160;<br/>advanced disease and/or distant metastatic disease, OR 2) neuroendocrine&#160;<br/>tumors&#160;of the thymus or&#160;lung in patients with&#160;locoregional unresectable&#160;<br/>disease and/or distant&#160;metastatic disease, OR&#160;3) unresected primary&#160;<br/>gastrinoma,&#160;OR&#160;4) thymomas and thymic carcinomas&#160;as second-line&#160;<br/>systemic&#160;therapy in patients with unresectable or&#160;extrathoracic metastatic&#160;<br/>disease, OR&#160;5) pheochromocytomas&#160;and paragangliomas, used for&#160;either&#160;<br/>of the following: a) symptomatic locally unresectable disease with&#160;<br/>somatostatin&#160;receptor&#160;positive imaging, OR b) secreting tumors&#160;in&#160;<br/>metastatic&#160;disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
248&#160;<br/>
<hr/>
<a name=249></a><b>SARCLISA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Sarclisa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
249&#160;<br/>
<hr/>
<a name=250></a><b>SCEMBLIX</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Scemblix&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;chronic&#160;myeloid leukemia&#160;(CML) in the chronic phase:&#160;1) the&#160;<br/>
<b>Medical&#160;</b><br/>
diagnosis was confirmed by detection of the Philadelphia&#160;chromosome&#160;or&#160;<br/>
<b>Information&#160;</b><br/>
BCR-ABL gene AND&#160;the patient meets&#160;either of&#160;the following: A) the&#160;<br/>patient has&#160;previously been treated with 2 or&#160;more tyrosine kinase&#160;<br/>inhibitors&#160;(TKIs)&#160;AND at least one&#160;of those was&#160;imatinib or dasatinib, OR&#160;<br/>B) the&#160;patient is positive for the T315I mutation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
250&#160;<br/>
<hr/>
<a name=251></a><b>SIGNIFOR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Signifor&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
Endocrinologist&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
251&#160;<br/>
<hr/>
<a name=252></a><b>SILDENAFIL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Sildenafil&#160;INJ&#160;<br/>
•&#160;&#160;Sildenafil Citrate&#160;TABS&#160;20MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For pulmonary&#160;arterial hypertension&#160;(PAH) (World Health Organization&#160;<br/>
<b>Medical&#160;</b><br/>
[WHO] Group 1): Diagnosis was confirmed by right heart catheterization.&#160;<br/>
<b>Information&#160;</b><br/>
For PAH&#160;new starts only: 1)&#160;Pretreatment mean&#160;pulmonary arterial&#160;<br/>pressure is greater than 20 mmHg, 2)&#160;Pretreatment pulmonary capillary&#160;<br/>wedge pressure&#160;is less than or&#160;equal to 15 mmHg, and 3)&#160;Pretreatment&#160;<br/>pulmonary vascular resistance&#160;is greater&#160;than or&#160;equal to 3 Wood units.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
252&#160;<br/>
<hr/>
<a name=253></a><b>SIRTURO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Sirturo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
Prescribed by&#160;or in consultation with an infectious disease specialist.&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
253&#160;<br/>
<hr/>
<a name=254></a><b>SKYRIZI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Skyrizi&#160;<br/>
•&#160;&#160;Skyrizi Pen&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For moderate&#160;to severe&#160;plaque&#160;psoriasis&#160;(new starts only): 1)&#160;at least 3%&#160;<br/>
<b>Medical&#160;</b><br/>
of body surface area (BSA) is affected OR crucial body areas&#160;(e.g., feet,&#160;<br/>
<b>Information&#160;</b><br/>
hands, face,&#160;neck, groin,&#160;intertriginous areas) are&#160;affected at the time of&#160;<br/>diagnosis, AND&#160;2) patient meets any&#160;of the following: a) patient has&#160;<br/>experienced&#160;an inadequate response&#160;or intolerance to either&#160;phototherapy&#160;<br/>(e.g., UVB,&#160;PUVA)&#160;or pharmacologic treatment with methotrexate,&#160;<br/>cyclosporine, or acitretin, or b) pharmacologic treatment with&#160;<br/>methotrexate, cyclosporine, or&#160;acitretin is contraindicated, or&#160;c)&#160;patient&#160;<br/>has severe psoriasis that warrants&#160;a biologic disease-modifying&#160;<br/>antirheumatic drug (DMARD) as first-line therapy (i.e. at least 10%&#160;of the&#160;<br/>body surface area or crucial&#160;body&#160;areas [e.g., hands, feet,&#160;face, neck,&#160;<br/>scalp, genitals/groin, intertriginous&#160;areas]&#160;are&#160;affected).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
254&#160;<br/>
<hr/>
<a name=255></a><b>SOMATULINE&#160;DEPOT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Somatuline Depot&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Tumor&#160;control&#160;of neuroendocrine tumors (NETs) of&#160;the lung, thymus&#160;<br/>(carcinoid&#160;tumors)&#160;or unresected primary&#160;gastrinoma, and&#160;<br/>pheochromocytoma/paraganglioma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For acromegaly&#160;(initial):&#160;1) patient has a high pretreatment insulin-like&#160;<br/>
<b>Medical&#160;</b><br/>
growth factor-1 (IGF-1) level for age&#160;and/or&#160;gender&#160;based on the&#160;<br/>
<b>Information&#160;</b><br/>
laboratory&#160;reference range, and 2)&#160;patient had an&#160;inadequate or partial&#160;<br/>response&#160;to&#160;surgery or radiotherapy&#160;OR&#160;there is&#160;a clinical&#160;reason for why&#160;<br/>the patient has not had surgery or&#160;radiotherapy.&#160;For acromegaly&#160;<br/>continuation&#160;of therapy:&#160;patient's IGF-1 level has decreased&#160;or normalized&#160;<br/>since&#160;initiation of therapy. For tumor control, the&#160;requested drug will&#160;be&#160;<br/>used for any&#160;of the following: 1)&#160;neuroendocrine&#160;tumor of the thymus or&#160;<br/>lung in patients with locoregional unresectable disease and/or distant&#160;<br/>metastatic&#160;disease, OR 2)&#160;unresected&#160;primary&#160;carcinoma, OR 3)&#160;<br/>pheochromocytomas and&#160;paragangliomas, used&#160;for either&#160;of the&#160;<br/>following: a) symptomatic locally unresectable disease with&#160;somatostatin&#160;<br/>receptor&#160;positive imaging OR b) secreting&#160;tumor in metastatic&#160;disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
255&#160;<br/>
<hr/>
<a name=256></a><b>SOMAVERT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Somavert&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For acromegaly&#160;(initial):&#160;1) patient has a high pretreatment insulin-like&#160;<br/>
<b>Medical&#160;</b><br/>
growth factor-1 (IGF-1) level for age&#160;and/or&#160;gender&#160;based on the&#160;<br/>
<b>Information&#160;</b><br/>
laboratory&#160;reference range, and 2)&#160;patient had an&#160;inadequate or partial&#160;<br/>response&#160;to&#160;surgery or radiotherapy&#160;OR&#160;there is&#160;a clinical reason for why&#160;<br/>the patient has not had surgery or&#160;radiotherapy.&#160;For acromegaly&#160;<br/>continuation&#160;of therapy:&#160;patient's IGF-1 level has decreased&#160;or normalized&#160;<br/>since&#160;initiation of therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
256&#160;<br/>
<hr/>
<a name=257></a><b>SPRITAM</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Spritam&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>Partial-Onset Seizures: 4&#160;years of&#160;age&#160;or older.&#160;Myoclonic Seizures:&#160;12&#160;<br/>
years of&#160;age&#160;or older. Primary Generalized&#160;Tonic-Clonic&#160;Seizures:&#160;6 years&#160;<br/>of age or&#160;older.&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
257&#160;<br/>
<hr/>
<a name=258></a><b>SPRYCEL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Sprycel&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Gastrointestinal stromal&#160;tumor&#160;(GIST), metastatic&#160;chondrosarcoma,&#160;<br/>recurrent&#160;chordoma, T-cell&#160;acute&#160;lymphoblastic&#160;leukemia (ALL),&#160;<br/>Philadelphia&#160;(Ph)-like B-ALL&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;myeloid leukemia&#160;(CML), including patients who have&#160;<br/>
<b>Medical&#160;</b><br/>
received a&#160;hematopoietic stem cell transplant:&#160;diagnosis was&#160;confirmed by&#160;<br/>
<b>Information&#160;</b><br/>
detection of&#160;the Philadelphia (Ph) chromosome or BCR-ABL&#160;gene. If&#160;<br/>patient experienced resistance to an alternative tyrosine&#160;kinase inhibitor&#160;<br/>for&#160;CML, patient is negative for T315I/A, F317L/V/I/C, and&#160;V299L&#160;<br/>mutations. For acute lymphoblastic leukemia&#160;(ALL), the&#160;patient has&#160;a&#160;<br/>diagnosis of&#160;one of&#160;the following: 1)&#160;Philadelphia&#160;chromosome positive&#160;<br/>ALL that&#160;has been confirmed by detection of the Ph chromosome or&#160;<br/>BCR-ABL gene, OR 2) Ph-like B-ALL with ABL-class kinase fusion, OR&#160;<br/>3) relapsed&#160;or refractory&#160;T-cell ALL with ABL-class translocation. For&#160;<br/>GIST, patient must have&#160;progressed&#160;on imatinib,&#160;sunitinib, and&#160;<br/>regorafenib.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
258&#160;<br/>
<hr/>
<a name=259></a><b>STELARA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Stelara&#160;INJ&#160;45MG/0.5ML, 90MG/ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For moderate&#160;to severe&#160;plaque&#160;psoriasis&#160;(new starts only): 1)&#160;At least 3%&#160;<br/>
<b>Medical&#160;</b><br/>
of body surface area (BSA) is affected OR crucial body areas&#160;(e.g., feet,&#160;<br/>
<b>Information&#160;</b><br/>
hands, face,&#160;neck, groin,&#160;intertriginous areas) are&#160;affected at the time of&#160;<br/>diagnosis and 2) Patient&#160;had an inadequate&#160;response, intolerance, or&#160;<br/>contraindication to&#160;two of the following products:&#160;Enbrel&#160;(etanercept),&#160;<br/>Humira (adalimumab), Skyrizi (risankizumab-rzaa).&#160;For active psoriatic&#160;<br/>arthritis (PsA) (new starts): patient had an inadequate&#160;response,&#160;<br/>intolerance,&#160;or contraindication to&#160;two of the following products: Enbrel&#160;<br/>(etanercept),&#160;Humira (adalimumab), Skyrizi (risankizumab-rzaa), Xeljanz&#160;<br/>(tofacitinib)/Xeljanz XR (tofacitinib&#160;extended-release).&#160;For&#160;moderately to&#160;<br/>severely active Crohn's&#160;disease (new&#160;starts): patient had&#160;an inadequate&#160;<br/>response,&#160;intolerance, or&#160;contraindication to Humira&#160;(adalimumab). For&#160;<br/>moderately&#160;to&#160;severely active ulcerative colitis (new starts): patient had an&#160;<br/>inadequate response, intolerance, or&#160;contraindication to Humira&#160;<br/>(adalimumab).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
259&#160;<br/>
<hr/>
<a name=260></a><b>STIVARGA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Stivarga&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Progressive&#160;gastrointestinal&#160;stromal tumors (GIST), osteosarcoma,&#160;<br/>glioblastoma, angiosarcoma, retroperitoneal/intra-abdominal soft tissue&#160;<br/>sarcoma, rhabdomyosarcoma, solitary fibrous&#160;tumor, and soft tissue&#160;<br/>sarcomas of&#160;the extremities, body wall, head and neck, advanced&#160;<br/>colorectal cancer.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For gastrointestinal&#160;stromal&#160;tumors:&#160;The disease&#160;is progressive, locally&#160;<br/>
<b>Medical&#160;</b><br/>
advanced, unresectable,&#160;or metastatic.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
260&#160;<br/>
<hr/>
<a name=261></a><b>SUTENT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Sunitinib Malate&#160;<br/>
•&#160;&#160;Sutent&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Thyroid carcinoma&#160;(follicular, medullary, papillary, and Hurthle cell), soft&#160;<br/>tissue sarcoma (angiosarcoma, solitary&#160;fibrous&#160;tumor, and alveolar soft&#160;<br/>part sarcoma subtypes), recurrent&#160;chordoma,&#160;thymic carcinoma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For renal&#160;cell carcinoma,&#160;the disease&#160;is relapsed,&#160;advanced, or&#160;stage IV.&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
261&#160;<br/>
<hr/>
<a name=262></a><b>SYMLIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Symlinpen 120&#160;<br/>
•&#160;&#160;Symlinpen 60&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
262&#160;<br/>
<hr/>
<a name=263></a><b>SYMPAZAN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Sympazan&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>2 years&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
263&#160;<br/>
<hr/>
<a name=264></a><b>SYNRIBO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Synribo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Follow-up therapy&#160;for chronic&#160;myeloid leukemia (CML) patients&#160;after&#160;<br/>hematopoietic stem cell&#160;transplant (HSCT)&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
264&#160;<br/>
<hr/>
<a name=265></a><b>TABRECTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tabrecta&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved&#160;Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Treatment&#160;of&#160;recurrent or advanced non-small cell lung cancer (NSCLC).&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For recurrent, advanced,&#160;or metastatic NSCLC: Tumor&#160;is&#160;positive for&#160;<br/>
<b>Medical&#160;</b><br/>
mesenchymal-epithelial&#160;transition (MET) exon 14 skipping&#160;mutation.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
265&#160;<br/>
<hr/>
<a name=266></a><b>TADALAFIL&#160;(PAH)</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Alyq&#160;<br/>
•&#160;&#160;Tadalafil&#160;TABS 20MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For pulmonary&#160;arterial hypertension&#160;(PAH) (World Health Organization&#160;<br/>
<b>Medical&#160;</b><br/>
[WHO] Group 1): Diagnosis was confirmed by right heart catheterization.&#160;<br/>
<b>Information&#160;</b><br/>
For PAH&#160;new starts only: 1)&#160;Pretreatment mean&#160;pulmonary arterial&#160;<br/>pressure is greater than 20 mmHg, 2)&#160;Pretreatment pulmonary capillary&#160;<br/>wedge pressure&#160;is less than or&#160;equal to 15 mmHg, and 3)&#160;Pretreatment&#160;<br/>pulmonary vascular resistance&#160;is greater&#160;than or&#160;equal to 3 Wood units.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
266&#160;<br/>
<hr/>
<a name=267></a><b>TAFINLAR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tafinlar&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Brain metastases&#160;from melanoma, thyroid carcinoma (papillary&#160;<br/>carcinoma,&#160;follicular carcinoma,&#160;and&#160;Hurthle cell carcinoma),&#160;central&#160;<br/>nervous system (CNS) cancer&#160;(i.e., glioma, meningioma, astrocytoma)&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For brain&#160;metastases&#160;from melanoma, adjuvant treatment of&#160;melanoma,&#160;<br/>
<b>Medical&#160;</b><br/>
and central&#160;nervous system (CNS) cancer&#160;(i.e., glioma, meningioma,&#160;<br/>
<b>Information&#160;</b><br/>
astrocytoma):&#160;1) The&#160;tumor&#160;is positive for&#160;a BRAF&#160;V600 activating&#160;<br/>mutation (e.g., V600E&#160;or V600K), and 2)&#160;The&#160;requested drug will&#160;be used&#160;<br/>in combination with trametinib. For&#160;unresectable&#160;or metastatic melanoma:&#160;<br/>1) The tumor is positive&#160;for&#160;a BRAF&#160;V600 activating mutation (e.g.,&#160;<br/>V600E&#160;or V600K), and 2) The&#160;requested drug will be used as&#160;a single&#160;<br/>agent&#160;or in combination&#160;with trametinib. For non-small cell&#160;lung cancer:&#160;<br/>1) The tumor is positive&#160;for&#160;a BRAF&#160;V600E&#160;mutation, and 2)&#160;The&#160;<br/>requested drug will&#160;be used in combination with trametinib. For&#160;thyroid&#160;<br/>carcinoma&#160;with papillary, follicular,&#160;or Hurthle histology: The tumor is&#160;<br/>positive for&#160;BRAF&#160;activating&#160;mutation (e.g., V600E or V600K).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
267&#160;<br/>
<hr/>
<a name=268></a><b>TAGRISSO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tagrisso&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Sensitizing&#160;epidermal&#160;growth factor&#160;receptor&#160;(EGFR) mutation-positive&#160;<br/>recurrent or&#160;advanced non-small cell&#160;lung cancer&#160;(NSCLC), brain&#160;<br/>metastases from&#160;sensitizing EGFR&#160;mutation-positive NSCLC,&#160;<br/>leptomeningeal&#160;metastases from EGFR&#160;mutation-positive NSCLC&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For NSCLC,&#160;the requested drug is used in any of the following settings:&#160;<br/>
<b>Medical&#160;</b><br/>
1) The patient meets both of the following: a)&#160;patient has&#160;metastatic,&#160;<br/>
<b>Information&#160;</b><br/>
advanced, or&#160;recurrent NSCLC (including brain and/or leptomeningeal&#160;<br/>metastases from&#160;NSCLC) and b) patient has a&#160;sensitizing EGFR&#160;mutation&#160;<br/>OR&#160;2) Patient meets both of the following: a)&#160;request&#160;is for&#160;adjuvant&#160;<br/>treatment of&#160;NSCLC following tumor resection and b) patient has EGFR&#160;<br/>mutation-positive disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
268&#160;<br/>
<hr/>
<a name=269></a><b>TALTZ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Taltz&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For moderate&#160;to severe&#160;plaque&#160;psoriasis&#160;(new starts only): 1)&#160;At least 3%&#160;<br/>
<b>Medical&#160;</b><br/>
of body surface area (BSA) is affected OR crucial body areas&#160;(e.g., feet,&#160;<br/>
<b>Information&#160;</b><br/>
hands, face,&#160;neck, groin,&#160;intertriginous areas) are&#160;affected at the time of&#160;<br/>diagnosis AND&#160;2) the patient had an&#160;inadequate response,&#160;intolerance, or&#160;<br/>contraindication to one of the following products:&#160;Enbrel&#160;(etanercept),&#160;<br/>Humira (adalimumab), Skyrizi (risankizumab-rzaa).&#160;For active ankylosing&#160;<br/>spondylitis&#160;(new&#160;starts only):&#160;the patient had an&#160;inadequate&#160;response,&#160;<br/>intolerance,&#160;or contraindication to either Enbrel (etanercept)&#160;or Humira&#160;<br/>(adalimumab). For&#160;active psoriatic arthritis (PsA) (new starts only):&#160;the&#160;<br/>patient had an inadequate&#160;response,&#160;intolerance, or contraindication&#160;to one&#160;<br/>of the following products:&#160;Enbrel (etanercept), Humira&#160;(adalimumab),&#160;<br/>Skyrizi (risankizumab-rzaa), Xeljanz (tofacitinib)/Xeljanz XR (tofacitinib&#160;<br/>extended-release).&#160;For&#160;active axial&#160;spondyloarthritis&#160;(new&#160;starts only):&#160;<br/>Patient meets any of the&#160;following: 1) has had an&#160;inadequate response&#160;to a&#160;<br/>non-steroidal anti-inflammatory drug&#160;(NSAID) trial or&#160;2) has&#160;an&#160;<br/>intolerance&#160;or contraindication to NSAIDs.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
269&#160;<br/>
<hr/>
<a name=270></a><b>TALZENNA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Talzenna&#160;CAPS 0.25MG, 1MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent&#160;germline&#160;breast cancer&#160;susceptibility gene (BRCA)-mutated&#160;<br/>breast&#160;cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For germline&#160;BRCA-mutated&#160;(gBRCAm) metastatic or recurrent breast&#160;<br/>
<b>Medical&#160;</b><br/>
cancer, the patient experienced an unacceptable&#160;toxicity with&#160;a trial of&#160;<br/>
<b>Information&#160;</b><br/>
Lynparza (olaparib).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
270&#160;<br/>
<hr/>
<a name=271></a><b>TARGRETIN&#160;TOPICAL</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Targretin&#160;GEL&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Mycosis fungoides, chronic or&#160;smoldering adult&#160;T-cell&#160;<br/>leukemia/lymphoma, primary cutaneous marginal zone&#160;lymphoma,&#160;<br/>primary&#160;cutaneous follicle center lymphoma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
271&#160;<br/>
<hr/>
<a name=272></a><b>TASIGNA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tasigna&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Philadelphia&#160;chromosome&#160;positive acute lymphoblastic leukemia&#160;(Ph+&#160;<br/>ALL), gastrointestinal stromal tumor (GIST)&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For chronic&#160;myeloid leukemia&#160;(CML) or&#160;acute lymphoblastic leukemia&#160;<br/>
<b>Medical&#160;</b><br/>
(ALL), diagnosis was confirmed by&#160;detection of&#160;the Philadelphia&#160;<br/>
<b>Information&#160;</b><br/>
chromosome or&#160;BCR-ABL gene. For CML, including patients newly&#160;<br/>diagnosed with CML and patients who have received a&#160;hematopoietic&#160;<br/>stem&#160;cell transplant: patient has experienced resistance or intolerance to&#160;<br/>imatinib or&#160;dasatinib. If&#160;patient experienced resistance to an alternative&#160;<br/>tyrosine kinase inhibitor for CML, patient is negative&#160;for&#160;T315I, Y253H,&#160;<br/>E255K/V, and F359V/C/I&#160;mutations.&#160;For GIST, patient must&#160;have&#160;<br/>progressed on imatinib,&#160;sunitinib, and regorafenib.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
272&#160;<br/>
<hr/>
<a name=273></a><b>TAZAROTENE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tazarotene&#160;CREA&#160;<br/>
•&#160;&#160;Tazorac&#160;CREA&#160;0.05%&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For plaque&#160;psoriasis:&#160;1)&#160;The requested drug is being prescribed to treat&#160;<br/>
<b>Medical&#160;</b><br/>
less than 20&#160;percent of&#160;the patient's body surface&#160;area AND 2) The patient&#160;<br/>
<b>Information&#160;</b><br/>
experienced&#160;an inadequate treatment response or&#160;intolerance&#160;to&#160;at least&#160;<br/>one topical corticosteroid&#160;OR&#160;has a&#160;contraindication that&#160;would&#160;prohibit a&#160;<br/>trial of&#160;topical corticosteroids.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
273&#160;<br/>
<hr/>
<a name=274></a><b>TAZVERIK</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tazverik&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>Epithelioid sarcoma: 16&#160;years of&#160;age&#160;or older, Follicular&#160;lymphoma:&#160;18&#160;<br/>
years of&#160;age&#160;or older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
274&#160;<br/>
<hr/>
<a name=275></a><b>TECENTRIQ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tecentriq&#160;<br/>
275&#160;<br/>
<hr/>
<a name=276></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent or&#160;advanced non-small cell lung cancer, PD-L1 positive triple&#160;<br/>negative recurrent breast cancer&#160;in combination with paclitaxel protein-<br/>bound&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For urothelial&#160;carcinoma, patient meets one of the following&#160;criteria: 1)&#160;<br/>
<b>Medical&#160;</b><br/>
Patient is&#160;ineligible&#160;for&#160;cisplatin&#160;therapy and tumors&#160;express&#160;PD-L1&#160;<br/>
<b>Information&#160;</b><br/>
(defined as PD-L1 stained tumor-infiltrating immune cells&#160;[IC] covering&#160;<br/>greater than&#160;or equal to 5&#160;percent of&#160;the tumor area) OR 2) Patient is&#160;<br/>ineligible for any platinum containing chemotherapy. For non-small cell&#160;<br/>lung cancer&#160;(NSCLC): 1)&#160;the patient&#160;has recurrent, advanced&#160;or metastatic&#160;<br/>disease AND the requested drug will be used as&#160;any of the following: a)&#160;<br/>first-line&#160;treatment of&#160;tumors with high PD-L1 expression (defined&#160;as PD-<br/>L1 stained greater than or equal to 50&#160;percent of&#160;tumor&#160;cells or PD-L1&#160;<br/>stained tumor-infiltrating immune cells&#160;[IC] covering greater&#160;than or&#160;<br/>equal&#160;to 10&#160;percent of&#160;the tumor area) and no EGFR&#160;or ALK&#160;genomic&#160;<br/>tumor aberrations, b) used in combination with&#160;carboplatin,&#160;paclitaxel,&#160;<br/>and bevacizumab, or&#160;in&#160;combination&#160;with carboplatin and albumin-bound&#160;<br/>paclitaxel for nonsquamous NSCLC, or&#160;c)&#160;the requested drug&#160;will&#160;be used&#160;<br/>as subsequent therapy or continuation maintenance therapy,&#160;OR&#160;2) the&#160;<br/>patient has&#160;stage&#160;II to&#160;IIIA&#160;disease AND&#160;the requested drug will be used&#160;<br/>as adjuvant treatment&#160;following resection and platinum-based&#160;<br/>chemotherapy for&#160;tumors with PD-L1 expression&#160;on greater than or equal&#160;<br/>to 1 percent&#160;of tumor&#160;cells. For hepatocellular&#160;carcinoma,&#160;the requested&#160;<br/>drug will be&#160;used as initial treatment&#160;in combination with bevacizumab.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
276&#160;<br/>
<hr/>
<a name=277></a><b>TECFIDERA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tecfidera&#160;<br/>
•&#160;&#160;Tecfidera&#160;Starter Pack&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
277&#160;<br/>
<hr/>
<a name=278></a><b>TEMAZEPAM&#160;30MG&#160;-&#160;65</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Temazepam&#160;CAPS 30MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Prescriber must&#160;acknowledge that the&#160;benefit of&#160;therapy with&#160;the&#160;<br/>
<b>Medical&#160;</b><br/>
requested drug outweighs the potential risks for the patient. (Note:&#160;The&#160;<br/>
<b>Information&#160;</b><br/>
American Geriatrics&#160;Society&#160;identifies the&#160;use of this medication as&#160;<br/>potentially inappropriate in older adults, meaning&#160;it&#160;is best&#160;avoided,&#160;<br/>prescribed at reduced dosage, or&#160;used with caution or carefully&#160;<br/>monitored.) The patient&#160;has experienced an inadequate&#160;treatment&#160;<br/>response,&#160;intolerance, or&#160;has a&#160;contraindication to&#160;doxepin (3&#160;mg or&#160;6&#160;<br/>mg).&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
This Prior&#160;Authorization&#160;requirement&#160;only applies&#160;to patients 65 years of&#160;<br/>age or&#160;older.&#160;<br/>
278&#160;<br/>
<hr/>
<a name=279></a><b>TEPMETKO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tepmetko&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
279&#160;<br/>
<hr/>
<a name=280></a><b>TESTOSTERONE&#160;CYPIONATE&#160;INJ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Testosterone&#160;Cypionate&#160;INJ&#160;<br/>
100MG/ML, 200MG/ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Gender Dysphoria&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Primary or&#160;hypogonadotropic hypogonadism: 1)&#160;Request&#160;is for&#160;<br/>
<b>Medical&#160;</b><br/>
continuation&#160;of testosterone therapy&#160;and the&#160;patient had a&#160;confirmed low&#160;<br/>
<b>Information&#160;</b><br/>
morning&#160;testosterone&#160;level according&#160;to current practice guidelines or&#160;<br/>your standard lab reference values before starting&#160;testosterone&#160;therapy&#160;<br/>[Note: Safety and efficacy of&#160;testosterone products&#160;in patients with &#34;age-<br/>related hypogonadism&#34; (also referred to as &#34;late-onset&#160;hypogonadism&#34;)&#160;<br/>have not&#160;been established.] OR 2) Request&#160;is not for&#160;continuation of&#160;<br/>testosterone&#160;therapy&#160;and&#160;the patient has at least two confirmed low&#160;<br/>morning&#160;testosterone&#160;levels according to current&#160;practice guidelines or&#160;<br/>your standard lab reference values [Note:&#160;Safety and efficacy&#160;of&#160;<br/>testosterone&#160;products in&#160;patients with &#34;age-related hypogonadism&#34;&#160;(also&#160;<br/>referred to as &#34;late-onset hypogonadism&#34;) have not been established.].&#160;<br/>Gender dysphoria: The patient is&#160;able to make&#160;an&#160;informed decision&#160;to&#160;<br/>engage in hormone&#160;therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
280&#160;<br/>
<hr/>
<a name=281></a><b>TESTOSTERONE&#160;ENANTHATE&#160;INJ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Testosterone&#160;Enanthate&#160;INJ&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Gender Dysphoria&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Primary or&#160;hypogonadotropic hypogonadism: 1)&#160;Request&#160;is for&#160;<br/>
<b>Medical&#160;</b><br/>
continuation&#160;of testosterone therapy&#160;and the&#160;patient had a&#160;confirmed low&#160;<br/>
<b>Information&#160;</b><br/>
morning&#160;testosterone&#160;level according&#160;to current practice guidelines or&#160;<br/>your standard lab reference values before starting&#160;testosterone&#160;therapy&#160;<br/>[Note: Safety and efficacy of&#160;testosterone products&#160;in patients with &#34;age-<br/>related hypogonadism&#34; (also referred to as &#34;late-onset&#160;hypogonadism&#34;)&#160;<br/>have not&#160;been established.] OR 2) Request&#160;is not for&#160;continuation of&#160;<br/>testosterone&#160;therapy&#160;and&#160;the patient has at least two confirmed low&#160;<br/>morning&#160;testosterone&#160;levels according to current&#160;practice guidelines or&#160;<br/>your standard lab reference values [Note:&#160;Safety and efficacy&#160;of&#160;<br/>testosterone&#160;products in&#160;patients with &#34;age-related hypogonadism&#34;&#160;(also&#160;<br/>referred&#160;to&#160;as &#34;late-onset hypogonadism&#34;) have not been established.].&#160;<br/>Gender dysphoria: The patient is&#160;able to make&#160;an&#160;informed decision&#160;to&#160;<br/>engage in hormone&#160;therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
281&#160;<br/>
<hr/>
<a name=282></a><b>TETRABENAZINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tetrabenazine&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some&#160;Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Tic disorders, tardive dyskinesia, hemiballismus, chorea not&#160;associated&#160;<br/>with Huntington's&#160;disease.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For treatment&#160;of chorea&#160;associated with Huntington's disease:&#160;The patient&#160;<br/>
<b>Medical&#160;</b><br/>
must&#160;have a&#160;prior inadequate&#160;response or&#160;intolerable adverse&#160;event&#160;with&#160;<br/>
<b>Information&#160;</b><br/>
deutetrabenazine&#160;therapy. For treatment of tardive dyskinesia: The patient&#160;<br/>must&#160;have a&#160;prior inadequate&#160;response or&#160;intolerable adverse&#160;event&#160;with&#160;<br/>deutetrabenazine&#160;or valbenazine&#160;therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
282&#160;<br/>
<hr/>
<a name=283></a><b>THALOMID</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Thalomid&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Myelofibrosis-related anemia,&#160;recurrent aphthous&#160;stomatitis, recurrent&#160;<br/>human immunodeficiency virus&#160;(HIV)-associated aphthous&#160;ulcers,&#160;<br/>cachexia, HIV-associated diarrhea, acquired&#160;immunodeficiency syndrome&#160;<br/>(AIDS)-related Kaposi's&#160;sarcoma, Behcet's syndrome, chronic graft-<br/>versus-host disease, Crohn's disease,&#160;multicentric&#160;Castleman's disease.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For cachexia: Cachexia&#160;must&#160;be due&#160;to cancer or&#160;HIV infection.&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
283&#160;<br/>
<hr/>
<a name=284></a><b>TIBSOVO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tibsovo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Conventional (grades 1-3) or&#160;dedifferentiated chondrosarcoma&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Patient has&#160;disease with a&#160;susceptible&#160;isocitrate dehydrogenase-1 (IDH1)&#160;<br/>
<b>Medical&#160;</b><br/>
mutation. For acute myeloid leukemia (AML):&#160;1) patient has&#160;newly-<br/>
<b>Information&#160;</b><br/>
diagnosed AML and meets one&#160;of the&#160;following: a) 75 years&#160;of age or&#160;<br/>older, b) patient has comorbidities that preclude&#160;use of&#160;intensive induction&#160;<br/>chemotherapy, or c)&#160;patient is 60 physiologic years&#160;of age or older&#160;and&#160;<br/>declines intensive induction chemotherapy, OR&#160;2) patient&#160;is 60&#160;<br/>physiologic years&#160;of age&#160;or older&#160;and&#160;the requested drug will&#160;be used as&#160;<br/>post-induction therapy&#160;following&#160;response to induction&#160;therapy with the&#160;<br/>requested drug, OR&#160;3) patient has&#160;relapsed or refractory AML. For&#160;<br/>unresectable&#160;or metastatic cholangiocarcinoma:&#160;the requested&#160;drug will be&#160;<br/>used as subsequent treatment&#160;for&#160;progression on&#160;or after systemic&#160;<br/>treatment.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
284&#160;<br/>
<hr/>
<a name=285></a><b>TOBRAMYCIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tobramycin&#160;NEBU&#160;300MG/5ML&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Non-cystic fibrosis&#160;bronchiectasis&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;cystic&#160;fibrosis and non-cystic fibrosis bronchiectasis,&#160;the patient must&#160;<br/>
<b>Medical&#160;</b><br/>
meet one of&#160;the following: 1)&#160;Pseudomonas&#160;aeruginosa is&#160;present in&#160;the&#160;<br/>
<b>Information&#160;</b><br/>
patient's airway cultures, OR&#160;2) the patient has a history of Pseudomonas&#160;<br/>aeruginosa infection or colonization&#160;in the airways.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
285&#160;<br/>
<hr/>
<a name=286></a><b>TOPICAL&#160;DOXEPIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Doxepin Hydrochloride&#160;CREA&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has experienced an inadequate&#160;response to a&#160;topical&#160;<br/>
<b>Medical&#160;</b><br/>
corticosteroid or a topical calcineurin&#160;inhibitor&#160;(e.g., tacrolimus).&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
1 month&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
286&#160;<br/>
<hr/>
<a name=287></a><b>TOPICAL&#160;LIDOCAINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Lidocaine&#160;OINT 5%&#160;<br/>
•&#160;&#160;&#160;Lidocaine Hcl&#160;EXTERNAL SOLN&#160;<br/>
4%&#160;<br/>
•&#160;&#160;&#160;Lidocaine/prilocaine&#160;CREA&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being used for topical&#160;anesthesia, AND&#160;2) If the&#160;<br/>
<b>Medical&#160;</b><br/>
requested drug will&#160;be used as part&#160;of a&#160;compounded product,&#160;then all the&#160;<br/>
<b>Information&#160;</b><br/>
active ingredients&#160;in the&#160;compounded product&#160;are Food and Drug&#160;<br/>Administration (FDA) approved for&#160;topical use.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
3 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
287&#160;<br/>
<hr/>
<a name=288></a><b>TOPICAL&#160;TESTOSTERONES</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Androderm&#160;PT24 2MG/24HR,&#160;<br/>
4MG/24HR&#160;<br/>
•&#160;&#160;&#160;Testosterone&#160;GEL 10MG/ACT,&#160;<br/>
25MG/2.5GM, 50MG/5GM&#160;<br/>
•&#160;&#160;&#160;Testosterone&#160;Pump&#160;GEL&#160;1%&#160;<br/>
•&#160;&#160;&#160;Testosterone&#160;Topical&#160;Solution&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Gender Dysphoria&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Primary or&#160;hypogonadotropic hypogonadism: 1)&#160;Request&#160;is for&#160;<br/>
<b>Medical&#160;</b><br/>
continuation&#160;of testosterone therapy&#160;and the&#160;patient had a&#160;confirmed low&#160;<br/>
<b>Information&#160;</b><br/>
morning&#160;testosterone&#160;level according&#160;to current practice guidelines or&#160;<br/>your standard lab reference values before starting&#160;testosterone&#160;therapy&#160;<br/>[Note: Safety and efficacy of&#160;testosterone products&#160;in patients with &#34;age-<br/>related hypogonadism&#34; (also referred to as &#34;late-onset&#160;hypogonadism&#34;)&#160;<br/>have not&#160;been established.] OR 2) Request&#160;is not for&#160;continuation of&#160;<br/>testosterone&#160;therapy&#160;and&#160;the patient has at least two confirmed low&#160;<br/>morning&#160;testosterone&#160;levels according to current&#160;practice guidelines or&#160;<br/>your standard lab reference values [Note:&#160;Safety and efficacy&#160;of&#160;<br/>testosterone&#160;products in&#160;patients with &#34;age-related hypogonadism&#34;&#160;(also&#160;<br/>referred&#160;to&#160;as &#34;late-onset hypogonadism&#34;) have not been established.].&#160;<br/>Gender dysphoria: The patient is&#160;able to make&#160;an&#160;informed decision&#160;to&#160;<br/>engage in hormone&#160;therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
288&#160;<br/>
<hr/>
<a name=289></a><b>TOPICAL&#160;TRETINOIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tretinoin&#160;CREA&#160;<br/>
•&#160;&#160;Tretinoin&#160;GEL&#160;<br/>
•&#160;&#160;Tretinoin Microsphere&#160;<br/>
•&#160;&#160;Tretinoin Microsphere&#160;Pump&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
289&#160;<br/>
<hr/>
<a name=290></a><b>TOREMIFENE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Toremifene&#160;Citrate&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
Congenital/acquired&#160;QT&#160;prolongation&#160;(long QT&#160;syndrome), uncorrected&#160;<br/>
<b>Criteria&#160;</b><br/>
hypokalemia, or uncorrected hypomagnesemia.&#160;<br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
290&#160;<br/>
<hr/>
<a name=291></a><b>TRELSTAR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Trelstar&#160;Mixject&#160;INJ 11.25MG,&#160;<br/>
3.75MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted&#160;Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Gender dysphoria&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For gender&#160;dysphoria, patient meets either of the following (1&#160;or 2): 1) the&#160;<br/>
<b>Medical&#160;</b><br/>
requested drug is&#160;used to&#160;suppress puberty and&#160;the patient is at Tanner&#160;<br/>
<b>Information&#160;</b><br/>
stage 2 or&#160;greater, OR 2) patient is&#160;undergoing gender transition, and the&#160;<br/>patient will receive&#160;the requested drug concomitantly with gender-<br/>affirming hormones.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
291&#160;<br/>
<hr/>
<a name=292></a><b>TREPROSTINIL&#160;INJ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Treprostinil&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For pulmonary&#160;arterial hypertension&#160;(World Health Organization [WHO]&#160;<br/>
<b>Medical&#160;</b><br/>
Group 1), the diagnosis was confirmed by right heart&#160;catheterization. For&#160;<br/>
<b>Information&#160;</b><br/>
new starts only:&#160;1) pretreatment mean pulmonary arterial pressure is&#160;<br/>greater than&#160;20 mmHg, 2) pretreatment pulmonary capillary&#160;wedge&#160;<br/>pressure is less than or equal to 15&#160;mmHg, AND 3)&#160;pretreatment&#160;<br/>pulmonary vascular resistance&#160;is greater&#160;than or&#160;equal to 3 Wood units.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
292&#160;<br/>
<hr/>
<a name=293></a><b>TRIENTINE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Trientine Hydrochloride&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
293&#160;<br/>
<hr/>
<a name=294></a><b>TRIKAFTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Trikafta&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The requested&#160;medication will&#160;not be used in combination with other&#160;<br/>
<b>Medical&#160;</b><br/>
medications&#160;containing ivacaftor.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>6 years&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
294&#160;<br/>
<hr/>
<a name=295></a><b>TRODELVY</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Trodelvy&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent&#160;triple-negative&#160;breast&#160;cancer&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
295&#160;<br/>
<hr/>
<a name=296></a><b>TRUSELTIQ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Truseltiq&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age&#160;Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
296&#160;<br/>
<hr/>
<a name=297></a><b>TUKYSA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Tukysa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent human&#160;epidermal&#160;growth&#160;factor receptor 2 (HER2)-positive&#160;<br/>breast&#160;cancer, including&#160;patients with brain&#160;metastases, who&#160;have received&#160;<br/>one or&#160;more&#160;lines of prior HER2-targeted therapy&#160;in the&#160;metastatic setting.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
297&#160;<br/>
<hr/>
<a name=298></a><b>TURALIO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Turalio&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
298&#160;<br/>
<hr/>
<a name=299></a><b>UBRELVY</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ubrelvy&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has experienced an inadequate&#160;treatment response,&#160;<br/>
<b>Medical&#160;</b><br/>
intolerance,&#160;or the patient has&#160;a contraindication&#160;to&#160;one triptan&#160;5-HT1&#160;<br/>
<b>Information&#160;</b><br/>
receptor&#160;agonist.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
299&#160;<br/>
<hr/>
<a name=300></a><b>UKONIQ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ukoniq&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
300&#160;<br/>
<hr/>
<a name=301></a><b>VALCHLOR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Valchlor&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Chronic&#160;or&#160;smoldering adult&#160;T-cell&#160;leukemia/lymphoma, Stage 2 or&#160;higher&#160;<br/>mycosis fungoides/Sezary syndrome,&#160;primary&#160;cutaneous marginal&#160;zone&#160;<br/>lymphoma,&#160;primary&#160;cutaneous follicle center lymphoma, lymphomatoid&#160;<br/>papulosis.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
301&#160;<br/>
<hr/>
<a name=302></a><b>VALTOCO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Valtoco&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>6 years&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
302&#160;<br/>
<hr/>
<a name=303></a><b>VELCADE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Bortezomib&#160;<br/>
•&#160;&#160;Velcade&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved&#160;Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Systemic light&#160;chain&#160;amyloidosis, Waldenstrom's&#160;<br/>macroglobulinemia/lymphoplasmacytic lymphoma, multicentric&#160;<br/>Castleman's&#160;disease, adult T-cell&#160;leukemia/lymphoma, acute&#160;<br/>lymphoblastic leukemia,&#160;AIDS-related Kaposi's&#160;sarcoma, Hodgkin&#160;<br/>lymphoma,&#160;POEMS syndrome&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
303&#160;<br/>
<hr/>
<a name=304></a><b>VELTASSA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Veltassa&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;has experienced an inadequate&#160;treatment response,&#160;<br/>
<b>Medical&#160;</b><br/>
intolerance,&#160;or has a contraindication&#160;to Lokelma.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
304&#160;<br/>
<hr/>
<a name=305></a><b>VENCLEXTA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Venclexta&#160;<br/>
•&#160;&#160;Venclexta Starting Pack&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Mantle cell&#160;lymphoma, blastic plasmacytoid dendritic cell&#160;neoplasm&#160;<br/>(BPDCN),&#160;multiple&#160;myeloma,&#160;relapsed or&#160;refractory acute myeloid&#160;<br/>leukemia (AML), AML in patients 60 physiologic years&#160;of age&#160;or older.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For acute&#160;myeloid&#160;leukemia&#160;(AML), any of the&#160;following criteria must be&#160;<br/>
<b>Medical&#160;</b><br/>
met: 1)&#160;the patient's physiologic age is 60 years&#160;of age or older OR 2) the&#160;<br/>
<b>Information&#160;</b><br/>
requested drug will&#160;be used as a component of&#160;repeating&#160;the initial&#160;<br/>successful&#160;induction&#160;regimen&#160;if&#160;late&#160;relapse OR&#160;3) the patient has&#160;<br/>comorbidities that preclude use&#160;of intensive&#160;induction chemotherapy OR&#160;<br/>4) the requested drug will be used for relapsed or refractory disease. For&#160;<br/>blastic plasmacytoid dendritic cell&#160;neoplasm (BPDCN), any&#160;of the&#160;<br/>following&#160;criteria must be met: 1)&#160;patient has systemic disease&#160;treated&#160;<br/>with palliative intent OR 2) patient&#160;has relapsed&#160;or refractory&#160;disease. For&#160;<br/>multiple&#160;myeloma,&#160;all&#160;of the following must be met:&#160;1) the disease is&#160;<br/>relapsed or&#160;progressive&#160;AND 2) the requested drug will be used in&#160;<br/>combination&#160;with dexamethasone AND&#160;3) patient has&#160;t(11:14)&#160;<br/>translocation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
305&#160;<br/>
<hr/>
<a name=306></a><b>VENTAVIS</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Ventavis&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For&#160;pulmonary&#160;arterial hypertension&#160;(World Health Organization [WHO]&#160;<br/>
<b>Medical&#160;</b><br/>
Group 1), the diagnosis was confirmed by right heart&#160;catheterization. For&#160;<br/>
<b>Information&#160;</b><br/>
new starts only:&#160;1) pretreatment mean pulmonary arterial pressure is&#160;<br/>greater than&#160;20 mmHg, 2) pretreatment pulmonary&#160;capillary&#160;wedge&#160;<br/>pressure is less than or equal to 15&#160;mmHg, AND 3)&#160;pretreatment&#160;<br/>pulmonary vascular resistance&#160;is greater&#160;than or&#160;equal to 3 Wood units.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
306&#160;<br/>
<hr/>
<a name=307></a><b>VERSACLOZ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Versacloz&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For the&#160;treatment of a severely&#160;ill patient&#160;with schizophrenia who failed&#160;to&#160;<br/>
<b>Medical&#160;</b><br/>
respond adequately&#160;to standard antipsychotic treatment (i.e., treatment-<br/>
<b>Information&#160;</b><br/>
resistant schizophrenia),&#160;1) the patient experienced an inadequate&#160;<br/>treatment response, intolerance, or contraindication to one of&#160;the&#160;<br/>following generic products:&#160;A) aripiprazole, B) asenapine, C)&#160;olanzapine,&#160;<br/>D) quetiapine, E) risperidone, F) ziprasidone AND 2) The patient&#160;<br/>experienced&#160;an inadequate treatment response, intolerance, or&#160;<br/>contraindication to one of the following brand products: A) Latuda, B)&#160;<br/>Rexulti, C)&#160;Secuado.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
307&#160;<br/>
<hr/>
<a name=308></a><b>VERZENIO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Verzenio&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent hormone&#160;receptor&#160;(HR)-positive, human epidermal growth&#160;<br/>factor receptor 2 (HER2)-negative breast&#160;cancer&#160;in&#160;combination with&#160;<br/>fulvestrant or an aromatase inhibitor, or as a single agent if progression on&#160;<br/>prior endocrine therapy&#160;and prior&#160;chemotherapy&#160;in the&#160;metastatic setting.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
308&#160;<br/>
<hr/>
<a name=309></a><b>VIGABATRIN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Vigabatrin&#160;<br/>
•&#160;&#160;Vigadrone&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For complex&#160;partial seizures&#160;(CPS): patient had an&#160;inadequate response&#160;to&#160;<br/>
<b>Medical&#160;</b><br/>
at least&#160;2 antiepileptic drugs for&#160;CPS.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
309&#160;<br/>
<hr/>
<a name=310></a><b>VITRAKVI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Vitrakvi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Advanced,&#160;recurrent, or persistent neurotrophic tyrosine receptor kinase&#160;<br/>(NTRK) gene fusion-positive solid tumors, first-line treatment of NTRK&#160;<br/>gene fusion-positive solid tumors.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For all&#160;neurotrophic tyrosine receptor kinase (NTRK) gene fusion-<br/>
<b>Medical&#160;</b><br/>
positive solid tumors,&#160;the disease is&#160;without&#160;a known acquired resistance&#160;<br/>
<b>Information&#160;</b><br/>
mutation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
310&#160;<br/>
<hr/>
<a name=311></a><b>VIZIMPRO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Vizimpro&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent or&#160;advanced non-small cell lung cancer (NSCLC).&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For non-small&#160;cell&#160;lung cancer (NSCLC): 1)&#160;the disease&#160;is recurrent,&#160;<br/>
<b>Medical&#160;</b><br/>
advanced or metastatic,&#160;and 2) the patient has sensitizing EGFR&#160;mutation-<br/>
<b>Information&#160;</b><br/>
positive disease.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
311&#160;<br/>
<hr/>
<a name=312></a><b>VORICONAZOLE</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Voriconazole&#160;INJ&#160;<br/>
•&#160;&#160;Voriconazole&#160;SUSR&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The patient&#160;will&#160;use&#160;the requested drug orally or&#160;intravenously.&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
6 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other&#160;Criteria&#160;</b><br/>
N/A&#160;<br/>
312&#160;<br/>
<hr/>
<a name=313></a><b>VOSEVI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Vosevi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
Decompensated cirrhosis/moderate&#160;or severe hepatic&#160;impairment&#160;(Child&#160;<br/>
<b>Criteria&#160;</b><br/>
Turcotte Pugh class B or C)&#160;<br/>
<b>Required&#160;</b><br/>
For hepatitis&#160;C: Infection&#160;confirmed by presence of HCV&#160;RNA in the&#160;<br/>
<b>Medical&#160;</b><br/>
serum prior&#160;to starting treatment. Planned treatment&#160;regimen,&#160;genotype,&#160;<br/>
<b>Information&#160;</b><br/>
prior treatment history,&#160;presence or&#160;absence of cirrhosis (compensated or&#160;<br/>decompensated [Child Turcotte Pugh&#160;class B or C]), presence&#160;or absence&#160;<br/>of HIV coinfection, presence or&#160;absence of&#160;resistance-associated&#160;<br/>substitutions where applicable, liver&#160;and kidney transplantation status&#160;if&#160;<br/>applicable.&#160;Coverage&#160;conditions and&#160;specific durations of approval will&#160;be&#160;<br/>based on current AASLD&#160;treatment&#160;guidelines.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Criteria will&#160;be applied consistent with current AASLD-IDSA guidance.&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
313&#160;<br/>
<hr/>
<a name=314></a><b>VOTRIENT</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Votrient&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Thyroid carcinoma&#160;(follicular, papillary, Hurthle&#160;cell, or medullary),&#160;<br/>uterine sarcoma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For renal&#160;cell carcinoma: The disease&#160;is advanced, relapsed, or stage&#160;IV.&#160;<br/>
<b>Medical&#160;</b><br/>
For soft&#160;tissue sarcoma (STS): The patient does not have&#160;an adipocytic&#160;<br/>
<b>Information&#160;</b><br/>
soft tissue&#160;sarcoma. For&#160;uterine sarcoma: The&#160;disease is recurrent or&#160;<br/>metastatic.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
314&#160;<br/>
<hr/>
<a name=315></a><b>WELIREG</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Welireg&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
315&#160;<br/>
<hr/>
<a name=316></a><b>XALKORI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xalkori&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent non-small&#160;cell lung cancer (NSCLC), NSCLC with high-level&#160;<br/>MET amplification or MET exon 14 skipping&#160;mutation, inflammatory&#160;<br/>myofibroblastic&#160;tumors&#160;(IMT).&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For NSCLC,&#160;the requested drug is used in any of the&#160;following&#160;settings:&#160;<br/>
<b>Medical&#160;</b><br/>
1) the patient has&#160;recurrent, advanced&#160;or metastatic ALK-positive&#160;<br/>
<b>Information&#160;</b><br/>
NSCLC, 2) the patient has recurrent,&#160;advanced or metastatic ROS-1&#160;<br/>positive NSCLC, or 3) the patient has NSCLC with high-level&#160;MET&#160;<br/>amplification or MET exon 14 skipping mutation. For IMT,&#160;the disease&#160;is&#160;<br/>ALK-positive. For anaplastic large cell lymphoma, the disease is relapsed&#160;<br/>or refractory&#160;and ALK-positive.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
316&#160;<br/>
<hr/>
<a name=317></a><b>XELJANZ</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xeljanz&#160;<br/>
•&#160;&#160;Xeljanz Xr&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For moderately&#160;to severely active rheumatoid arthritis (new&#160;starts&#160;only):&#160;<br/>
<b>Medical&#160;</b><br/>
1) Inadequate response,&#160;intolerance or contraindication to methotrexate&#160;<br/>
<b>Information&#160;</b><br/>
(MTX), OR 2) Inadequate response or intolerance to a prior biologic&#160;<br/>disease-modifying&#160;antirheumatic drug (DMARD) or&#160;a targeted synthetic&#160;<br/>DMARD. For&#160;active psoriatic&#160;arthritis (new starts&#160;only): The&#160;requested&#160;<br/>drug is used&#160;in combination with a&#160;nonbiologic DMARD. For&#160;moderately&#160;<br/>to severely active ulcerative colitis (new starts only):&#160;Inadequate response,&#160;<br/>intolerance&#160;or contraindication to a&#160;tumor&#160;necrosis factor&#160;(TNF) blocker.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
317&#160;<br/>
<hr/>
<a name=318></a><b>XERMELO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xermelo&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
318&#160;<br/>
<hr/>
<a name=319></a><b>XGEVA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xgeva&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For hypercalcemia&#160;of malignancy: condition&#160;is refractory to&#160;intravenous&#160;<br/>
<b>Medical&#160;</b><br/>
(IV) bisphosphonate&#160;therapy or there is a clinical&#160;reason to&#160;avoid IV&#160;<br/>
<b>Information&#160;</b><br/>
bisphosphonate&#160;therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
Coverage&#160;under&#160;Part&#160;D will be denied&#160;if&#160;coverage&#160;is available under Part&#160;<br/>A or Part&#160;B as the&#160;medication&#160;is prescribed&#160;and dispensed or&#160;administered&#160;<br/>for&#160;the individual.&#160;<br/>
319&#160;<br/>
<hr/>
<a name=320></a><b>XIFAXAN</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xifaxan&#160;TABS&#160;550MG&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The requested drug&#160;is being prescribed to&#160;reduce the&#160;risk of overt&#160;<br/>
<b>Medical&#160;</b><br/>
hepatic encephalopathy&#160;(HE) recurrence OR 2) The patient has the&#160;<br/>
<b>Information&#160;</b><br/>
diagnosis of&#160;irritable bowel syndrome with diarrhea (IBS-D) AND 3) If&#160;<br/>the patient has previously received treatment with the requested drug, the&#160;<br/>patient has&#160;experienced a&#160;recurrence&#160;of symptoms AND 4) The patient&#160;<br/>has not&#160;already received an initial 14-day course of treatment&#160;and two&#160;<br/>additional 14-day courses of&#160;treatment with&#160;the requested drug OR 5) The&#160;<br/>patient has&#160;not previously received treatment with the requested&#160;drug.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Reduction in&#160;risk of&#160;overt&#160;HE&#160;recurrence:&#160;6&#160;months, IBS-D:&#160;14 days&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
320&#160;<br/>
<hr/>
<a name=321></a><b>XOLAIR</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xolair&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For allergic&#160;asthma initial therapy: 1) Patient has&#160;positive skin test&#160;(or&#160;<br/>
<b>Medical&#160;</b><br/>
blood test)&#160;to&#160;at least&#160;1 perennial aeroallergen, 2) Patient has&#160;baseline&#160;IgE&#160;<br/>
<b>Information&#160;</b><br/>
level greater than or&#160;equal to 30&#160;IU/mL, and 3)&#160;Patient has&#160;inadequate&#160;<br/>asthma control&#160;despite&#160;current treatment&#160;with both of&#160;the following&#160;<br/>medications&#160;at optimized&#160;doses: a) Inhaled corticosteroid, and b)&#160;<br/>Additional controller&#160;(long acting beta2-agonist,&#160;leukotriene&#160;modifier, or&#160;<br/>sustained-release theophylline)&#160;unless patient has&#160;an intolerance or&#160;<br/>contraindication to such&#160;therapies. For allergic asthma&#160;continuation&#160;<br/>therapy only: Patient's asthma control&#160;has improved on treatment with&#160;the&#160;<br/>requested drug since&#160;initiation of&#160;therapy. For chronic&#160;idiopathic urticaria&#160;<br/>(CIU) initial&#160;therapy: 1)&#160;Patient has&#160;been evaluated for&#160;other causes&#160;of&#160;<br/>urticaria, including bradykinin-related&#160;angioedema and IL-1-associated&#160;<br/>urticarial&#160;syndromes&#160;(auto-inflammatory disorders, urticarial&#160;vasculitis),&#160;<br/>and 2)&#160;Patient has experienced a spontaneous onset&#160;of wheals,&#160;<br/>angioedema, or both, for&#160;at least&#160;6 weeks. For&#160;CIU continuation therapy:&#160;<br/>Patient has&#160;experienced a&#160;response&#160;(e.g., improved&#160;symptoms)&#160;since&#160;<br/>initiation of&#160;therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>For CIU: 12 years&#160;of age&#160;or older. For allergic asthma:&#160;6 years of age or&#160;<br/>
older. For nasal&#160;polyps:&#160;18 years&#160;of age or older.&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Allergic asthma&#160;and nasal polyps: Plan Year. CIU initial: 6&#160;months. CIU&#160;<br/>
<b>Duration&#160;</b><br/>
continuation: Plan Year&#160;<br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
321&#160;<br/>
<hr/>
<a name=322></a><b>XOSPATA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xospata&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Myeloid,&#160;lymphoid, or&#160;mixed&#160;lineage neoplasms with eosinophilia and&#160;<br/>FLT3 rearrangement&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For myeloid, lymphoid,&#160;or mixed lineage neoplasms&#160;with eosinophilia and&#160;<br/>
<b>Medical&#160;</b><br/>
FLT3 rearrangement: the disease is&#160;in&#160;chronic or&#160;blast phase.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age&#160;Restrictions&#160;&#160;</b>18 years&#160;of age or older&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
322&#160;<br/>
<hr/>
<a name=323></a><b>XPOVIO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xpovio&#160;<br/>
•&#160;&#160;Xpovio 100 Mg Once&#160;Weekly&#160;<br/>
•&#160;&#160;Xpovio 40 Mg Once Weekly&#160;<br/>
•&#160;&#160;Xpovio 40 Mg Twice Weekly&#160;<br/>
•&#160;&#160;Xpovio 60 Mg Once Weekly&#160;<br/>
•&#160;&#160;Xpovio 60 Mg Twice Weekly&#160;<br/>
•&#160;&#160;Xpovio 80 Mg Once Weekly&#160;<br/>
•&#160;&#160;Xpovio 80 Mg Twice Weekly&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
323&#160;<br/>
<hr/>
<a name=324></a><b>XTANDI</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xtandi&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
The requested&#160;drug will&#160;be used in combination with a gonadotropin-<br/>
<b>Medical&#160;</b><br/>
releasing hormone (GnRH) analog or&#160;after bilateral orchiectomy.&#160;<br/>
<b>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
324&#160;<br/>
<hr/>
<a name=325></a><b>XYREM</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Xyrem&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
1)&#160;The&#160;requested drug&#160;is being prescribed for the&#160;treatment of&#160;excessive&#160;<br/>
<b>Medical&#160;</b><br/>
daytime sleepiness in a patient 7 years of&#160;age or&#160;older&#160;with narcolepsy&#160;<br/>
<b>Information&#160;</b><br/>
AND 2) The&#160;diagnosis has been confirmed by sleep lab evaluation AND&#160;<br/>3)The patient experienced an inadequate&#160;treatment&#160;response or intolerance&#160;<br/>to at&#160;least one central&#160;nervous system&#160;(CNS) stimulant&#160;drug (e.g.,&#160;<br/>amphetamine, dextroamphetamine,&#160;or methylphenidate) OR&#160;has a&#160;<br/>contraindication that would prohibit&#160;a trial of central nervous&#160;system&#160;<br/>(CNS) stimulant&#160;drugs&#160;(e.g., amphetamine, dextroamphetamine, or&#160;<br/>methylphenidate)&#160;[Note:&#160;Coverage&#160;of amphetamines may require prior&#160;<br/>authorization.] AND&#160;4) If the patient is 18 years&#160;of age or&#160;older,&#160;the&#160;<br/>patient experienced an inadequate&#160;treatment response or&#160;intolerance&#160;to at&#160;<br/>least one central nervous system (CNS) wakefulness&#160;promoting drug (e.g.,&#160;<br/>armodafinil) OR has a contraindication that&#160;would&#160;prohibit a trial&#160;of&#160;<br/>central nervous system (CNS) wakefulness promoting drugs&#160;(e.g.,&#160;<br/>armodafinil) [Note:&#160;coverage of&#160;armodafinil&#160;may&#160;require prior&#160;<br/>authorization.] OR 5) The requested drug is being prescribed&#160;for&#160;the&#160;<br/>treatment of&#160;cataplexy in&#160;a patient 7 years of&#160;age or older&#160;with&#160;narcolepsy&#160;<br/>AND 6) The&#160;diagnosis has been confirmed by sleep lab evaluation.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>7 years&#160;of age or&#160;older&#160;<br/>
<b>Prescriber&#160;</b><br/>
Prescribed by&#160;or in consultation with a sleep disorder&#160;specialist or&#160;<br/>
<b>Restrictions&#160;</b><br/>
neurologist.&#160;<br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
If&#160;the&#160;request is for a&#160;continuation of&#160;therapy,&#160;then the patient experienced&#160;<br/>a decrease in daytime&#160;sleepiness with&#160;narcolepsy&#160;or a&#160;decrease in&#160;<br/>cataplexy episodes with narcolepsy.&#160;<br/>
325&#160;<br/>
<hr/>
<a name=326></a>326&#160;<br/>
<hr/>
<a name=327></a><b>YERVOY</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Yervoy&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All Medically-accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
327&#160;<br/>
<hr/>
<a name=328></a><b>ZARXIO</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zarxio&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Neutropenia&#160;in&#160;myelodysplastic syndromes&#160;(MDS), agranulocytosis,&#160;<br/>neutropenia in aplastic anemia, human immunodeficiency virus (HIV)-<br/>related neutropenia, neutropenia related to renal transplant.&#160;<br/>
<b>Exclusion&#160;</b><br/>
Use of&#160;the requested product within&#160;24 hours&#160;prior to or&#160;following&#160;<br/>
<b>Criteria&#160;</b><br/>
chemotherapy.&#160;<br/>
<b>Required&#160;</b><br/>
For prophylaxis&#160;or treatment of myelosuppressive chemotherapy-induced&#160;<br/>
<b>Medical&#160;</b><br/>
febrile neutropenia (FN)&#160;patient must&#160;meet both of the following: 1)&#160;<br/>
<b>Information&#160;</b><br/>
Patient has&#160;a&#160;solid tumor&#160;or non-myeloid cancer, and 2) Patient has&#160;<br/>received, is&#160;currently&#160;receiving, or will&#160;be&#160;receiving treatment&#160;with&#160;<br/>myelosuppressive anti-cancer&#160;therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
6 months&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
328&#160;<br/>
<hr/>
<a name=329></a><b>ZEJULA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zejula&#160;<br/>
329&#160;<br/>
<hr/>
<a name=330></a><b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
In combination&#160;with bevacizumab for persistent&#160;or recurrent&#160;epithelial&#160;<br/>ovarian, fallopian tube,&#160;or primary peritoneal&#160;cancer&#160;for platinum-<br/>sensitive disease.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For ovarian,&#160;fallopian&#160;tube, or&#160;primary&#160;peritoneal&#160;cancer, the&#160;requested&#160;<br/>
<b>Medical&#160;</b><br/>
drug is used&#160;in any of&#160;the following settings: 1) as&#160;maintenance treatment&#160;<br/>
<b>Information&#160;</b><br/>
of stage&#160;II-IV&#160;epithelial ovarian,&#160;fallopian tube,&#160;or primary peritoneal&#160;<br/>cancer&#160;in patients who are in a&#160;complete&#160;or partial response&#160;to&#160;first-line&#160;<br/>platinum-based chemotherapy AND if it is known that&#160;the patient has&#160;<br/>breast&#160;cancer susceptibility gene&#160;(BRCA)-mutated disease,&#160;the patient&#160;<br/>experienced&#160;an unacceptable toxicity&#160;with a&#160;trial&#160;of Lynparza&#160;(olaparib),&#160;<br/>2) as maintenance treatment of recurrent epithelial&#160;ovarian,&#160;fallopian tube,&#160;<br/>or primary peritoneal&#160;cancer&#160;in patients who are&#160;in a complete or&#160;partial&#160;<br/>response&#160;to&#160;chemotherapy AND&#160;the&#160;patient experienced an unacceptable&#160;<br/>toxicity with a trial&#160;of Lynparza&#160;(olaparib), 3) as&#160;treatment of&#160;advanced,&#160;<br/>persistent, or recurrent ovarian, fallopian tube, or primary peritoneal&#160;<br/>cancer&#160;in patients treated&#160;with three or&#160;more prior&#160;chemotherapy regimens&#160;<br/>and whose cancer&#160;is associated with&#160;homologous&#160;recombination&#160;<br/>deficiency&#160;(HRD) positive status defined by either&#160;a)&#160;a deleterious or&#160;<br/>suspected deleterious BRCA&#160;mutation AND if prescribed for&#160;advanced,&#160;<br/>persistent, or recurrent ovarian cancer with deleterious or&#160;suspected&#160;<br/>deleterious&#160;germline BRCA mutation, the patient experienced an&#160;<br/>unacceptable toxicity with a trial of&#160;Lynparza (olaparib), or&#160;b) genomic&#160;<br/>instability and progression more&#160;than six months after response to the last&#160;<br/>platinum-based chemotherapy, or 4)&#160;in combination with bevacizumab for&#160;<br/>platinum-sensitive persistent or recurrent epithelial&#160;ovarian,&#160;fallopian&#160;<br/>tube, or&#160;primary peritoneal&#160;cancer.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
330&#160;<br/>
<hr/>
<a name=331></a><b>ZELBORAF</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zelboraf&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Non-small cell&#160;lung cancer,&#160;hairy cell leukemia, thyroid carcinoma (i.e.,&#160;<br/>papillary carcinoma,&#160;follicular&#160;carcinoma, and Hurthle cell carcinoma),&#160;<br/>central nervous system cancer&#160;(i.e., glioma, meningioma, astrocytoma),&#160;<br/>adjuvant&#160;systemic therapy for cutaneous melanoma.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For adjuvant&#160;treatment of melanoma, and central&#160;nervous system (CNS)&#160;<br/>
<b>Medical&#160;</b><br/>
cancer&#160;(i.e.,&#160;glioma, meningioma, astrocytoma):&#160;1) The tumor is positive&#160;<br/>
<b>Information&#160;</b><br/>
for&#160;BRAF&#160;V600 activating mutation&#160;(e.g., V600E&#160;or V600K) and 2)&#160;The&#160;<br/>requested drug will&#160;be used in combination with&#160;cobimetinib.&#160;For&#160;<br/>unresectable&#160;or metastatic melanoma: 1)&#160;The tumor is positive for BRAF&#160;<br/>V600 activating mutation (e.g., V600E&#160;or V600K) and 2)&#160;the requested&#160;<br/>drug will be&#160;used as a single agent, or in combination with cobimetinib&#160;<br/>(with or without atezolizumab). For&#160;Erdheim-Chester Disease: Tumor is&#160;<br/>positive for&#160;BRAF&#160;V600 mutation. For non-small&#160;cell&#160;lung cancer: 1)&#160;<br/>Tumor&#160;is positive for the&#160;BRAF&#160;V600E mutation, and 2)&#160;The&#160;patient has&#160;<br/>recurrent,&#160;advanced, or&#160;metastatic&#160;disease. For thyroid carcinoma:&#160;1)&#160;<br/>Tumor&#160;is positive for BRAF mutation, and 2) Patient has&#160;radioiodine&#160;<br/>refractory follicular, Hurthle cell, or&#160;papillary thyroid carcinoma. For&#160;<br/>hairy cell&#160;leukemia: The&#160;requested drug will be used for subsequent&#160;<br/>therapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
331&#160;<br/>
<hr/>
<a name=332></a><b>ZEPZELCA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zepzelca&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All&#160;FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Relapsed small&#160;cell&#160;lung&#160;cancer, primary&#160;progressive small&#160;cell lung&#160;<br/>cancer.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For small&#160;cell&#160;lung&#160;cancer: the requested medication will be used as a&#160;<br/>
<b>Medical&#160;</b><br/>
single&#160;agent&#160;in one&#160;of the&#160;following settings:&#160;1) the disease has relapsed&#160;<br/>
<b>Information&#160;</b><br/>
following&#160;complete or&#160;partial response or&#160;stable disease with initial&#160;<br/>treatment, 2) the patient&#160;has primary&#160;progressive&#160;disease, or 3) the patient&#160;<br/>has metastatic disease&#160;following disease progression on or&#160;after&#160;platinum-<br/>based chemotherapy.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
332&#160;<br/>
<hr/>
<a name=333></a><b>ZOLINZA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zolinza&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Mycosis&#160;fungoides, Sezary syndrome.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
333&#160;<br/>
<hr/>
<a name=334></a><b>ZYDELIG</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zydelig&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Relapsed or&#160;refractory chronic&#160;lymphocytic&#160;leukemia&#160;(CLL)/small&#160;<br/>lymphocytic&#160;lymphoma (SLL), relapsed or refractory follicular&#160;<br/>lymphoma,&#160;and marginal zone&#160;lymphomas&#160;[nodal marginal&#160;zone&#160;<br/>lymphoma,&#160;gastric mucosa associated lymphoid&#160;tissue (MALT)&#160;<br/>lymphoma,&#160;non-gastric&#160;MALT lymphoma, and&#160;splenic marginal&#160;zone&#160;<br/>lymphoma].&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
N/A&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
334&#160;<br/>
<hr/>
<a name=335></a><b>ZYKADIA</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zykadia&#160;TABS&#160;<br/>
<b>PA Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications, Some Medically&#160;accepted Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
Recurrent or&#160;advanced ALK-positive&#160;non-small cell&#160;lung cancer&#160;<br/>(NSCLC), recurrent, advanced, or&#160;metastatic&#160;ROS1-positive NSCLC,&#160;<br/>inflammatory myofibroblastic tumor&#160;(IMT), brain&#160;metastases from&#160;<br/>NSCLC.&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
For NSCLC:&#160;the patient&#160;has recurrent, advanced,&#160;or metastatic ALK-<br/>
<b>Medical&#160;</b><br/>
positive or&#160;ROS1-positive disease.&#160;For inflammatory&#160;myofibroblastic&#160;<br/>
<b>Information&#160;</b><br/>
tumor: the disease is ALK-positive.&#160;For brain metastases&#160;from NSCLC:&#160;<br/>the patient has ALK-positive NSCLC.&#160;<br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
335&#160;<br/>
<hr/>
<a name=336></a><b>ZYPREXA&#160;RELPREVV</b>&#160;<br/>
<b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;Zyprexa&#160;Relprevv&#160;<br/>
<b>PA&#160;Criteria&#160;</b><br/>
<b>Criteria&#160;Details&#160;</b><br/>
<b>Indications&#160;</b><br/>
All FDA-approved Indications.&#160;<br/>
<b>Off-Label Uses&#160;</b><br/>
N/A&#160;<br/>
<b>Exclusion&#160;</b><br/>
N/A&#160;<br/>
<b>Criteria&#160;</b><br/>
<b>Required&#160;</b><br/>
Tolerability&#160;with&#160;oral olanzapine&#160;has&#160;been established.&#160;<br/>
<b>Medical&#160;<br/>Information&#160;</b><br/>
<b>Age Restrictions&#160;&#160;</b>N/A&#160;<br/>
<b>Prescriber&#160;</b><br/>
N/A&#160;<br/>
<b>Restrictions&#160;</b><br/>
<b>Coverage&#160;</b><br/>
Plan Year&#160;<br/>
<b>Duration&#160;</b><br/>
<b>Other Criteria&#160;</b><br/>
N/A&#160;<br/>
336&#160;<br/>
<hr/>
<a name=337></a><b>PART&#160;B&#160;VERSUS&#160;PART&#160;D</b>&#160;<br/>
337&#160;<br/>
<hr/>
<a name=338></a><b>Products&#160;Affected&#160;</b><br/>
•&#160;&#160;&#160;Abelcet&#160;<br/>
•&#160;&#160;&#160;Acetylcysteine&#160;INHALATION&#160;SOLN&#160;<br/>
•&#160;&#160;&#160;Acyclovir Sodium&#160;INJ 50MG/ML&#160;<br/>
•&#160;&#160;&#160;Albuterol Sulfate&#160;NEBU&#160;0.083%,&#160;<br/>
0.63MG/3ML, 1.25MG/3ML,&#160;<br/>2.5MG/0.5ML&#160;<br/>
•&#160;&#160;&#160;Ambisome&#160;<br/>
•&#160;&#160;&#160;Aminosyn-pf 7%&#160;INJ 32.5MEQ/L;&#160;<br/>
490MG/100ML;&#160;861MG/100ML;&#160;<br/>370MG/100ML;&#160;576MG/100ML;&#160;<br/>270MG/100ML;&#160;220MG/100ML;&#160;<br/>534MG/100ML;&#160;831MG/100ML;&#160;<br/>475MG/100ML;&#160;125MG/100ML;&#160;<br/>10.69GM/L; 300MG/100ML;&#160;<br/>570MG/100ML;&#160;70GM/L;&#160;<br/>347MG/100ML;&#160;50MG/100ML;&#160;<br/>360MG/100ML;&#160;125MG/100ML;&#160;<br/>44MG/100ML;&#160;452MG/100ML&#160;<br/>
•&#160;&#160;&#160;Amphotericin B&#160;INJ&#160;<br/>
•&#160;&#160;&#160;Aprepitant&#160;CAPS&#160;<br/>
•&#160;&#160;&#160;Azathioprine&#160;INJ&#160;<br/>
•&#160;&#160;&#160;Azathioprine&#160;TABS&#160;50MG&#160;<br/>
•&#160;&#160;&#160;Bleomycin Sulfate&#160;INJ&#160;<br/>
•&#160;&#160;&#160;Budesonide&#160;SUSP&#160;<br/>
•&#160;&#160;&#160;Cladribine&#160;<br/>
•&#160;&#160;&#160;Clinimix 4.25%/dextrose 10%&#160;<br/>
•&#160;&#160;&#160;Clinimix 4.25%/dextrose 5%&#160;<br/>
•&#160;&#160;&#160;Clinimix 5%/dextrose&#160;15%&#160;<br/>
•&#160;&#160;&#160;Clinimix 5%/dextrose&#160;20%&#160;<br/>
•&#160;&#160;&#160;Clinimix 6/5&#160;<br/>
•&#160;&#160;&#160;Clinimix 8/10&#160;<br/>
•&#160;&#160;&#160;Clinimix 8/14&#160;<br/>
•&#160;&#160;&#160;Clinisol Sf&#160;15%&#160;<br/>
•&#160;&#160;&#160;Clinolipid&#160;<br/>
•&#160;&#160;&#160;Cromolyn Sodium&#160;NEBU&#160;<br/>
•&#160;&#160;&#160;Cyclophosphamide&#160;CAPS&#160;<br/>
•&#160;&#160;&#160;Cyclophosphamide&#160;TABS&#160;<br/>
•&#160;&#160;&#160;Cyclosporine&#160;CAPS&#160;<br/>
•&#160;&#160;&#160;Cyclosporine&#160;INJ&#160;<br/>
•&#160;&#160;&#160;Cyclosporine Modified&#160;<br/>
•&#160;&#160;&#160;Cytarabine&#160;INJ&#160;100MG/ML&#160;<br/>
•&#160;&#160;&#160;Cytarabine&#160;Aqueous&#160;<br/>
338&#160;<br/>
<hr/>
<a name=339></a>•&#160;&#160;&#160;Dextrose 50%&#160;<br/>
•&#160;&#160;&#160;Dextrose 70%&#160;<br/>
•&#160;&#160;&#160;Diphtheria/tetanus Toxoids Adsorbed&#160;<br/>
Pediatric&#160;<br/>
•&#160;&#160;&#160;Emend&#160;SUSR&#160;<br/>
•&#160;&#160;&#160;Engerix-b&#160;<br/>
•&#160;&#160;&#160;Epoprostenol Sodium&#160;<br/>
•&#160;&#160;&#160;Everolimus&#160;TABS&#160;0.25MG, 0.5MG,&#160;<br/>
0.75MG, 1MG&#160;<br/>
•&#160;&#160;&#160;Fluorouracil&#160;INJ 1GM/20ML,&#160;<br/>
2.5GM/50ML, 500MG/10ML,&#160;<br/>5GM/100ML&#160;<br/>
•&#160;&#160;&#160;Freamine&#160;Hbc 6.9%&#160;<br/>
•&#160;&#160;&#160;Freamine&#160;III&#160;INJ 89MEQ/L;&#160;<br/>
710MG/100ML;&#160;950MG/100ML;&#160;<br/>3MEQ/L; 24MG/100ML;&#160;<br/>1400MG/100ML;&#160;280MG/100ML;&#160;<br/>690MG/100ML;&#160;910MG/100ML;&#160;<br/>730MG/100ML;&#160;530MG/100ML;&#160;<br/>560MG/100ML;&#160;10MMOLE/L;&#160;<br/>120MG/100ML;&#160;1120MG/100ML;&#160;<br/>590MG/100ML;&#160;10MEQ/L;&#160;<br/>400MG/100ML;&#160;150MG/100ML;&#160;<br/>660MG/100ML&#160;<br/>
•&#160;&#160;&#160;Gamastan&#160;<br/>
•&#160;&#160;&#160;Ganciclovir&#160;INJ 500MG,&#160;<br/>
500MG/10ML&#160;<br/>
•&#160;&#160;&#160;Gengraf&#160;CAPS 100MG,&#160;25MG&#160;<br/>
•&#160;&#160;&#160;Gengraf&#160;SOLN&#160;<br/>
•&#160;&#160;&#160;Granisetron&#160;Hcl&#160;TABS&#160;<br/>
•&#160;&#160;&#160;Hepatamine&#160;INJ 62MEQ/L;&#160;<br/>
770MG/100ML;&#160;600MG/100ML;&#160;<br/>3MEQ/L; 20MG/100ML;&#160;<br/>900MG/100ML;&#160;240MG/100ML;&#160;<br/>900MG/100ML;&#160;1100MG/100ML;&#160;<br/>610MG/100ML;&#160;100MG/100ML;&#160;<br/>100MG/100ML;&#160;115MG/100ML;&#160;<br/>800MG/100ML;&#160;500MG/100ML;&#160;<br/>450MG/100ML;&#160;66MG/100ML;&#160;<br/>840MG/100ML&#160;<br/>
•&#160;&#160;&#160;Humulin R&#160;U-500 (concentrated)&#160;<br/>
•&#160;&#160;&#160;Hydromorphone Hcl&#160;INJ 10MG/ML,&#160;<br/>
1MG/ML, 4MG/ML&#160;<br/>
339&#160;<br/>
<hr/>
<a name=340></a><hr/>
<a name=341></a>•&#160;&#160;&#160;Plenamine&#160;INJ 147.4MEQ/L;&#160;<br/>
2.17GM/100ML;&#160;1.47GM/100ML;&#160;<br/>434MG/100ML;&#160;749MG/100ML;&#160;<br/>1.04GM/100ML;&#160;894MG/100ML;&#160;<br/>749MG/100ML;&#160;1.04GM/100ML;&#160;<br/>1.18GM/100ML;&#160;749MG/100ML;&#160;<br/>1.04GM/100ML;&#160;894MG/100ML;&#160;<br/>592MG/100ML;&#160;749MG/100ML;&#160;<br/>250MG/100ML;&#160;39MG/100ML;&#160;<br/>960MG/100ML&#160;<br/>
•&#160;&#160;&#160;Prednisolone&#160;SOLN&#160;<br/>
•&#160;&#160;&#160;Prednisolone Sodium Phosphate&#160;<br/>
ORAL&#160;SOLN 10MG/5ML,&#160;<br/>15MG/5ML, 20MG/5ML,&#160;<br/>25MG/5ML, 5MG/5ML&#160;<br/>
•&#160;&#160;&#160;Prednisone&#160;SOLN&#160;<br/>
•&#160;&#160;&#160;Prednisone&#160;TABS&#160;10MG, 1MG,&#160;<br/>
2.5MG, 20MG, 50MG, 5MG&#160;<br/>
•&#160;&#160;&#160;Prednisone&#160;Intensol&#160;<br/>
•&#160;&#160;&#160;Premasol&#160;INJ 52MEQ/L;&#160;<br/>
1760MG/100ML;&#160;880MG/100ML;&#160;<br/>34MEQ/L; 1760MG/100ML;&#160;<br/>372MG/100ML;&#160;406MG/100ML;&#160;<br/>526MG/100ML; 492MG/100ML;&#160;<br/>492MG/100ML;&#160;526MG/100ML;&#160;<br/>356MG/100ML;&#160;356MG/100ML;&#160;<br/>390MG/100ML;&#160;34MG/100ML;&#160;<br/>152MG/100ML&#160;<br/>
•&#160;&#160;&#160;Procalamine&#160;<br/>
•&#160;&#160;&#160;Prograf&#160;PACK&#160;<br/>
•&#160;&#160;&#160;Prosol&#160;<br/>
•&#160;&#160;&#160;Rabavert&#160;<br/>
•&#160;&#160;&#160;Recombivax&#160;Hb&#160;<br/>
•&#160;&#160;&#160;Sandimmune&#160;SOLN&#160;<br/>
•&#160;&#160;&#160;Sirolimus&#160;SOLN&#160;<br/>
•&#160;&#160;&#160;Sirolimus&#160;TABS&#160;<br/>
•&#160;&#160;&#160;Tacrolimus&#160;CAPS&#160;<br/>
•&#160;&#160;&#160;Tdvax&#160;<br/>
•&#160;&#160;&#160;Tenivac&#160;<br/>
•&#160;&#160;&#160;Tpn Electrolytes&#160;INJ&#160;<br/>
29.5MEQ/20ML; 4.5MEQ/20ML;&#160;<br/>35MEQ/20ML;&#160;5MEQ/20ML;&#160;<br/>20MEQ/20ML; 35MEQ/20ML&#160;<br/>
341&#160;<br/>
<hr/>
<a name=342></a>•&#160;&#160;&#160;Travasol&#160;INJ 52MEQ/L;&#160;<br/>
1760MG/100ML;&#160;880MG/100ML;&#160;<br/>34MEQ/L; 1760MG/100ML;&#160;<br/>372MG/100ML;&#160;406MG/100ML;&#160;<br/>526MG/100ML;&#160;492MG/100ML;&#160;<br/>492MG/100ML;&#160;526MG/100ML;&#160;<br/>356MG/100ML;&#160;500MG/100ML;&#160;<br/>356MG/100ML;&#160;390MG/100ML;&#160;<br/>34MG/100ML;&#160;152MG/100ML&#160;<br/>
•&#160;&#160;&#160;Trophamine&#160;INJ 97MEQ/L;&#160;<br/>
0.54GM/100ML;&#160;1.2GM/100ML;&#160;<br/>0.32GM/100ML;&#160;0; 0;&#160;<br/>0.5GM/100ML;&#160;0.36GM/100ML;&#160;<br/>0.48GM/100ML;&#160;0.82GM/100ML;&#160;<br/>1.4GM/100ML;&#160;1.2GM/100ML;&#160;<br/>0.34GM/100ML;&#160;0.48GM/100ML;&#160;<br/>0.68GM/100ML;&#160;0.38GM/100ML;&#160;<br/>5MEQ/L; 0.025GM/100ML;&#160;<br/>0.42GM/100ML;&#160;0.2GM/100ML;&#160;<br/>0.24GM/100ML;&#160;0.78GM/100ML&#160;<br/>
•&#160;&#160;&#160;Vinblastine&#160;Sulfate&#160;INJ&#160;1MG/ML&#160;<br/>
•&#160;&#160;&#160;Vincristine Sulfate&#160;INJ&#160;<br/>
•&#160;&#160;&#160;Zortress&#160;TABS&#160;1MG&#160;<br/>
<b>Details&#160;</b><br/>
This&#160;&#160;drug&#160;&#160;may&#160;&#160;be&#160;&#160;covered&#160;&#160;under&#160;&#160;Medicare&#160;&#160;Part&#160;&#160;B&#160;&#160;or&#160;&#160;D&#160;&#160;depending&#160;&#160;upon&#160;&#160;the&#160;&#160;circumstances.&#160;<br/>Information&#160;&#160;may&#160;&#160;need&#160;&#160;to&#160;&#160;be&#160;&#160;submitted&#160;&#160;describing&#160;&#160;the&#160;&#160;use&#160;&#160;and&#160;&#160;setting&#160;&#160;of&#160;&#160;the&#160;&#160;drug&#160;&#160;to&#160;&#160;make&#160;&#160;the&#160;<br/>determination.&#160;<br/>
342&#160;<br/>
<hr/>
<a name=343></a>&#160;<br/>&#160;<br/>
<b>INDEX</b><br/>
<i><b>A</b>&#160;</i><br/>
Ayvakit&#160;.................................................................17<br/>
&#160;&#160;&#160;<br/>
Abelcet&#160;..............................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Azathioprine&#160;.......................................................338<br/>
&#160;<br/>
&#160;<br/>
Abiraterone&#160;............................................................&#160;1<br/>
&#160;&#160;&#160;<br/>
<i><b>B</b>&#160;</i><br/>
Abiraterone&#160;Acetate...............................................&#160;1<br/>
&#160;&#160;&#160;<br/>
Balversa................................................................18<br/>
&#160;&#160;&#160;<br/>
Accutane&#160;............................................................&#160;153<br/>
&#160;<br/>
&#160;<br/>
Banzel&#160;..................................................................19<br/>
&#160;&#160;&#160;<br/>
Acetylcysteine&#160;...................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Beleodaq&#160;..............................................................20<br/>
&#160;&#160;&#160;<br/>
Acitretin&#160;.................................................................&#160;3<br/>
&#160;&#160;&#160;<br/>
Benlysta................................................................&#160;21&#160;<br/>
Actimmune&#160;............................................................&#160;4<br/>
&#160;&#160;&#160;<br/>
Benztropine&#160;Mesylate&#160;........................................116<br/>
&#160;<br/>
&#160;<br/>
Acyclovir Sodium&#160;.............................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Besremi&#160;................................................................22<br/>
&#160;&#160;&#160;<br/>
Adempas&#160;................................................................&#160;5<br/>
&#160;&#160;&#160;<br/>
Betaseron..............................................................23<br/>
&#160;&#160;&#160;<br/>
Afinitor&#160;................................................................&#160;83<br/>
&#160;&#160;&#160;<br/>
Bevacizumab&#160;........................................................24<br/>
&#160;&#160;&#160;<br/>
Afinitor Disperz...................................................&#160;83<br/>
&#160;&#160;&#160;<br/>
Bexarotene&#160;...........................................................26<br/>
&#160;&#160;&#160;<br/>
Aimovig&#160;.................................................................&#160;6<br/>
&#160;&#160;&#160;<br/>
Bivigam&#160;..............................................................156<br/>
&#160;<br/>
&#160;<br/>
Albuterol Sulfate&#160;...............................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Blenrep&#160;.................................................................27<br/>
&#160;&#160;&#160;<br/>
Alecensa&#160;................................................................&#160;7<br/>
&#160;&#160;&#160;<br/>
Bleomycin Sulfate&#160;..............................................338<br/>
&#160;<br/>
&#160;<br/>
Alosetron&#160;...............................................................&#160;8<br/>
&#160;&#160;&#160;<br/>
Bortezomib&#160;.........................................................303<br/>
&#160;<br/>
&#160;<br/>
Alosetron Hydrochloride&#160;.......................................&#160;8<br/>
&#160;&#160;&#160;<br/>
Bosentan&#160;...............................................................28<br/>
&#160;&#160;&#160;<br/>
Alpha1-proteinase&#160;Inhibitor&#160;..................................&#160;9<br/>
&#160;&#160;&#160;<br/>
Bosulif&#160;..................................................................29<br/>
&#160;&#160;&#160;<br/>
Alunbrig&#160;..............................................................&#160;10<br/>
&#160;&#160;&#160;<br/>
Braftovi&#160;................................................................30<br/>
&#160;&#160;&#160;<br/>
Alyq&#160;...................................................................&#160;266<br/>
&#160;<br/>
&#160;<br/>
Briviact&#160;...........................................................31, 32<br/>
&#160;<br/>
&#160;<br/>
Ambisome&#160;.........................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Briviact Inj&#160;...........................................................32<br/>
&#160;&#160;&#160;<br/>
Ambrisentan&#160;........................................................&#160;11<br/>
&#160;&#160;&#160;<br/>
Brukinsa&#160;...............................................................33<br/>
&#160;&#160;&#160;<br/>
Aminosyn-pf 7%&#160;...............................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Budesonide&#160;.........................................................338<br/>
&#160;<br/>
&#160;<br/>
Amitriptyline Hcl&#160;..............................................&#160;127<br/>
&#160;<br/>
&#160;<br/>
Buprenorphine................................................34, 35<br/>
&#160;<br/>
&#160;<br/>
Amitriptyline Hydrochloride&#160;.............................&#160;127<br/>
&#160;<br/>
&#160;<br/>
Buprenorphine Hcl&#160;...............................................34<br/>
&#160;&#160;&#160;<br/>
Amnesteem&#160;........................................................&#160;153<br/>
&#160;<br/>
&#160;<br/>
Buprenorphine Patch&#160;............................................35<br/>
&#160;&#160;&#160;<br/>
Amphotericin B&#160;.................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Androderm&#160;........................................................&#160;288<br/>
&#160;<br/>
&#160;<br/>
<i><b>C</b>&#160;</i><br/>
Apo-varenicline&#160;...................................................&#160;45<br/>
&#160;&#160;&#160;<br/>
Cabometyx&#160;...........................................................36<br/>
&#160;&#160;&#160;<br/>
Aprepitant&#160;..........................................................&#160;3<br/>
&#160;&#160;38&#160;<br/>
Calcipotriene&#160;........................................................37<br/>
&#160;&#160;&#160;<br/>
Arcalyst&#160;...............................................................&#160;12<br/>
&#160;&#160;&#160;<br/>
Calcipotriene/betamethasone Dipropionate&#160;.........37<br/>
&#160;&#160;&#160;<br/>
Armodafinil&#160;.........................................................&#160;13<br/>
&#160;&#160;&#160;<br/>
Calcitriol&#160;..............................................................37<br/>
&#160;&#160;&#160;<br/>
Asparlas&#160;...............................................................&#160;14<br/>
&#160;&#160;&#160;<br/>
Calquence&#160;.............................................................38<br/>
&#160;&#160;&#160;<br/>
Atovaquone&#160;.......................................................&#160;187<br/>
&#160;<br/>
&#160;<br/>
Caplyta&#160;.................................................................39<br/>
&#160;&#160;&#160;<br/>
Austedo&#160;...............................................................&#160;15<br/>
&#160;&#160;&#160;<br/>
Caprelsa................................................................40<br/>
&#160;&#160;&#160;<br/>
Avonex&#160;................................................................&#160;16<br/>
&#160;&#160;&#160;<br/>
Carac&#160;....................................................................41<br/>
&#160;&#160;&#160;<br/>
Avonex Pen&#160;.........................................................&#160;16<br/>
&#160;&#160;&#160;<br/>
Carbaglu&#160;...............................................................42<br/>
&#160;&#160;&#160;<br/>
343&#160;<br/>
<hr/>
<a name=344></a>&#160;<br/>&#160;<br/>
Carbinoxamine Maleate&#160;....................................&#160;129<br/>
&#160;<br/>
&#160;<br/>
Cystaran&#160;...............................................................&#160;56&#160;<br/>
Cayston&#160;................................................................&#160;43<br/>
&#160;&#160;&#160;<br/>
Cytarabin&#160;&#160;<br/>
e&#160;..........................................................&#160;338&#160;<br/>
Cerdelga&#160;..............................................................&#160;44<br/>
&#160;&#160;&#160;<br/>
Cytarabine&#160;Aqueous&#160;...........................................&#160;338&#160;<br/>
Chantix&#160;................................................................&#160;45<br/>
&#160;&#160;&#160;<br/>
<i><b>D</b>&#160;</i><br/>
Chantix Continuing Month Pak&#160;..........................&#160;45<br/>
&#160;&#160;&#160;<br/>
Chantix Starting Month&#160;Pak&#160;................................&#160;45<br/>
&#160;&#160;&#160;<br/>
Dalfampridine&#160;......................................................&#160;57&#160;<br/>
Chlordiazepoxide&#160;-&#160;65&#160;.........................................&#160;46<br/>
&#160;&#160;&#160;<br/>
Dalfampridine Er&#160;.................................................&#160;57&#160;<br/>
Chlordiazepoxide Hcl&#160;..........................................&#160;46<br/>
&#160;&#160;&#160;<br/>
Daurismo................................<br/>
&#160;<br/>
..............................&#160;58&#160;<br/>
Chlordiazepoxide Hydrochloride&#160;........................&#160;46<br/>
&#160;&#160;&#160;<br/>
Deferasirox................................<br/>
&#160;<br/>
...........................&#160;59&#160;<br/>
Chlordiazepoxide/amitriptyline&#160;.........................&#160;110<br/>
&#160;<br/>
&#160;<br/>
Demser&#160;................................<br/>
&#160;<br/>
.................................&#160;60&#160;<br/>
Chlorzoxazone&#160;...................................................&#160;133<br/>
&#160;<br/>
&#160;<br/>
Desipramine&#160;Hydrochloride...............................<br/>
&#160;<br/>
&#160;127&#160;<br/>
Cladribine&#160;..........................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Desvenlafaxine................................<br/>
&#160;<br/>
.....................&#160;61&#160;<br/>
Claravis..............................................................&#160;153<br/>
&#160;<br/>
&#160;<br/>
Desvenlafax<br/>
................................<br/>
ine Er&#160;<br/>
................&#160;61&#160;<br/>
Clemastine&#160;Fumarate&#160;.........................................&#160;130<br/>
&#160;<br/>
&#160;<br/>
Dextrose 50%................................<br/>
&#160;<br/>
.....................&#160;339&#160;<br/>
Clinimix 4.25%/dextrose 10%&#160;..........................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Dextrose 70%................................<br/>
&#160;<br/>
.....................&#160;339&#160;<br/>
Clinimix 4.25%/dextrose 5%&#160;............................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Dhe Nasal................................<br/>
&#160;<br/>
.............................&#160;62&#160;<br/>
Clinimix 5%/dextrose&#160;15%&#160;...............................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Diacomit................................<br/>
&#160;<br/>
...............................&#160;63&#160;<br/>
Clinimix 5%/dextrose&#160;20%&#160;...............................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Diazepam&#160;................................<br/>
&#160;<br/>
.............................&#160;64&#160;<br/>
Clinimix 6/5&#160;......................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Diclofenac&#160;Gel 1%................................<br/>
&#160;<br/>
...............&#160;65&#160;<br/>
Clinimix 8/10&#160;....................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Diclofenac&#160;Sodium................................<br/>
&#160;<br/>
...............&#160;65&#160;<br/>
Clinimix 8/14&#160;....................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Diclofenac&#160;Soln................................<br/>
&#160;<br/>
....................&#160;66&#160;<br/>
Clinisol Sf&#160;15%&#160;.................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Dicyclomine Hcl&#160;................................<br/>
&#160;<br/>
................&#160;110&#160;<br/>
Clinolipid&#160;...........................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Dicyclomine Hydrochloride...............................<br/>
&#160;<br/>
&#160;110&#160;<br/>
Clobazam&#160;.............................................................&#160;47<br/>
&#160;&#160;&#160;<br/>
Dihydroergotamine Mesylat&#160;.......................<br/>
e<br/>
&#160;62, 110&#160;<br/>
Clomipramine&#160;......................................................&#160;48<br/>
&#160;&#160;&#160;<br/>
Diphenhydramine&#160;Hcl................................<br/>
&#160;<br/>
........&#160;110&#160;<br/>
Clomipramine Hcl&#160;...............................................&#160;48<br/>
&#160;&#160;&#160;<br/>
Diphtheria/tetanus Toxoids Adsorbed Pediatric&#160;339&#160;<br/>
Clorazepate&#160;..........................................................&#160;49<br/>
&#160;&#160;&#160;<br/>
Dipyridamole&#160;................................<br/>
&#160;<br/>
.....................&#160;110&#160;<br/>
Clorazepate&#160;Dipotassium.....................................&#160;49<br/>
&#160;&#160;&#160;<br/>
Disopyramide Phosphate&#160;................................<br/>
&#160;<br/>
...&#160;110&#160;<br/>
Clozapine Odt&#160;......................................................&#160;50<br/>
&#160;&#160;&#160;<br/>
Doptelet................................<br/>
&#160;<br/>
................................&#160;67&#160;<br/>
Colistimethate Sodium&#160;........................................&#160;51<br/>
&#160;&#160;&#160;<br/>
Doxepin Hcl&#160;................................<br/>
&#160;<br/>
.......................&#160;119&#160;<br/>
Coly-mycin&#160;..........................................................&#160;51<br/>
&#160;&#160;&#160;<br/>
Doxepin Hydrochloride&#160;.............................<br/>
&#160;<br/>
&#160;119, 286&#160;<br/>
Cometriq&#160;..............................................................&#160;52<br/>
&#160;&#160;&#160;<br/>
Doxycycline&#160;................................<br/>
&#160;<br/>
.......................&#160;208&#160;<br/>
Copaxone&#160;...........................................................&#160;101<br/>
&#160;<br/>
&#160;<br/>
Drizalma................................<br/>
&#160;<br/>
...............................&#160;68&#160;<br/>
Copiktra&#160;...............................................................&#160;53<br/>
&#160;&#160;&#160;<br/>
Drizalma Sprinkle&#160;................................<br/>
&#160;<br/>
................&#160;68&#160;<br/>
Cotellic&#160;................................................................&#160;54<br/>
&#160;&#160;&#160;<br/>
Dronabinol&#160;................................<br/>
&#160;<br/>
...........................&#160;69&#160;<br/>
Cromolyn Sodium&#160;.............................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Droxidopa&#160;................................<br/>
&#160;<br/>
..........................&#160;198&#160;<br/>
Cyclobenzaprine Hydrochloride&#160;.......................&#160;133<br/>
&#160;<br/>
&#160;<br/>
Duexis&#160;................................<br/>
&#160;<br/>
..................................&#160;70&#160;<br/>
Cyclophosphamide&#160;............................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
<i><b>E</b>&#160;</i><br/>
Cyclosporine&#160;.....................................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Emend&#160;................................<br/>
&#160;<br/>
................................&#160;339&#160;<br/>
Cyclosporine Modified&#160;......................................&#160;338<br/>
&#160;<br/>
&#160;<br/>
Emsam<br/>
................................<br/>
................................<br/>
..&#160;71&#160;<br/>
Cyproheptadine Hcl...........................................&#160;118<br/>
&#160;<br/>
&#160;<br/>
Enbrel................................<br/>
&#160;<br/>
...................................&#160;72&#160;<br/>
Cyproheptadine Hydrochloride&#160;.........................&#160;118<br/>
&#160;<br/>
&#160;<br/>
Enbrel&#160;Mini&#160;<br/>
..........................<br/>
................................<br/>
&#160;72&#160;<br/>
Cystagon&#160;..............................................................&#160;55<br/>
&#160;&#160;&#160;<br/>
344&#160;<br/>
<hr/>
<a name=345></a>&#160;<br/>&#160;<br/>
Enbrel&#160;Sureclick&#160;..................................................&#160;72&#160;<br/>
Gammaked&#160;.........................................................&#160;156&#160;<br/>
Engerix-b................................<br/>
&#160;<br/>
...........................&#160;339&#160;<br/>
Gammapl&#160;&#160;<br/>
ex&#160;........................................................&#160;156&#160;<br/>
Enhertu&#160;..<br/>
&#160;&#160;..............................................................&#160;74&#160;<br/>
Gamunex-&#160;&#160;<br/>
c.........................................................&#160;156&#160;<br/>
Ensti&#160;&#160;<br/>
lar&#160;................................................................&#160;37&#160;<br/>
Ganciclov&#160;&#160;<br/>
ir.........................................................&#160;339&#160;<br/>
&#160;<br/>
Epclusa&#160;................................................................&#160;75&#160;<br/>
Gatte&#160;&#160;<br/>
x...................................................................&#160;97&#160;<br/>
Epidi<br/>
&#160;<br/>
olex&#160;.............................................................&#160;76&#160;<br/>
Gavret&#160;&#160;<br/>
o.................................................................&#160;98&#160;<br/>
Epo&#160;...................<br/>
&#160;<br/>
.............<br/>
........&#160;<br/>
..............................<br/>
77&#160;<br/>
&#160;<br/>
Gengraf&#160;..............................................................&#160;339&#160;<br/>
Epoprostenol Sodium&#160;............................<br/>
&#160;<br/>
......&#160;<br/>
......<br/>
339&#160;<br/>
Genotr<br/>
&#160;<br/>
opin&#160;.........................................................&#160;102&#160;<br/>
Erivedge&#160;<br/>
.....<br/>
...............<br/>
.............................<br/>
........&#160;<br/>
.....<br/>
79&#160;<br/>
Genotropin&#160;Miniquick................................<br/>
&#160;<br/>
........&#160;102&#160;<br/>
Erleada.......................<br/>
&#160;<br/>
.............................<br/>
........&#160;<br/>
.....<br/>
80&#160;<br/>
Gilenya................................<br/>
&#160;<br/>
.................................&#160;99&#160;<br/>
Erlotinib&#160;<br/>
..............<br/>
.......<br/>
...........<br/>
........&#160;<br/>
.....<br/>
..................<br/>
81&#160;<br/>
Gilot&#160;................................<br/>
rif<br/>
................................&#160;100&#160;<br/>
Erlotinib Hydrochloride&#160;.........................<br/>
&#160;<br/>
........&#160;<br/>
.....<br/>
81&#160;<br/>
Glatiramer&#160;................................<br/>
&#160;<br/>
..........................&#160;101&#160;<br/>
Esbrie&#160;........................<br/>
t<br/>
.............................<br/>
........&#160;<br/>
.....<br/>
82&#160;<br/>
Granisetron&#160;Hcl................................<br/>
&#160;<br/>
..................&#160;339&#160;<br/>
Eszopiclon&#160;&#160;<br/>
e&#160;................................<br/>
......&#160;<br/>
.................<br/>
113&#160;<br/>
Growth Hormone&#160;................................<br/>
&#160;<br/>
...............&#160;102&#160;<br/>
Everolimus&#160;................................<br/>
&#160;<br/>
..................&#160;83, 339&#160;<br/>
Guanfacine Er&#160;................................<br/>
&#160;<br/>
....................&#160;110&#160;<br/>
Exkivity&#160;................................<br/>
&#160;<br/>
...............................&#160;84&#160;<br/>
Guanfacine Hcl&#160;................................<br/>
&#160;<br/>
..................&#160;110&#160;<br/>
<i><b>F</b></i><br/>
Guanfacine Hydrochloride................................<br/>
&#160;<br/>
.&#160;110&#160;<br/>
<i>&#160;</i><br/>
Fanapt................................<br/>
&#160;<br/>
..................................&#160;85&#160;<br/>
<i><b>H</b>&#160;</i><br/>
Fanapt Titrati<br/>
..........................................&#160;<br/>
on Pack&#160;<br/>
85&#160;<br/>
Haegarda&#160;................................<br/>
&#160;<br/>
............................&#160;105&#160;<br/>
Farydak................................<br/>
&#160;<br/>
................................&#160;86&#160;<br/>
Harvoni&#160;................................<br/>
&#160;<br/>
..............................&#160;106&#160;<br/>
Fasenra&#160;................................<br/>
&#160;<br/>
................................&#160;87&#160;<br/>
Hepatamine&#160;................................<br/>
&#160;<br/>
........................&#160;339&#160;<br/>
Fasenra Pen&#160;................................<br/>
&#160;<br/>
.........................&#160;87&#160;<br/>
Herceptin Hylecta&#160;................................<br/>
&#160;<br/>
..............&#160;107&#160;<br/>
Fentanyl................................<br/>
&#160;<br/>
...............................&#160;88&#160;<br/>
Hetlioz................................<br/>
&#160;<br/>
................................&#160;108&#160;<br/>
Fentanyl&#160;Citrate Oral Transmucosal&#160;.................&#160;<br/>
&#160;<br/>
209&#160;<br/>
Hetlioz Lq&#160;................................<br/>
&#160;<br/>
..........................&#160;109&#160;<br/>
Fentanyl&#160;Patch.....................................................&#160;<br/>
&#160;<br/>
88&#160;<br/>
High Risk Medication&#160;-<br/>
................................<br/>
&#160;65&#160;<br/>
.&#160;110&#160;<br/>
Fetzima................................<br/>
&#160;<br/>
................................&#160;89&#160;<br/>
Hrm&#160;-&#160;Anticonvulsants&#160;-&#160;65................................&#160;112&#160;<br/>
Fetzima Titrati<br/>
........................................&#160;<br/>
on Pack&#160;<br/>
89&#160;<br/>
Hrm&#160;-&#160;Hypnotics&#160;-&#160;65&#160;................................<br/>
&#160;<br/>
.........&#160;113&#160;<br/>
Fintepla................................<br/>
&#160;<br/>
................................&#160;90&#160;<br/>
Hrm&#160;-&#160;Scopolamine&#160;-&#160;65................................<br/>
&#160;<br/>
.....&#160;115&#160;<br/>
Flebogamma Dif................................................&#160;<br/>
&#160;<br/>
156&#160;<br/>
Hrm-antiparkinson&#160;-&#160;65......................................<br/>
&#160;<br/>
&#160;116&#160;<br/>
Fluoroplex&#160;................................<br/>
&#160;<br/>
...........................&#160;91&#160;<br/>
Hrm-cyproheptadine&#160;-&#160;65................................<br/>
&#160;<br/>
...&#160;118&#160;<br/>
Fluorouracil&#160;................................<br/>
&#160;<br/>
...........&#160;41, 91, 339&#160;<br/>
Hrm-doxepin&#160;-<br/>
................................<br/>
&#160;65&#160;<br/>
...............&#160;119&#160;<br/>
Fortamet/glumetz&#160;...............................................&#160;<br/>
a&#160;<br/>
92&#160;<br/>
Hrm-hydroxyzine&#160;-<br/>
................................<br/>
&#160;65<br/>
........&#160;121&#160;<br/>
Forteo&#160;................................<br/>
&#160;<br/>
..................................&#160;93&#160;<br/>
Hrm-hydroxyzine&#160;Inj&#160;-&#160;65&#160;................................<br/>
&#160;<br/>
..&#160;123&#160;<br/>
Fotivda................................<br/>
&#160;<br/>
.................................&#160;95&#160;<br/>
Hrm-promethazine&#160;-&#160;65&#160;<br/>
......<br/>
................................<br/>
&#160;125&#160;<br/>
Freamine&#160;Hbc 6.9%...........................................&#160;<br/>
&#160;<br/>
339&#160;<br/>
Hrms&#160;-&#160;Antidepressan&#160;................................<br/>
ts&#160;<br/>
......&#160;127&#160;<br/>
Freamine&#160;III................................<br/>
&#160;<br/>
.......................&#160;339&#160;<br/>
Hrms&#160;-&#160;Carbinoxamine&#160;<br/>
.......<br/>
................................<br/>
&#160;129&#160;<br/>
Fycompa................................<br/>
&#160;<br/>
..............................&#160;96&#160;<br/>
Hrms&#160;-&#160;Clemastine-&#160;65.......................................<br/>
&#160;<br/>
&#160;130&#160;<br/>
<i><b>G</b></i><br/>
Hrms&#160;-&#160;Meclizine&#160;-&#160;65................................<br/>
&#160;<br/>
........&#160;131&#160;<br/>
<i>&#160;</i><br/>
Hrms&#160;-&#160;Tcas&#160;<br/>
........................<br/>
................................<br/>
&#160;132&#160;<br/>
Gamastan................................<br/>
&#160;<br/>
...........................&#160;339&#160;<br/>
Hrm-skeletal Muscle Relaxants&#160;-&#160;65..................<br/>
&#160;<br/>
&#160;133&#160;<br/>
Gammagard Liquid&#160;...........................................&#160;<br/>
&#160;<br/>
156&#160;<br/>
Humira&#160;<br/>
...............................<br/>
................................<br/>
&#160;134&#160;<br/>
Gammagard S/d Iga Less Than 1mcg/ml..........&#160;<br/>
&#160;<br/>
156&#160;<br/>
Humira Pediatric Crohns&#160;Disease Starte<br/>
&#160;<br/>
r Pack..&#160;134&#160;<br/>
345&#160;<br/>
<hr/>
<a name=346></a>&#160;<br/>&#160;<br/>
Humira Pen&#160;........................................................&#160;134&#160;<br/>
Ivermectin&#160;Tab&#160;...................................................&#160;155&#160;<br/>
Humira Pen-cd/uc/hs Starte&#160;.............................&#160;<br/>
r&#160;<br/>
134&#160;<br/>
Ivig&#160;................................<br/>
&#160;<br/>
.....................................&#160;156&#160;<br/>
Humira Pen-pediatric Uc Starter&#160;Pack&#160;..............&#160;<br/>
&#160;<br/>
134&#160;<br/>
<i><b>J</b>&#160;</i><br/>
Humira Pen-ps/uv&#160;Starter&#160;..................................&#160;<br/>
&#160;<br/>
134&#160;<br/>
Humulin R&#160;U-500 (concentrated)......................&#160;<br/>
&#160;<br/>
339&#160;<br/>
Jakafi................................<br/>
&#160;<br/>
..................................&#160;158&#160;<br/>
Hydrocodone Bitartrate&#160;Er&#160;................................&#160;<br/>
&#160;<br/>
150&#160;<br/>
<i><b>K</b>&#160;</i><br/>
Hydromorphone Hcl..........................................&#160;<br/>
&#160;<br/>
339&#160;<br/>
Kalydeco&#160;................................<br/>
&#160;<br/>
............................&#160;159&#160;<br/>
Hydromorphone Hydrochloride&#160;........................&#160;<br/>
&#160;<br/>
340&#160;<br/>
Kesimpta&#160;................................<br/>
&#160;<br/>
............................&#160;160&#160;<br/>
Hydroxyzine Hcl&#160;.......................................&#160;<br/>
&#160;<br/>
121, 123&#160;<br/>
Ketoconazole......................................................&#160;161&#160;<br/>
Hydroxyzine Hydrochloride......................&#160;<br/>
&#160;<br/>
121, 123&#160;<br/>
Ketorolac Tromethamine&#160;................................<br/>
&#160;<br/>
...&#160;110&#160;<br/>
Hydroxyzine Pamoate&#160;.......................................&#160;<br/>
&#160;<br/>
121&#160;<br/>
Keytruda................................<br/>
&#160;<br/>
.............................&#160;162&#160;<br/>
Hyperlyte-cr&#160;................................<br/>
&#160;<br/>
......................&#160;340&#160;<br/>
Khapzory................................<br/>
&#160;<br/>
............................&#160;340&#160;<br/>
Hypnotic-benzodiazepines&#160;-&#160;65.........................&#160;<br/>
&#160;<br/>
136&#160;<br/>
Kisqali................................<br/>
&#160;<br/>
................................&#160;163&#160;<br/>
Hysingla Er................................<br/>
&#160;<br/>
........................&#160;150&#160;<br/>
Kisqali Femara&#160;200 Dose................................<br/>
&#160;<br/>
...&#160;163&#160;<br/>
<i><b>I</b>&#160;</i><br/>
Kisqali Femara&#160;400 Dose................................<br/>
&#160;<br/>
...&#160;163&#160;<br/>
Ibrance................................<br/>
&#160;<br/>
...............................&#160;137&#160;<br/>
Kisqali Femara&#160;600 Dose................................<br/>
&#160;<br/>
...&#160;163&#160;<br/>
Ibuprofen/famotidine...........................................&#160;<br/>
&#160;<br/>
70&#160;<br/>
Korlym&#160;................................<br/>
&#160;<br/>
...............................&#160;165&#160;<br/>
Icatibant................................<br/>
&#160;<br/>
.............................&#160;138&#160;<br/>
Kristalose&#160;................................<br/>
&#160;<br/>
...........................&#160;166&#160;<br/>
Icatibant Acetate................................................&#160;<br/>
&#160;<br/>
138&#160;<br/>
Kuvan................................<br/>
&#160;<br/>
.................................&#160;167&#160;<br/>
Iclusig................................<br/>
&#160;<br/>
................................&#160;139&#160;<br/>
Kynmobi&#160;................................<br/>
&#160;<br/>
............................&#160;168&#160;<br/>
Idhifa&#160;................................<br/>
&#160;<br/>
.................................&#160;140&#160;<br/>
<i><b>L</b>&#160;</i><br/>
Imatinib&#160;................................<br/>
&#160;<br/>
.............................&#160;141&#160;<br/>
Lapatinib&#160;................................<br/>
&#160;<br/>
............................&#160;169&#160;<br/>
Imatinib&#160;Mesylate..............................................&#160;<br/>
&#160;<br/>
141&#160;<br/>
Lapatinib Ditosylate................................<br/>
&#160;<br/>
...........&#160;169&#160;<br/>
Imbruvica&#160;................................<br/>
&#160;<br/>
..........................&#160;142&#160;<br/>
Lenvima&#160;................................<br/>
&#160;<br/>
.............................&#160;170&#160;<br/>
Imipramine Hcl&#160;.................................................&#160;<br/>
&#160;<br/>
127&#160;<br/>
Lenvima 10&#160;Mg Daily Dose...............................<br/>
&#160;<br/>
&#160;170&#160;<br/>
Imipramine Hydrochloride................................&#160;<br/>
&#160;<br/>
127&#160;<br/>
Lenvima 12mg Daily Dose&#160;................................<br/>
&#160;<br/>
&#160;170&#160;<br/>
Imipramine Pamoate&#160;.........................................&#160;<br/>
&#160;<br/>
127&#160;<br/>
Lenvima 14&#160;Mg Daily Dose...............................<br/>
&#160;<br/>
&#160;170&#160;<br/>
Imlygic&#160;................................<br/>
&#160;<br/>
..............................&#160;145&#160;<br/>
Lenvima 18&#160;Mg Daily Dose...............................<br/>
&#160;<br/>
&#160;170&#160;<br/>
Imovax Rabies&#160;(h.d.c.v.)&#160;...................................&#160;<br/>
&#160;<br/>
340&#160;<br/>
Lenvima 20&#160;Mg Daily Dose...............................<br/>
&#160;<br/>
&#160;170&#160;<br/>
Increlex................................<br/>
&#160;<br/>
..............................&#160;146&#160;<br/>
Lenvima 24&#160;Mg Daily Dose...............................<br/>
&#160;<br/>
&#160;170&#160;<br/>
Inlyt&#160;................................<br/>
a<br/>
..................................&#160;147&#160;<br/>
Lenvima 4&#160;Mg Daily Dose................................<br/>
&#160;<br/>
.&#160;170&#160;<br/>
Inqovi&#160;................................<br/>
&#160;<br/>
................................&#160;148&#160;<br/>
Lenvima 8&#160;Mg Daily Dose................................<br/>
&#160;<br/>
.&#160;170&#160;<br/>
Inr<br/>
................................<br/>
ebic<br/>
................................&#160;149&#160;<br/>
Leuprolide&#160;................................<br/>
&#160;<br/>
..........................&#160;171&#160;<br/>
Ipratropium&#160;Bromi&#160;.........................................&#160;<br/>
de&#160;<br/>
340&#160;<br/>
Leuprolide&#160;Acetate................................<br/>
&#160;<br/>
.............&#160;171&#160;<br/>
Ipratropium&#160;Bromide/albuterol Sulfate&#160;.............&#160;<br/>
&#160;<br/>
340&#160;<br/>
Levalbuterol&#160;................................<br/>
&#160;<br/>
.......................&#160;340&#160;<br/>
Ir<br/>
................................<br/>
&#160;Before Er<br/>
........................&#160;150&#160;<br/>
Levalbuterol&#160;Hcl&#160;................................<br/>
&#160;<br/>
................&#160;340&#160;<br/>
Ir<br/>
................................<br/>
essa<br/>
..................................&#160;152&#160;<br/>
Libtayo&#160;................................<br/>
&#160;<br/>
...............................&#160;172&#160;<br/>
Isolyte-s&#160;................................<br/>
&#160;<br/>
.............................&#160;340&#160;<br/>
Lidoca<br/>
................................<br/>
ine<br/>
....................&#160;173, 287&#160;<br/>
Isolyte-s Ph&#160;7.4..................................................&#160;<br/>
&#160;<br/>
340&#160;<br/>
Lidocaine Hcl................................<br/>
&#160;<br/>
.....................&#160;287&#160;<br/>
Isotretinoin&#160;................................<br/>
&#160;<br/>
........................&#160;153&#160;<br/>
Lidocaine Patches&#160;<br/>
..............<br/>
................................<br/>
&#160;173&#160;<br/>
Itraconazole&#160;................................<br/>
&#160;<br/>
.......................&#160;154&#160;<br/>
Lidocaine/prilocaine&#160;................................<br/>
&#160;<br/>
..........&#160;287&#160;<br/>
Ive<br/>
................................<br/>
rmectin<br/>
..........................&#160;155&#160;<br/>
Linezolid&#160;<br/>
............................<br/>
................................<br/>
&#160;174&#160;<br/>
346&#160;<br/>
<hr/>
<a name=347></a>&#160;<br/>&#160;<br/>
Lonsurf&#160;..............................................................&#160;175&#160;<br/>
Myorisan&#160;............................................................&#160;153&#160;<br/>
Lorbrena&#160;................................<br/>
&#160;<br/>
............................&#160;176&#160;<br/>
<i><b>N</b>&#160;</i><br/>
Lumakras................................<br/>
&#160;<br/>
...........................&#160;177&#160;<br/>
Lumoxiti................................<br/>
&#160;<br/>
............................&#160;178&#160;<br/>
Naproxen/esomeprazole&#160;Magnesium.................<br/>
&#160;<br/>
&#160;191&#160;<br/>
Lupron Depot (1-month)&#160;...................................&#160;<br/>
&#160;<br/>
180&#160;<br/>
Naproxen-esomepra<br/>
................................<br/>
zole&#160;<br/>
....&#160;191&#160;<br/>
Lupron Depot (3-month)&#160;...................................&#160;<br/>
&#160;<br/>
180&#160;<br/>
Natpara................................<br/>
&#160;<br/>
...............................&#160;192&#160;<br/>
Lupron Depot-ped (1-month)............................&#160;<br/>
&#160;<br/>
179&#160;<br/>
Nayzilam&#160;................................<br/>
&#160;<br/>
............................&#160;193&#160;<br/>
Lupron Depot-ped (3-month)............................&#160;<br/>
&#160;<br/>
179&#160;<br/>
Nephramine................................<br/>
&#160;<br/>
........................&#160;340&#160;<br/>
Lupron Ped&#160;................................<br/>
&#160;<br/>
........................&#160;179&#160;<br/>
Nerlynx&#160;................................<br/>
&#160;<br/>
..............................&#160;194&#160;<br/>
Lupron-endometriosis&#160;.......................................&#160;<br/>
&#160;<br/>
180&#160;<br/>
Nexavar&#160;................................<br/>
&#160;<br/>
..............................&#160;195&#160;<br/>
Lynparza................................<br/>
&#160;<br/>
............................&#160;181&#160;<br/>
Ninlaro&#160;................................<br/>
&#160;<br/>
...............................&#160;196&#160;<br/>
Lyrica Cr&#160;................................<br/>
&#160;<br/>
...........................&#160;182&#160;<br/>
Nitisinone................................<br/>
&#160;<br/>
...........................&#160;197&#160;<br/>
Northera&#160;................................<br/>
&#160;<br/>
.............................&#160;198&#160;<br/>
<i><b>M</b>&#160;</i><br/>
Nubeqa&#160;...............................................................<br/>
&#160;<br/>
&#160;199&#160;<br/>
Mavyret&#160;................................<br/>
&#160;<br/>
.............................&#160;183&#160;<br/>
Nuedexta&#160;................................<br/>
&#160;<br/>
............................&#160;200&#160;<br/>
Meclizine Hcl&#160;....................................................&#160;<br/>
&#160;<br/>
131&#160;<br/>
Nulojix&#160;................................<br/>
&#160;<br/>
...............................&#160;340&#160;<br/>
Meclizine Hydrochloride...................................&#160;131&#160;<br/>
Nuplazid................................<br/>
&#160;<br/>
.............................&#160;201&#160;<br/>
Mekinist................................<br/>
&#160;<br/>
.............................&#160;184&#160;<br/>
Nutrilipid................................<br/>
&#160;<br/>
............................&#160;340&#160;<br/>
Mektovi&#160;................................<br/>
&#160;<br/>
.............................&#160;185&#160;<br/>
<i><b>O</b>&#160;</i><br/>
Melphalan................................<br/>
&#160;<br/>
..........................&#160;340&#160;<br/>
Memantine................................<br/>
&#160;<br/>
.........................&#160;186&#160;<br/>
Octagam&#160;.............................................................<br/>
&#160;<br/>
&#160;156&#160;<br/>
Memantine&#160;Hcl Titration Pak............................&#160;<br/>
&#160;<br/>
186&#160;<br/>
Octreotide................................<br/>
&#160;<br/>
...........................&#160;202&#160;<br/>
Memantine&#160;Hydrochloride&#160;................................&#160;<br/>
&#160;<br/>
186&#160;<br/>
Octreotide&#160;Acetate&#160;................................<br/>
&#160;<br/>
.............&#160;202&#160;<br/>
Memantine&#160;Hydrochloride Er&#160;...........................&#160;<br/>
&#160;<br/>
186&#160;<br/>
Odomzo................................<br/>
&#160;<br/>
..............................&#160;203&#160;<br/>
Meprobamate.....................................................&#160;<br/>
&#160;<br/>
110&#160;<br/>
Ofev....................................................................&#160;204&#160;<br/>
Mepron&#160;................................<br/>
&#160;<br/>
..............................&#160;187&#160;<br/>
Oncaspar&#160;................................<br/>
&#160;<br/>
............................&#160;205&#160;<br/>
Metformin&#160;Hydrochloride Er&#160;..............................&#160;<br/>
&#160;<br/>
92&#160;<br/>
Ondansetron&#160;Hcl&#160;................................<br/>
&#160;<br/>
................&#160;340&#160;<br/>
Methadone&#160;Hcl&#160;..................................................&#160;<br/>
&#160;<br/>
150&#160;<br/>
Ondansetron&#160;Hydrochloride...............................<br/>
&#160;<br/>
&#160;340&#160;<br/>
Methadone&#160;Hydrochloride&#160;................................&#160;<br/>
&#160;<br/>
150&#160;<br/>
Ondansetron&#160;Odt&#160;................................<br/>
&#160;<br/>
................&#160;340&#160;<br/>
Methscopolamine&#160;Bromide&#160;...............................&#160;<br/>
&#160;<br/>
110&#160;<br/>
Onureg................................................................&#160;206&#160;<br/>
Met<br/>
................................<br/>
hyldopa<br/>
........................&#160;110&#160;<br/>
Opsumit................................<br/>
&#160;<br/>
..............................&#160;207&#160;<br/>
Methylprednisol<br/>
...........................................&#160;<br/>
one&#160;<br/>
340&#160;<br/>
Oracea&#160;................................<br/>
&#160;<br/>
................................&#160;208&#160;<br/>
Methylprednisolone Acetate&#160;.............................&#160;<br/>
&#160;<br/>
340&#160;<br/>
Oral-intranasal&#160;Fentanyl................................<br/>
&#160;<br/>
.....&#160;209&#160;<br/>
Methylprednisolone Sodium&#160;Succinate.............&#160;<br/>
&#160;<br/>
340&#160;<br/>
Orgovyx&#160;................................<br/>
&#160;<br/>
.............................&#160;210&#160;<br/>
Methylprednisolone Sodiumsuccinate&#160;..............&#160;<br/>
&#160;<br/>
340&#160;<br/>
Orkambi&#160;................................<br/>
&#160;<br/>
.............................&#160;211&#160;<br/>
Metyrosine................................<br/>
&#160;<br/>
...........................&#160;60&#160;<br/>
Oxandrolone................................<br/>
&#160;<br/>
.......................&#160;212&#160;<br/>
Modafinil................................<br/>
&#160;<br/>
...........................&#160;188&#160;<br/>
Oxazepam&#160;<br/>
..........................<br/>
................................<br/>
&#160;213&#160;<br/>
Monjuvi&#160;................................<br/>
&#160;<br/>
.............................&#160;189&#160;<br/>
Oxazepam&#160;-&#160;65&#160;...................................................<br/>
&#160;<br/>
&#160;213&#160;<br/>
Morphine Sulfate...............................................&#160;<br/>
&#160;<br/>
340&#160;<br/>
<i><b>P</b>&#160;</i><br/>
Morphine Sulfate Er&#160;..........................................&#160;<br/>
&#160;<br/>
150&#160;<br/>
Padcev&#160;................................................................&#160;214&#160;<br/>
Mycophenolate Mofetil&#160;.....................................&#160;<br/>
&#160;<br/>
340&#160;<br/>
Panzyga&#160;................................<br/>
&#160;<br/>
..............................&#160;156&#160;<br/>
Mycophenolic&#160;Acid Dr......................................&#160;<br/>
&#160;<br/>
340&#160;<br/>
Part&#160;B Versus Part&#160;D................................<br/>
&#160;<br/>
..........&#160;337&#160;<br/>
Mylotarg................................<br/>
&#160;<br/>
............................&#160;190&#160;<br/>
Pegasys&#160;<br/>
...............................<br/>
................................<br/>
&#160;215&#160;<br/>
347&#160;<br/>
<hr/>
<a name=348></a>&#160;<br/>&#160;<br/>
Pemazyre&#160;...........................................................&#160;216&#160;<br/>
Quetiapine&#160;Xr&#160;.....................................................&#160;232&#160;<br/>
Pennsaid&#160;................................<br/>
&#160;<br/>
..............................&#160;66&#160;<br/>
Quinine&#160;Sulfate&#160;................................<br/>
&#160;<br/>
..................&#160;233&#160;<br/>
Pentamidine&#160;Isethionate&#160;....................................&#160;<br/>
&#160;<br/>
340&#160;<br/>
<i><b>R</b>&#160;</i><br/>
Pepaxto................................<br/>
&#160;<br/>
..............................&#160;217&#160;<br/>
Perphenazine/amitriptyline................................&#160;110&#160;<br/>
Rabavert&#160;................................<br/>
&#160;<br/>
.............................&#160;341&#160;<br/>
Phenobarbital.....................................................&#160;<br/>
&#160;<br/>
112&#160;<br/>
Recombivax&#160;Hb&#160;................................<br/>
&#160;<br/>
.................&#160;341&#160;<br/>
Phenobarbital Sodium&#160;.......................................&#160;<br/>
&#160;<br/>
112&#160;<br/>
Regranex&#160;................................<br/>
&#160;<br/>
............................&#160;234&#160;<br/>
Phenylbutyrate...................................................&#160;<br/>
&#160;<br/>
218&#160;<br/>
Retevmo&#160;................................<br/>
&#160;<br/>
.............................&#160;235&#160;<br/>
Phesgo&#160;................................<br/>
&#160;<br/>
...............................&#160;219&#160;<br/>
Revlimid................................<br/>
&#160;<br/>
.............................&#160;236&#160;<br/>
Piqray&#160;................................<br/>
&#160;<br/>
................................&#160;220&#160;<br/>
Rezurock&#160;................................<br/>
&#160;<br/>
............................&#160;238&#160;<br/>
Piqray 200mg Daily Dose&#160;.................................&#160;<br/>
&#160;<br/>
220&#160;<br/>
................................<br/>
Rinvoq&#160;<br/>
................................&#160;239&#160;<br/>
Piqray 250mg Daily Dose&#160;.................................&#160;<br/>
&#160;<br/>
220&#160;<br/>
Rituxan................................<br/>
&#160;<br/>
...............................&#160;241&#160;<br/>
Piqray 300mg Daily Dose&#160;.................................&#160;<br/>
&#160;<br/>
220&#160;<br/>
Rituxan Hycela................................<br/>
&#160;<br/>
...................&#160;240&#160;<br/>
Plenamine................................<br/>
&#160;<br/>
..........................&#160;341&#160;<br/>
Rituximab................................<br/>
&#160;<br/>
...........................&#160;241&#160;<br/>
Polivy&#160;................................<br/>
&#160;<br/>
................................&#160;221&#160;<br/>
Rozlytrek................................<br/>
&#160;<br/>
............................&#160;244&#160;<br/>
Pomalyst................................<br/>
&#160;<br/>
............................&#160;222&#160;<br/>
Rubraca&#160;................................<br/>
&#160;<br/>
..............................&#160;245&#160;<br/>
Poteligeo................................<br/>
&#160;<br/>
............................&#160;223&#160;<br/>
Rufinamide................................<br/>
&#160;<br/>
...........................&#160;19&#160;<br/>
Praluen&#160;................................<br/>
t<br/>
..............................&#160;224&#160;<br/>
Ruxience&#160;................................<br/>
&#160;<br/>
............................&#160;241&#160;<br/>
Predni<br/>
................................<br/>
solone&#160;<br/>
......................&#160;341&#160;<br/>
Rydapt&#160;................................<br/>
&#160;<br/>
................................&#160;246&#160;<br/>
Prednisolone Sodium Phosphate&#160;.......................&#160;<br/>
&#160;<br/>
341&#160;<br/>
<i><b>S</b>&#160;</i><br/>
Prednisone&#160;................................<br/>
&#160;<br/>
.........................&#160;341&#160;<br/>
Sajazir&#160;................................<br/>
&#160;<br/>
................................&#160;138&#160;<br/>
Prednisone&#160;Intensol&#160;...........................................&#160;<br/>
&#160;<br/>
341&#160;<br/>
Sandimmune&#160;................................<br/>
&#160;<br/>
......................&#160;341&#160;<br/>
Pregabalin................................<br/>
&#160;<br/>
..........................&#160;225&#160;<br/>
Sandostatin&#160;Lar&#160;................................<br/>
&#160;<br/>
..................&#160;247&#160;<br/>
Pregabalin&#160;Er&#160;.....................................................&#160;<br/>
&#160;<br/>
182&#160;<br/>
Sandostatin&#160;Lar Depot................................<br/>
&#160;<br/>
........&#160;247&#160;<br/>
Premasol................................<br/>
&#160;<br/>
............................&#160;341&#160;<br/>
Sapropterin&#160;Dihydrochloride&#160;.............................<br/>
&#160;<br/>
&#160;167&#160;<br/>
Pretomanid&#160;................................<br/>
&#160;<br/>
........................&#160;226&#160;<br/>
Sarclisa................................<br/>
&#160;<br/>
...............................&#160;249&#160;<br/>
Privigen&#160;................................<br/>
&#160;<br/>
.............................&#160;156&#160;<br/>
Scemblix&#160;................................<br/>
&#160;<br/>
............................&#160;250&#160;<br/>
Procalamine................................<br/>
&#160;<br/>
.......................&#160;341&#160;<br/>
Scopolamine................................<br/>
&#160;<br/>
.......................&#160;115&#160;<br/>
Procrit................................<br/>
&#160;<br/>
..................................&#160;77&#160;<br/>
Signifor&#160;................................<br/>
&#160;<br/>
..............................&#160;251&#160;<br/>
Prograf................................<br/>
&#160;<br/>
...............................&#160;341&#160;<br/>
Sildenafil................................<br/>
&#160;<br/>
............................&#160;252&#160;<br/>
Prolastin-&#160;................................<br/>
c<br/>
..............................&#160;9&#160;<br/>
Sildenafil Citrate&#160;................................<br/>
&#160;<br/>
................&#160;252&#160;<br/>
Promacta................................<br/>
&#160;<br/>
............................&#160;227&#160;<br/>
Sirolimus................................<br/>
&#160;<br/>
............................&#160;341&#160;<br/>
Promethazine Hcl&#160;..............................................&#160;<br/>
&#160;<br/>
125&#160;<br/>
Sirturo&#160;................................<br/>
&#160;<br/>
................................&#160;253&#160;<br/>
Promethazine Hcl Plain.....................................&#160;<br/>
&#160;<br/>
125&#160;<br/>
Skyrizi................................<br/>
&#160;<br/>
................................&#160;254&#160;<br/>
Promethazine Hydrochloride.............................&#160;125&#160;<br/>
Skyrizi Pen................................<br/>
&#160;<br/>
.........................&#160;254&#160;<br/>
Promethegan................................<br/>
&#160;<br/>
......................&#160;125&#160;<br/>
Sodium&#160;Phenylbutyrate................................<br/>
&#160;<br/>
......&#160;218&#160;<br/>
Prosol................................<br/>
&#160;<br/>
.................................&#160;341&#160;<br/>
Somatuline Depot...............................................&#160;255&#160;<br/>
Protriptyline&#160;Hcl................................................&#160;<br/>
&#160;<br/>
132&#160;<br/>
Somavert&#160;................................<br/>
&#160;<br/>
............................&#160;256&#160;<br/>
Pulmozyme................................<br/>
&#160;<br/>
........................&#160;230&#160;<br/>
Spritam................................<br/>
&#160;<br/>
...............................&#160;257&#160;<br/>
<i><b>Q</b>&#160;</i><br/>
Sprycel&#160;................................<br/>
&#160;<br/>
...............................&#160;258&#160;<br/>
Qinlock................................<br/>
&#160;<br/>
..............................&#160;231&#160;<br/>
Stelara&#160;................................<br/>
&#160;<br/>
................................&#160;259&#160;<br/>
Quetiapine&#160;Fumarate Er&#160;....................................&#160;<br/>
&#160;<br/>
232&#160;<br/>
Stivarga&#160;<br/>
..............................<br/>
................................<br/>
&#160;260&#160;<br/>
348&#160;<br/>
<hr/>
<a name=349></a>&#160;<br/>&#160;<br/>
Sunitinib Malate&#160;................................................&#160;261&#160;<br/>
Topical&#160;Doxepin&#160;.................................................&#160;286&#160;<br/>
Sutent................................<br/>
&#160;<br/>
.................................&#160;261&#160;<br/>
Topical&#160;Lidocaine&#160;................................<br/>
&#160;<br/>
..............&#160;287&#160;<br/>
Symlin&#160;................................<br/>
&#160;<br/>
...............................&#160;262&#160;<br/>
Topical&#160;Testosterones&#160;................................<br/>
&#160;<br/>
........&#160;288&#160;<br/>
Symlinpen 120&#160;..................................................&#160;<br/>
&#160;<br/>
262&#160;<br/>
Topical&#160;Tretinoin&#160;................................<br/>
&#160;<br/>
...............&#160;289&#160;<br/>
Symlinpen 60&#160;....................................................&#160;<br/>
&#160;<br/>
262&#160;<br/>
Toremifene................................<br/>
&#160;<br/>
.........................&#160;290&#160;<br/>
Sympazan&#160;................................<br/>
&#160;<br/>
..........................&#160;263&#160;<br/>
Toremifene&#160;Citra&#160;................................<br/>
te&#160;<br/>
.............&#160;290&#160;<br/>
Synribo&#160;................................<br/>
&#160;<br/>
..............................&#160;264&#160;<br/>
Tpn Electrol<br/>
................................<br/>
ytes&#160;<br/>
.................&#160;341&#160;<br/>
<i><b>T</b></i><br/>
Tracleer&#160;................................<br/>
&#160;<br/>
................................&#160;28&#160;<br/>
<i>&#160;</i><br/>
Tramadol Hcl Er&#160;................................<br/>
&#160;<br/>
................&#160;150&#160;<br/>
Tabrecta................................<br/>
&#160;<br/>
.............................&#160;265&#160;<br/>
Trava<br/>
................................<br/>
sol<br/>
..............................&#160;342&#160;<br/>
Tacrolimus................................<br/>
&#160;<br/>
.........................&#160;341&#160;<br/>
Trelstar&#160;................................<br/>
&#160;<br/>
...............................&#160;291&#160;<br/>
Tadalafil&#160;................................<br/>
&#160;<br/>
............................&#160;266&#160;<br/>
Trelstar&#160;Mixject................................<br/>
&#160;<br/>
..................&#160;291&#160;<br/>
Tadalafil&#160;(pah)&#160;...................................................&#160;<br/>
&#160;<br/>
266&#160;<br/>
Treprostinil................................<br/>
&#160;<br/>
.........................&#160;292&#160;<br/>
Tafinlar................................<br/>
&#160;<br/>
..............................&#160;267&#160;<br/>
Treprostinil&#160;Inj&#160;...................................................<br/>
&#160;<br/>
&#160;292&#160;<br/>
Tagrisso&#160;................................<br/>
&#160;<br/>
.............................&#160;268&#160;<br/>
Tretinoin................................<br/>
&#160;<br/>
.............................&#160;289&#160;<br/>
Taltz................................<br/>
&#160;<br/>
...................................&#160;269&#160;<br/>
Tretinoin Microsphere&#160;................................<br/>
&#160;<br/>
.......&#160;289&#160;<br/>
Talzenna&#160;................................<br/>
&#160;<br/>
............................&#160;270&#160;<br/>
Tretinoin Microsphere&#160;Pump&#160;.............................<br/>
&#160;<br/>
&#160;289&#160;<br/>
Targretin................................<br/>
&#160;<br/>
............................&#160;271&#160;<br/>
Triazolam&#160;................................<br/>
&#160;<br/>
...........................&#160;136&#160;<br/>
Targretin Topical...............................................&#160;<br/>
&#160;<br/>
271&#160;<br/>
Trientine................................<br/>
&#160;<br/>
.............................&#160;293&#160;<br/>
Tasigna&#160;................................<br/>
&#160;<br/>
..............................&#160;272&#160;<br/>
Trientine Hydrochloride................................<br/>
&#160;<br/>
.....&#160;293&#160;<br/>
Tazarotene&#160;................................<br/>
&#160;<br/>
.........................&#160;273&#160;<br/>
Trihexyphenidyl&#160;Hcl&#160;................................<br/>
&#160;<br/>
..........&#160;116&#160;<br/>
Tazorac................................<br/>
&#160;<br/>
..............................&#160;273&#160;<br/>
Trihexyphenidyl&#160;Hydrochloride.........................<br/>
&#160;<br/>
&#160;116&#160;<br/>
Tazverik................................<br/>
&#160;<br/>
.............................&#160;274&#160;<br/>
Trikafta................................<br/>
&#160;<br/>
...............................&#160;294&#160;<br/>
................................<br/>
Tdvax&#160;<br/>
.................................&#160;341&#160;<br/>
Trimethobenzamide Hydrochloride&#160;...................<br/>
&#160;<br/>
&#160;110&#160;<br/>
Tecent<br/>
................................<br/>
riq<br/>
............................&#160;275&#160;<br/>
Trimipramine Maleate&#160;................................<br/>
&#160;<br/>
.......&#160;132&#160;<br/>
Tecfide&#160;................................<br/>
ra<br/>
............................&#160;277&#160;<br/>
Trodelvy................................<br/>
&#160;<br/>
.............................&#160;295&#160;<br/>
Tecfidera&#160;Starter Pack&#160;.......................................&#160;<br/>
&#160;<br/>
277&#160;<br/>
Trophamine&#160;................................<br/>
&#160;<br/>
........................&#160;342&#160;<br/>
Temazepam&#160;................................<br/>
&#160;<br/>
...............&#160;136, 278&#160;<br/>
Truseltiq&#160;................................<br/>
&#160;<br/>
.............................&#160;296&#160;<br/>
Temazepam&#160;30mg&#160;-&#160;65......................................&#160;<br/>
&#160;<br/>
278&#160;<br/>
Tukysa................................<br/>
&#160;<br/>
................................&#160;297&#160;<br/>
Tenivac................................<br/>
&#160;<br/>
..............................&#160;341&#160;<br/>
Turalio................................<br/>
&#160;<br/>
................................&#160;298&#160;<br/>
Tepmetko................................<br/>
&#160;<br/>
...........................&#160;279&#160;<br/>
Testosterone&#160;................................<br/>
&#160;<br/>
......................&#160;288&#160;<br/>
<i><b>U</b>&#160;</i><br/>
Testosterone&#160;Cypionate&#160;.....................................&#160;<br/>
&#160;<br/>
280&#160;<br/>
Ubrelvy&#160;................................<br/>
&#160;<br/>
..............................&#160;299&#160;<br/>
Testosterone&#160;Cypionate&#160;Inj&#160;...............................&#160;<br/>
&#160;<br/>
280&#160;<br/>
................................<br/>
Ukoniq<br/>
................................&#160;300&#160;<br/>
Testosterone&#160;Enanthat&#160;.....................................&#160;<br/>
e&#160;<br/>
281&#160;<br/>
<i><b>V</b>&#160;</i><br/>
Testosterone&#160;Enanthate&#160;Inj&#160;................................&#160;<br/>
&#160;<br/>
281&#160;<br/>
Testosterone&#160;Pump&#160;............................................&#160;<br/>
&#160;<br/>
288&#160;<br/>
Valchl&#160;................................<br/>
or<br/>
..............................&#160;301&#160;<br/>
Testosterone&#160;Topical Solution...........................&#160;<br/>
&#160;<br/>
288&#160;<br/>
Valtoco................................<br/>
&#160;<br/>
...............................&#160;302&#160;<br/>
Tetrabenazine&#160;....................................................&#160;<br/>
&#160;<br/>
282&#160;<br/>
Varenicline&#160;Tartrate&#160;................................<br/>
&#160;<br/>
.............&#160;45&#160;<br/>
Thalomid&#160;................................<br/>
&#160;<br/>
...........................&#160;283&#160;<br/>
Velcade&#160;................................<br/>
&#160;<br/>
..............................&#160;303&#160;<br/>
Thioridazine Hcl................................................&#160;<br/>
&#160;<br/>
110&#160;<br/>
Veltassa................................<br/>
&#160;<br/>
..............................&#160;304&#160;<br/>
Tibsovo................................<br/>
&#160;<br/>
..............................&#160;284&#160;<br/>
Venclexta&#160;................................<br/>
&#160;<br/>
...........................&#160;305&#160;<br/>
Tobramycin&#160;................................<br/>
&#160;<br/>
.......................&#160;285&#160;<br/>
Venclexta Starting Pack................................<br/>
&#160;<br/>
.....&#160;305&#160;<br/>
349&#160;<br/>
<hr/>
<a name=350></a>&#160;<br/>&#160;<br/>
Ventavis&#160;.............................................................&#160;306&#160;<br/>
Xpovio 40 Mg Once Weekly&#160;.............................&#160;323&#160;<br/>
Versacloz................................<br/>
&#160;<br/>
...........................&#160;307&#160;<br/>
Xpovio 40 Mg Twice We<br/>
............................<br/>
ekly<br/>
&#160;323&#160;<br/>
Verzenio&#160;................................<br/>
&#160;<br/>
............................&#160;308&#160;<br/>
Xpovio 60 Mg Once Weekly&#160;.............................<br/>
&#160;<br/>
&#160;323&#160;<br/>
Vigabatrin................................<br/>
&#160;<br/>
..........................&#160;309&#160;<br/>
Xpovio 60 Mg Twice We<br/>
............................<br/>
ekly<br/>
&#160;323&#160;<br/>
Vigadrone................................<br/>
&#160;<br/>
..........................&#160;309&#160;<br/>
Xpovio 80 Mg Once Weekly&#160;.............................<br/>
&#160;<br/>
&#160;323&#160;<br/>
Vinblastine&#160;Sulfate&#160;............................................&#160;<br/>
&#160;<br/>
342&#160;<br/>
Xpovio 80 Mg Twice We<br/>
............................<br/>
ekly<br/>
&#160;323&#160;<br/>
Vincristine Sulfate.............................................&#160;<br/>
&#160;<br/>
342&#160;<br/>
Xtandi................................<br/>
&#160;<br/>
.................................&#160;324&#160;<br/>
Vitrakv&#160;................................<br/>
i<br/>
..............................&#160;310&#160;<br/>
Xyrem&#160;................................<br/>
&#160;<br/>
................................&#160;325&#160;<br/>
Vizimp&#160;................................<br/>
ro<br/>
............................&#160;311&#160;<br/>
<i><b>Y</b>&#160;</i><br/>
Voriconazole&#160;.....................................................&#160;<br/>
&#160;<br/>
312&#160;<br/>
Vosevi&#160;................................<br/>
&#160;<br/>
...............................&#160;313&#160;<br/>
Yervoy................................................................&#160;327&#160;<br/>
Votrien&#160;................................<br/>
t<br/>
..............................&#160;314&#160;<br/>
<i><b>Z</b>&#160;</i><br/>
<i><b>W</b>&#160;</i><br/>
Zaleplon&#160;................................<br/>
&#160;<br/>
.............................&#160;113&#160;<br/>
Welireg................................<br/>
&#160;<br/>
..............................&#160;315&#160;<br/>
Zarxio................................<br/>
&#160;<br/>
.................................&#160;328&#160;<br/>
Zejula&#160;................................<br/>
&#160;<br/>
.................................&#160;329&#160;<br/>
<i><b>X</b>&#160;</i><br/>
Zelboraf................................<br/>
&#160;<br/>
..............................&#160;331&#160;<br/>
Xalkori................................<br/>
&#160;<br/>
...............................&#160;316&#160;<br/>
Zenatane................................<br/>
&#160;<br/>
.............................&#160;153&#160;<br/>
Xeljanz&#160;................................<br/>
&#160;<br/>
..............................&#160;317&#160;<br/>
Zepzelca&#160;................................<br/>
&#160;<br/>
.............................&#160;332&#160;<br/>
Xeljanz Xr&#160;................................<br/>
&#160;<br/>
.........................&#160;317&#160;<br/>
Zirabev&#160;................................<br/>
&#160;<br/>
.................................&#160;24&#160;<br/>
Xermelo................................<br/>
&#160;<br/>
.............................&#160;318&#160;<br/>
Zolinza&#160;................................<br/>
&#160;<br/>
...............................&#160;333&#160;<br/>
................................<br/>
Xgeva&#160;<br/>
................................&#160;319&#160;<br/>
Zolpidem Tartrate&#160;................................<br/>
&#160;<br/>
..............&#160;113&#160;<br/>
Xifaxan................................<br/>
&#160;<br/>
..............................&#160;320&#160;<br/>
Zortress&#160;................................<br/>
&#160;<br/>
..............................&#160;342&#160;<br/>
................................<br/>
Xolair&#160;<br/>
.................................&#160;321&#160;<br/>
Zydelig&#160;................................<br/>
&#160;<br/>
...............................&#160;334&#160;<br/>
Xospata................................<br/>
&#160;<br/>
..............................&#160;322&#160;<br/>
Zykadia&#160;<br/>
..............................<br/>
................................<br/>
&#160;335&#160;<br/>
Xpovio................................<br/>
&#160;<br/>
...............................&#160;323&#160;<br/>
Zyprexa&#160;Relprevv................................<br/>
&#160;<br/>
...............&#160;336&#160;<br/>
Xpovio 100 Mg Once Wee<br/>
..........................&#160;<br/>
kly&#160;<br/>
323&#160;<br/>
Zytiga&#160;<br/>
................................<br/>
................................<br/>
.....&#160;1&#160;<br/>
&#160;<br/>
<b>&#160;</b><br/>
350&#160;<br/>
<hr/>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="PA_2022_22007_PPOs.html#1">ABIRATERONE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#3">ACITRETIN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#4">ACTIMMUNE</a></li>
<li><a href="PA_2022_22007_PPOs.html#5">ADEMPAS</a></li>
<li><a href="PA_2022_22007_PPOs.html#6">AIMOVIG</a></li>
<li><a href="PA_2022_22007_PPOs.html#7">ALECENSA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#8">ALOSETRON</a></li>
<li><a href="PA_2022_22007_PPOs.html#9">ALPHA1-PROTEINASE &#160;INHIBITOR&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#10">ALUNBRIG &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#11">AMBRISENTAN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#12">ARCALYST</a></li>
<li><a href="PA_2022_22007_PPOs.html#13">ARMODAFINIL &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#14">ASPARLAS</a></li>
<li><a href="PA_2022_22007_PPOs.html#15">AUSTEDO</a></li>
<li><a href="PA_2022_22007_PPOs.html#16">AVONEX. &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#17">AYVAKIT&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#18">BALVERSA</a></li>
<li><a href="PA_2022_22007_PPOs.html#19">BANZEL</a></li>
<li><a href="PA_2022_22007_PPOs.html#20">BELEODAQ</a></li>
<li><a href="PA_2022_22007_PPOs.html#21">BENLYSTA</a></li>
<li><a href="PA_2022_22007_PPOs.html#22">BESREMI&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#23">BETASERON</a></li>
<li><a href="PA_2022_22007_PPOs.html#24">BEVACIZUMAB&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#26">BEXAROTENE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#27">BLENREP</a></li>
<li><a href="PA_2022_22007_PPOs.html#28">BOSENTAN&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#29">BOSULIF&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#30">BRAFTOVI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#31">BRIVIACT &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#32">BRIVIACT INJ &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#33">BRUKINSA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#34">BUPRENORPHINE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#35">BUPRENORPHINE PATCH&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#36">CABOMETYX &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#37">CALCIPOTRIENE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#38">CALQUENCE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#39">CAPLYTA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#40">CAPRELSA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#41">CARAC &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#42">CARBAGLU &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#43">CAYSTON &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#44">CERDELGA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#45">CHANTIX &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#46">CHLORDIAZEPOXIDE - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#47">CLOBAZAM &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#48">CLOMIPRAMINE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#49">CLORAZEPATE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#50">CLOZAPINE ODT &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#51">COLY-MYCIN&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#52">COMETRIQ</a></li>
<li><a href="PA_2022_22007_PPOs.html#53">COPIKTRA</a></li>
<li><a href="PA_2022_22007_PPOs.html#54">COTELLIC&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#55">CYSTAGON &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#56">CYSTARAN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#58">DAURISMO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#59">DEFERASIROX &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#60">DEMSER&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#57">DALFAMPRIDINE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#61">DESVENLAFAXINE</a></li>
<li><a href="PA_2022_22007_PPOs.html#62">DHE NASAL &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#63">DIACOMIT &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#64">DIAZEPAM &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#65">DICLOFENAC GEL &#160;1%&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#66">DICLOFENAC SOLN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#67">DOPTELET</a></li>
<li><a href="PA_2022_22007_PPOs.html#68">DRIZALMA</a></li>
<li><a href="PA_2022_22007_PPOs.html#69">DRONABINOL&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#70">DUEXIS &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#71">EMSAM&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#72">ENBREL &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#74">ENHERTU</a></li>
<li><a href="PA_2022_22007_PPOs.html#75">EPCLUSA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#76">EPIDIOLEX &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#77">EPO&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#79">ERIVEDGE</a></li>
<li><a href="PA_2022_22007_PPOs.html#80">ERLEADA</a></li>
<li><a href="PA_2022_22007_PPOs.html#81">ERLOTINIB &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#82">ESBRIET &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#83">EVEROLIMUS &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#84">EXKIVITY &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#85">FANAPT &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#86">FARYDAK &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#87">FASENRA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#88">FENTANYL PATCH &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#89">FETZIMA</a></li>
<li><a href="PA_2022_22007_PPOs.html#90">FINTEPLA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#91">FLUOROURACIL &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#92">FORTAMET/GLUMETZA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#93">FORTEO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#95">FOTIVDA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#96">FYCOMPA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#97">GATTEX</a></li>
<li><a href="PA_2022_22007_PPOs.html#98">GAVRETO&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#99">GILENYA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#100">GILOTRIF &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#101">GLATIRAMER &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#102">GROWTH HORMONE</a></li>
<li><a href="PA_2022_22007_PPOs.html#105">HAEGARDA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#106">HARVONI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#107">HERCEPTIN HYLECTA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#108">HETLIOZ &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#109">HETLIOZ LQ &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#110">HIGH RISK &#160;MEDICATION - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#112">HRM - ANTICONVULSANTS - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#113">HRM - HYPNOTICS - 65&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#115">HRM - SCOPOLAMINE &#160;- 65&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#116">HRM-ANTIPARKINSON - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#118">HRM-CYPROHEPTADINE - 65&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#119">HRM-DOXEPIN - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#121">HRM-HYDROXYZINE &#160;- 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#123">HRM-HYDROXYZINE &#160;INJ &#160;- 65&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#125">HRM-PROMETHAZINE - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#127">HRMS - ANTIDEPRESSANTS &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#129">HRMS - CARBINOXAMINE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#130">HRMS - CLEMASTINE- 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#131">HRMS - MECLIZINE - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#132">HRMS - TCAS &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#133">HRM-SKELETAL MUSCLE &#160;RELAXANTS - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#134">HUMIRA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#136">HYPNOTIC-BENZODIAZEPINES - 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#137">IBRANCE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#138">ICATIBANT &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#139">ICLUSIG &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#140">IDHIFA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#141">IMATINIB &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#142">IMBRUVICA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#145">IMLYGIC &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#146">INCRELEX &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#147">INLYTA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#148">INQOVI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#149">INREBIC&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#150">IR BEFORE &#160;ER&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#152">IRESSA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#153">ISOTRETINOIN</a></li>
<li><a href="PA_2022_22007_PPOs.html#154">ITRACONAZOLE</a></li>
<li><a href="PA_2022_22007_PPOs.html#155">IVERMECTIN TAB &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#156">IVIG &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#158">JAKAFI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#159">KALYDECO</a></li>
<li><a href="PA_2022_22007_PPOs.html#160">KESIMPTA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#161">KETOCONAZOLE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#162">KEYTRUDA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#163">KISQALI&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#165">KORLYM &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#166">KRISTALOSE</a></li>
<li><a href="PA_2022_22007_PPOs.html#167">KUVAN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#168">KYNMOBI</a></li>
<li><a href="PA_2022_22007_PPOs.html#169">LAPATINIB &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#170">LENVIMA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#171">LEUPROLIDE</a></li>
<li><a href="PA_2022_22007_PPOs.html#172">LIBTAYO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#173">LIDOCAINE PATCHES</a></li>
<li><a href="PA_2022_22007_PPOs.html#174">LINEZOLID &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#175">LONSURF &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#176">LORBRENA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#177">LUMAKRAS &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#178">LUMOXITI</a></li>
<li><a href="PA_2022_22007_PPOs.html#179">LUPRON PED</a></li>
<li><a href="PA_2022_22007_PPOs.html#180">LUPRON-ENDOMETRIOSIS &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#181">LYNPARZA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#182">LYRICA CR</a></li>
<li><a href="PA_2022_22007_PPOs.html#183">MAVYRET&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#184">MEKINIST &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#185">MEKTOVI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#186">MEMANTINE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#187">MEPRON&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#188">MODAFINIL&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#189">MONJUVI&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#190">MYLOTARG&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#191">NAPROXEN-ESOMEPRAZOLE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#192">NATPARA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#193">NAYZILAM&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#194">NERLYNX</a></li>
<li><a href="PA_2022_22007_PPOs.html#195">NEXAVAR</a></li>
<li><a href="PA_2022_22007_PPOs.html#196">NINLARO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#197">NITISINONE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#198">NORTHERA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#199">NUBEQA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#200">NUEDEXTA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#201">NUPLAZID &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#202">OCTREOTIDE</a></li>
<li><a href="PA_2022_22007_PPOs.html#203">ODOMZO</a></li>
<li><a href="PA_2022_22007_PPOs.html#204">OFEV &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#205">ONCASPAR &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#206">ONUREG &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#207">OPSUMIT</a></li>
<li><a href="PA_2022_22007_PPOs.html#208">ORACEA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#209">ORAL-INTRANASAL FENTANYL &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#210">ORGOVYX &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#211">ORKAMBI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#212">OXANDROLONE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#213">OXAZEPAM - 65&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#214">PADCEV &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#215">PEGASYS &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#216">PEMAZYRE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#217">PEPAXTO&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#218">PHENYLBUTYRATE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#219">PHESGO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#220">&#160;PIQRAY</a></li>
<li><a href="PA_2022_22007_PPOs.html#221">&#160;POLIVY &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#222">POMALYST&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#223">POTELIGEO&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#224">PRALUENT &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#225">&#160;PREGABALIN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#226">PRETOMANID&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#227">PROMACTA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#230">PULMOZYME</a></li>
<li><a href="PA_2022_22007_PPOs.html#231">QINLOCK&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#232">QUETIAPINE XR &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#233">QUININE SULFATE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#234">REGRANEX &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#235">RETEVMO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#236">REVLIMID &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#238">REZUROCK &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#239">RINVOQ &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#240">RITUXAN HYCELA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#241">RITUXIMAB &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#244">ROZLYTREK &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#245">RUBRACA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#246">RYDAPT &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#247">SANDOSTATIN &#160;LAR &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#249">SARCLISA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#250">SCEMBLIX &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#253">SIRTURO&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#254">SKYRIZI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#256">SOMAVERT&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#257">SPRITAM &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#258">SPRYCEL&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#259">STELARA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#260">STIVARGA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#261">SUTENT</a></li>
<li><a href="PA_2022_22007_PPOs.html#263">SYMPAZAN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#264">SYNRIBO&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#265">TABRECTA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#267">TAFINLAR&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#268">TAGRISSO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#269">TALTZ</a></li>
<li><a href="PA_2022_22007_PPOs.html#270">TALZENNA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#271">TARGRETIN TOPICAL&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#272">TASIGNA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#273">TAZAROTENE</a></li>
<li><a href="PA_2022_22007_PPOs.html#274">TAZVERIK&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#275">TECENTRIQ&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#277">TECFIDERA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#278">TEMAZEPAM 30MG &#160;- 65 &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#279">TEPMETKO&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#280">TESTOSTERONE CYPIONATE &#160;INJ &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#281">TESTOSTERONE ENANTHATE &#160;INJ</a></li>
<li><a href="PA_2022_22007_PPOs.html#282">TETRABENAZINE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#283">THALOMID &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#284">TIBSOVO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#285">TOBRAMYCIN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#286">TOPICAL DOXEPIN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#287">TOPICAL LIDOCAINE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#288">TOPICAL TESTOSTERONES &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#289">TOPICAL TRETINOIN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#290">TOREMIFENE&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#291">TRELSTAR &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#292">TREPROSTINIL INJ&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#293">TRIENTINE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#294">TRIKAFTA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#295">TRODELVY &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#296">TRUSELTIQ &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#297">TUKYSA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#298">TURALIO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#299">UBRELVY &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#300">UKONIQ &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#301">VALCHLOR &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#302">VALTOCO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#303">VELCADE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#304">VELTASSA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#305">VENCLEXTA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#306">VENTAVIS&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#307">VERSACLOZ</a></li>
<li><a href="PA_2022_22007_PPOs.html#308">VERZENIO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#309">VIGABATRIN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#310">VITRAKVI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#311">VIZIMPRO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#312">VORICONAZOLE &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#313">VOSEVI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#314">VOTRIENT &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#315">WELIREG &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#316">XALKORI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#317">XELJANZ &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#318">XERMELO&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#319">XGEVA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#320">XIFAXAN &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#321">XOLAIR &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#322">XOSPATA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#323">XPOVIO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#324">XTANDI &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#325">XYREM &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#327">YERVOY &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#328">ZARXIO &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#329">ZEJULA. &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#331">ZELBORAF &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#332">ZEPZELCA&#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#333">ZOLINZA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#334">ZYDELIG &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#335">ZYKADIA &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#336">ZYPREXA RELPREVV &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#337">PART B &#160;VERSUS PART D &#160;</a></li>
<li><a href="PA_2022_22007_PPOs.html#343">INDEX</a></li>
</ul>
<hr/>
</body>
</html>
